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Abstract 
 
Heart and lung transplantation activity is frustrated by the lack of availability of donor 
organs. The haemodynamic, hormonal and inflammatory changes that follow brain 
stem death leads to donor organ injury. Appropriate donor management is essential 
to avoid further damage to already injured donor heart and lungs. Hormone 
replacement therapy with tri-iodothyronine and methylprednisolone in organ donors 
has been reported to increase the retrieval rate of heart and lungs with improved 
function. In a prospective, randomised, double blind, controlled trial the role of 
hormone replacement therapy and early donor management on the donor heart and 
lung function and their retrieval rate was studied. 
Heart donor Outcome 
Early donor management was associated with significant improvement in donor heart 
function. It may also increase the retrieval rate of hearts for transplantation. However, 
administration of hormones neither influenced the donor heart function nor the heart 
retrieval rate. Serial echocardiography guides in identifying suitable donor hearts for 
transplantation during intensive management. 
Lung donor outcomes 
Early donor management was associated with significant increase in lung retrieval 
rate for transplantation. Despite management donor lung function deteriorated 
following brain stem death. Hormone replacement therapy did not increase the lung 
retrieval rate or affect the donor lung function. However, methylprednisolone 
administration leads to significant reduction in progressive donor lung water 
iii 
 
accumulation. Measurement of thermodilution lung water index predicted ultimate 
lung suitability for transplantation and recipient outcome.  
 
Conclusion 
Early donor management is the cornerstone to improve the donor heart function and 
to increase the lung retrieval rate. It may also increase the heart retrieval rate. Serial 
transthoracic echocardiography may guide in identifying suitable hearts that respond 
to donor management. 
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SECTION-1: INTRODUCTION 
2 
 
1. HEART AND LUNG TRANSPLANTATION 
1.1. History and development 
1.1.1. Heart transplantation 
Heart and lung transplantation are established treatment option for patients suffering 
from end stage heart and lung diseases. This is relatively a young speciality with a 
first successful heart transplantation performed just over 40 years ago. Although the 
first successful transplantation was performed in December, 1967 by Dr. Christiaan 
Barnard a South African surgeon, heart transplantation evolved through much earlier 
experimental development. Alexis Carrel a French surgeon first performed 
experimental transplantation of puppy’s heart into the neck of an adult dog in 1905.  
In the mid-1940s Demikhov a Russian surgeon performed series of animal 
experiments on intrathoracic heterotopic heart transplantation. Most of his work was 
not reported in the West until 1960. Demikhov successfully performed first heart-lung 
transplantation in the dog. He had performed a total of 67 procedures with two of the 
recipients surviving 5 and 6 days. Most of the initial experimental procedures were 
carried out as heterotopic or parallel heart transplantation. The development of 
cardiopulmonary bypass in 1950s paved way for further refinement of surgical 
technique of heart transplantation (1;2). 
Norman Shumway and colleagues from Stanford University in California developed 
the surgical technique of performing heart transplantation by suturing the atrial cuffs, 
aorta and pulmonary artery separately using cardiopulmonary bypass on dogs. 
Following successful operation the animal survived for 3 weeks followed by death 
due to haemorrhagic rejection. This lead to further understanding of the role of 
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immunological mechanisms involved in rejection of the graft and Immunosuppressant 
was used to prevent rejection leading to long term survival of experimental animals. 
Following this initial success a series of heart transplantations was performed 
worldwide. However, disappointing results, multiple complications and rejections lead 
to dampening of initial enthusiasm. Following the development of endomyocardial 
biopsy techniques which was pioneered and developed by Dr. Philip Caves a British 
surgeon, to monitor rejection and the discovery of cyclosporine in 1980s lead to 
explosion in number of heart transplantation performed worldwide (1).  
 
1.1.2. Lung transplantation 
Experimental lung transplantation developed simultaneously with heart 
transplantation as most of the researchers performed combined heart-lung 
transplantations. Demikhov performed the first lung transplantation by implanting 
canine lobes. The concept of suturing left atrial cuff for pulmonary venous 
anastomosis was first introduced by a French surgeon Dr. Henry Metras.  The first 
human lung transplantation was performed by Dr. James Hardy at the University of 
Mississippi. The recipient survived for 18 days. Michael Woodruff in Edinburgh (1968) 
and Donald Ross in London (1969) attempted the initial lung transplantation in the 
UK without success. First successful lung transplantation in the Europe was 
performed by Dr. Fritz Derom, a Belgian surgeon. Following this initial success many 
attempts on lung transplantation continued with disappointing results. Rejection, 
infection and airway complication were major contributors for failure. Following the 
advent of cyclosporine the lung transplantation activity started to expand. Joel 
Cooper in Toronto performed single lung transplantation for idiopathic pulmonary 
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fibrosis with the recipient surviving for 6 years. Followed by Alec Patterson in St. 
Louis introduced the concept of double-lung transplantation with both lungs 
implanted with single tracheal anastomosis. However, the technical difficulties and 
tracheal anastomotic complication of this procedure, lead to the development bilateral 
sequential single lung transplantations, where the lungs were implanted individually. 
There had been a gradual increase in lung transplant activity in late 1990s and 
currently the lung transplant activity has taken over by larger number than heart 
transplantations performed in the UK (1;3). 
 
1.2. Indications 
 
1.2.1. Heart transplantation 
 
Patients with end stage heart failure of any aetiology with severe ongoing symptoms 
despite optimal medical therapy are suitable candidates. 
1. Peak oxygen uptake on exercise less than 14.ml/kg or less than 12 ml/kg for 
patients receiving beta-blockers 
2. History of recurrent admission to hospital with worsening heart failure 
3. Refractory ischaemia not amenable to revascularisation with severe left 
ventricular impairment 
4. Recurrent symptomatic ventricular arrhythmia associated with severe 
impairment of ventricular function 
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1.2.2. Lung transplantation 
 
Patients suffering with severe chronic lung disorder with an expected 2 year 
survival of less than 50%  
 
1. Patients with COPD-emphysema (alpha-1antitrypsin deficiency) 
a. FEV1 <25% predicted 
b. Resting PCO2 >6 KPa 
c. Resting PO2 <8 KPa 
d. Poor quality of life 
e. Oxygen dependency and repeated hospitalisation 
f. Rapid decline in FEV1 with life threatening exacerbations 
 
2. Patients with cystic fibrosis 
a. FEV1 <30% predicted 
b. Rapid decline in lung function 
c. PO2 <7.5 KPa 
d. PCO2 >6.5 KPa 
 
3. Idiopathic pulmonary fibrosis 
a. 
 
Resting hypoxaemia with TLC and VC <60% predicted 
b. DLCO <50% predicted 
c. Symptomatic disease on non-responsive to medical therapy 
d. Secondary pulmonary hypertension 
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4. Primary pulmonary hypertension 
a. NYHA class 3 or 4 
b. Poor exercise tolerance- less than 350 metres on 6 minute walk test 
c. Mean RA pressure >15 mm Hg 
d. Mean pulmonary artery pressure > 50 mm Hg 
e. Uncontrolled syncope, haemoptysis or right heart failure 
f. Cardiac index <2.5 L.min-1.m-2 
1.3. Outcome following heart and lung transplantation 
 
The operative mortality for the heart and lung transplantation procedure remains at 
10%. The median survival for the entire cohort of heart transplantation recipients on 
the ISHLT database (the time at which 50% of those transplanted remain alive) is 
currently 10 years. However, the median survival increases to 13 years for those who 
survive the operation and the first year following transplantation (4). Despite 
accepting marginal donor hearts and operating on sicker older recipients the outcome 
following heart transplantation in the recent era is better due to the improved survival 
in the first year of transplantation.  
The outcome following lung transplantation is 79% at 1 year, 65% at 3 years, 54% at 
5 years and 29% at 10 years. The median survival for the entire cohort of patients in 
ISHLT database is 5.4 years and for those who survive the operation and the first 
year post-transplantation the median survival increases to 7.4 years (5). Similar to 
heart transplantation the outcome for lung transplantation recipients since 2000 is 
better than the previous years due to the improved operative mortality and one year 
survival.  
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1.4. Current status of heart and lung transplantation 
 
The number of heart transplantation performed worldwide peaked to 4,460 in mid 
1990s followed by a steady decline in the activity. The activity rate has achieved a 
steady plateau down to 3,300 in the last few years (Figure-1.1). The number of adult 
heart transplantation performed in the UK has been declining from 350 per year in 
early-1990s to less than 100 in the last year. This reduction in activity is due to an 
improvement in neurosurgical intensive care, reduction in road traffic accidents 
following strict legislation on the use of seat belts, change in donor demographics 
and finally donors with pre-existing co-morbidities that preclude them from donating 
their heart.    
 
In contrast the lung transplantation activity has been increasing over the last decade. 
The number of single lung transplants performed worldwide is stable with consistent 
growth in the activity of bilateral lung transplantation. In the UK the lung 
transplantation activity is higher than the number of heart transplantation performed 
per year.  This is due to liberalisation of donor acceptance criteria, increase in non-
heart beating lung donation and resuscitation of unsuitable lungs in ex-vivo lung 
perfusion rigs (EVLP).  
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Figure 1-1- Number of heart transplant procedures reported to the ISHLT 
registry by year, stratified by continent 
Despite initiatives to increase the number of available donor pool, there is an 
imbalance between supply and demand of donor heart and lungs. This leads to 
increase in waiting times and higher waiting list mortality (6).  One of the major 
factors is the poor retrieval rate of hearts and lungs from the existing donor pool. The 
current heart retrieval rate remains between 30% and the lung retrieval rate is around 
20 and 25%. Donor organs with marginal functions are considered for transplantation 
that could lead to increased incidence of primary graft dysfunction (PGD) and worse 
recipient outcome.  
Therefore efforts need to be directed towards increasing the retrieval rate of donor 
organs from the existing donor pool and also to improve the quality of the organs to 
reduce the incidence of PGD. This could be achieved only by better understanding of 
the pathophysiology of brain stem death, its impact on heart and lung function and 
the role of various interventions that could improve the donor heart and lung function. 
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2. BRAIN STEM DEATH 
2.1. Anatomy 
The normal functioning of the heart and lungs is regulated by groups of neurons 
located in the brain stem. From here parasympathetic (vagal) neurones and pre-
sympathetic neurones play a vital role in regulating heart rate, blood pressure, 
cardiac output and vascular tone as well as smooth muscle tone of the airways. In 
addition normal rhythmic respiration is regulated by groups of neurones in the brain 
stem, controlling the spinal phrenic motor neurones to the diaphragm. Importantly, 
the activity of the brain stem cell groups is regulated by afferent input from receptors 
situated in the cardiovascular system and the airways (7). Therefore any neurological 
insult involving the brain stem can lead to loss of neural control of both heart and 
lungs. 
The brain, spinal cord and spinal fluid along with cerebral vessels are encased in a 
rigid bony enclosure. Because brain tissue and spinal fluid are essentially 
incompressible, the volume of brain tissue, blood and spinal fluid in the cranium must 
remain constant at any one time (Monro-Kelly doctrine). When the intracranial 
pressure (ICP) increases the cerebral vessels are compressed leading to ischaemia.   
The cerebral blood flow is maintained relatively at constant levels between 50 to 150 
mm Hg (6.7 to 20 KPa) by a process of autoregulation keeping the normal steady 
state of flow despite variations in perfusion pressure (8) 
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2.2. Coning 
Any CNS pathology (head injury, sub-arachnoid haemorrhage, sub-dural 
haemorrhage, intracranial haemorrhage, infections and tumours) that increases the 
pressure within the skull leads to increase in ICP. As the brain lies within a closed 
non-expandable bony cavity any increase in ICP leads to decrease in brain blood 
flow. The resultant ischaemia stimulates the vasomotor area in the brain stem leading 
to increase in blood pressure and fall in heart rate (bradycardia). This response is 
called Cushing’s reflex. However, as the ICP increases beyond certain limit the brain 
blood flow completely ceases and the brain stem is pushed through the foramen 
magnum (8). This process is called coning.  The process of coning leads to 
haemodynamic, hormonal, inflammatory and bio-chemical changes, each one of 
these changes inflict cardio-pulmonary damage (Figure-2.1). 
 
 
 
   
 
 
 
   
  
 
Figure 2-1-Demonstrating various changes that follow brain stem death 
impacting on donor heart and lung function 
Coning-Brain stem death 
Haemodynamic 
changes 
Hormonal 
changes 
Inflammatory 
changes 
Bio-chemical 
changes 
Cardio-pulmonary injury 
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2.3. Pathophysiological changes during and after brain stem death 
2.3.1. Haemodynamic changes 
Haemodynamic effects following BSD demonstrate biphasic changes. Immediately 
after coning an initial massive sympathetic neural outflow is associated with a 
catecholamine surge (catecholamine storm) with release of both adrenaline and nor-
adrenaline from the sympathetic nerve terminals (9;10). This results in increased 
blood pressure, systemic vascular resistance (SVR), and cardiac work-load which in 
turn lead to increased myocardial oxygen consumption (11). Due to the high SVR the 
peripheral tissue perfusion is reduced leading to tissue hypoxia and metabolic 
acidosis. Experimental studies have shown that the catecholamine release follows a 
biphasic pattern with an initial release followed by a return to normal levels and 
another release into the systemic circulation after 2 hours associated with myocardial 
injury (12).  
 
This catecholamine storm is followed by vasoparetic phase which leads to reduction 
in sympathetic neural output and complete loss of vascular tone. As a consequence 
blood pressure falls together with cardiac output and vascular tone (13;14). During 
this phase vasopressin (VP) (a vasoconstrictor) infusion can help in maintaining SVR 
(15) (Figure-2.2).    
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Figure 2-2- Graph demonstrating changes to SVR following coning 
 
2.3.1. 1. Pathophysiology of neurogenic pulmonary oedema 
 
Novitzky and colleagues using an experimental brain death animal model 
demonstrated the mechanism of development of neurogenic pulmonary oedema (16). 
During the catecholamine storm phase there is an increase in SVR and mean arterial 
blood pressure (MAP) along with a reduction in systemic blood flow (Qs). During the 
same time the pulmonary vascular resistance (PVR) (resistance against which the 
right ventricle pumps blood to the pulmonary arteries) is also elevated along with 
mean pulmonary artery pressure (MPAP) with a reduction in pulmonary blood flow 
(Qp). However, the PVR then falls below normal levels, this occurring much earlier 
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than a drop in SVR. This leads to reduction in MPAP and increase in pulmonary 
blood flow with still reduced systemic blood flow due to high SVR. This imbalance 
between the pulmonary and systemic blood flow (Qp>Qs) leads to blood pooling in 
the lungs (Figure-2.3). 
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Figure 2-3-Graph demonstrating the relationship between systemic and 
pulmonary blood flow following BSD leading to blood pooling in the lungs 
Y-axis represents SVR, PVR and systemic and pulmonary blood flow (ml) 
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Due to this imbalance in pulmonary and systemic blood flow, the left atrial pressure 
increases with associated increase in MPAP. This imbalance leads to an increase in 
gradient across the pulmonary vascular tree (trans-pulmonary gradient (TPG)) which 
in turn causes pulmonary oedema. The increase in LAP and TPG also induces sub-
endocardial ischaemic damage of the myocardium (Figure-2.4). 
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Figure 2-4-Graph demonstrating the increased trans-pulmonary gradient 
following BSD 
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2.3.2. Hormonal changes following BSD 
Immediately following the coning induced catecholamine storm, increased plasma 
levels of both adrenaline and nor-adrenaline by many folds was noted (12). Shivalker 
et al showed that the catecholamine release was increased with an acute increase in 
ICP, as compared to gradual increase (17;18). In experimental studies bilateral 
sympathectomised animals did not show any histological evidence of myocyte injury 
in comparison with animals with no or incomplete cardiac denervation (19) or β-
blockers (20). This demonstrates that most of the catecholamines are released from 
the sympathetic nerve terminals. High concentration of catecholamines is known to 
cause cardiac damage and myocardial dysfunction. Areas of myocytolysis, 
contraction band necrosis, focal coagulative necrosis, sub-endocardial haemorrhage 
and oedema with infiltration of mononuclear cells have all been described (21;22).   
There are many theories of the mechanism of catecholamine induced cardiac 
damage. These include hypoxia, direct catecholamine toxicity (21), alteration in 
coronary microcirculation (23;24), alteration in membrane permeability and rapid 
desensitisation of myocardial β-adrenoreceptors (25).  Therefore catecholamine 
release following coning causes severe myocardial damage by its haemodynamic 
changes and direct effects which manifests as cardiac dysfunction (26) affecting both 
left and right ventricle. In experimental brain death canine model Bittner and 
colleagues demonstrated significant right ventricular dysfunction which further 
deteriorated following graft (27;28) preservation and transplantation.  
Following coning the neural connections between the midbrain and the brain stem 
are severed (Hypothalamo-pituitary axis). This leads to loss of hypothalamic control 
over the pituitary gland and rapid significant decrease of thyroid, adrenal hormones 
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and vasopressin (VP) (29).  This is followed by a rapid reduction in serum 
catecholamines (30) and rapid fall in posterior pituitary hormone (31). Lack of VP 
impairs water retention in the kidneys causing diabetes insipidus. During this time the 
patients produce large volumes of urine leading to rapid fluid shift in the vascular 
compartment which further worsens the hypotension during the vasoparetic phase.  
Serum levels of tri-iodothyronine (T3), cortisol and insulin levels gradually fall after 
BSD (31). T3
 
levels are found to be reduced in serum in 85% of donors following 
BSD and the T4 (thyroxine)
 
levels are found to normal with a low to normal levels of 
TSH (thyroid stimulating hormone) and elevated levels of reverse T3
 
(rT3) (32;33).  
This condition is called the euthyroid sick syndrome. Administration of thyroxine T4 
will lead to preferential conversion of T4 to rT3. This hormone depleted state has 
been shown to be associated with deterioration in cardiac function and depletion of 
myocardial energy stores and lactic acidosis (34;35). Administration of T3 in animal 
BSD model was associated with reduction in plasma lactate and free fatty acid levels 
suggesting a reversal from anaerobic to aerobic metabolism (36). Fall in cortisol and 
insulin levels will lead to abnormal anti-inflammatory mechanism and abnormal blood 
sugar control respectively (14). Table-2.1 describes the hormonal changes that occur 
following BSD and their effect on the donor physiology.  
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Table 2-1- showing hormonal changes following BSD and their effect on the 
donor 
 
Hormone        Effects 
 
Catecholamines Increase in heart rate, MAP, cardiac 
output, SVR 
  Increase in myocardial work-load and 
oxygen consumption 
  Catecholamine induced direct injury 
 
Vasopressin     Diabetes insipidus 
 
     T3/T4  Essential for aerobic myocardial 
metabolism   
 
Insulin  Altered glucose metabolism-high 
blood sugars 
Adrenal steroids Poor response to stress, Loss of 
normal anti-inflammatory 
mechanisms 
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2.3.3. Inflammatory changes following BSD 
 
Brain stem death generates a pro-inflammatory environment after catecholamine 
storm. This promotes the release of large amounts of pro-inflammatory cytokines that 
worsens the already injured cardio-pulmonary function (37). Studies have shown that 
cytokines, like interleukin-1, 6 and 8 (IL-1, IL-6 and IL-8), tumour necrosis factor-α 
(TNF-α) and procalcitonin (PCT), levels were elevated in both serum and the 
myocardium following BSD especially in dysfunctional hearts (38). 
  
2.3.3.1. Interleukins 
 
Interleukins are signalling molecules from the super family of cytokines and are 
mainly involved in communicating signals between the white cells.  The term 
interleukin refers to inter (communicating between) and leukins (white blood cells) 
was given after their function. IL-1 is the first to be described. Both IL-1 and IL-6 are 
secreted by the T-cells and also from the activated macrophages. Their main function 
is to further stimulate more T cells and is involved in elaboration of inflammation and 
acute phase proteins. Elevated levels of IL-1 and IL-6 have been associated with 
worse donor heart function. Serum and myocardial IL-6 levels were found to be 
significantly elevated in hearts that were not used for transplantation compared to the 
transplanted hearts (39) (Figure-2.5). Elevation of such cytokines are associated not 
only with donor heart dysfunction (40) but also implicated in increased risk of post-
transplant rejection (41-43) and increased post-operative inotrope requirement. 
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Figure 2-5-Bar chart demonstrating increased levels of serum IL-6 in hearts 
that were unused for transplantation compared to the normal donor hearts 
 
 
P<0.001 
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Interleukin-8 is another cytokine secreted by macrophages and endothelial cells. It is 
associated with immune response to bacterial infections. IL-8 has been implicated in 
acute inflammatory lung diseases. It is a potent chemotactic factor promotes 
neutrophilic adhesion, aggregation and degranuation. It has been implicated in 
ischaemia-reperfusion injury of lungs following transplantation. The level of IL-8 from 
lung tissue was found to be directly related to poor lung function (PaO2/FiO2 ratio), 
high airway pressure, and prolonged ICU stay thereby predicting early graft function 
post-transplantation (44). In another study the level of IL-8 in donor broncho-alveolar 
lavage (BAL) predicted the early graft function and also the recipient outcome (45).  
 
2.3.3.2. Tumour necrosis factor 
 
TNF-α is another cytokine produced by the activated lymphocytes that can induce 
inflammation and apoptosis (programmed cell death). TNF-α mRNA is expressed in 
the failing or stressed nucleated myocyte generating and releasing TNF-α (46). In 
patients with heart failure,  serum TNF- α levels correlate with disease severity and 
are predictive of mortality (11;37;42;47). In heart donors, myocardial upregulation of 
TNF-α mRNA and elevated serum TNF-α levels have been reported previously and 
the greatest increase has been found in donor hearts rejected for transplantation due 
to poor function (38;39;48). In these donors, TNF-α levels exceed those seen in 
patients with advanced heart failure (39) (Figure-2.6).  
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Figure 2-6-Bar chart showing the significantly elevated Serum TNF-α level in 
donor hearts that were unused for transplantation compared with normal donor 
hearts 
 
Similarly other inflammatory markers like procalcitonin (precursor of hormone 
calcitonin) and C-reactive protein, which is prognostically valuable in heart failure, 
have also been predictive of primary graft failure and graft dysfunction following heart 
transplantation (49-51). Wagner et al. retrospectively analyzed the serum levels of 
PCT and CRP in 79 donors. They grouped the donor hearts into two, based on the 
post-transplant mortality related to graft dysfunction. Assessment of donor heart 
function was limited and ischemic times were significantly greater in the high PCT 
donors. They reported that higher PCT levels were associated with significantly 
elevated graft failure-related mortality and that a PCT >2ng.ml-1 had 96% specificity 
and 50% sensitivity for predicting post-transplant mortality (50).  
P<0.01 
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2.3.4. Bio-chemical changes following BSD 
Troponin-I and T are myocardial proteins released into the blood following injury and 
cell death (52). Measurement of troponins is an invaluable, non-invasive tool for the 
assessment of myocardial injury (53;54). Haemodynamic changes that follow BSD 
leads to sub-endocardial ischaemia and muscle death. Cardiac troponin I (CTnI) 
elevation has also been observed in patients with subarachnoid haemorrhage and in 
this setting is associated with increased LV dysfunction, pulmonary oedema, 
hypotension requiring inotropic support and is predictive of worse outcome (55). 
Serum cardiac troponin-I and T levels are found to be elevated in most donors.  
Elevation of CTnI has been associated with worse donor heart function and 
increased inotropic requirement following transplantation and increased risk of acute 
graft failure (56;57). Elevated troponins may predict adverse recipient outcome, being 
associated in some studies with increased risk of early graft failure and increased 
rates of inotrope requirement post-transplantation and post-transplant rejection 
(49;56-59) However, this association remains controversial as equivalent outcomes 
have been achieved in other studies with no increased risk of rejection (60-62). 
Elevated CTnI levels represent a marker of myocardial injury but whether they predict 
the ultimate heart usability following donor management is unknown.  
 
2.4. Summary 
 
Each of the above described changes that happen following BSD injures the heart 
and lungs either directly or indirectly. The catecholamine storm induced 
haemodynamic changes leads to direct ischaemic injury to the myocardium. This also 
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leads to direct changes in the pulmonary and systemic vascular resistance causing 
haemodynamic shear force in pulmonary endothelium causing pulmonary oedema.  
Following the catecholamine storm the inflammatory response sets in along with 
hormonal deficiency state, indirectly affecting donor heart and lungs.  
The inflammatory environment leads to release of large amounts of cytokines which 
further worsens already injured heart and lungs. These changes may add insult to the 
injuries sustained by the heart and lungs prior to BSD, like trauma to chest, 
aspiration, infection, positive pressure ventilation. In addition the donor heart may be 
suffering from pre-existing coronary artery disease and hypertension. Therefore heart 
and lungs even in an otherwise healthy donor gets severely injured during BSD and 
the management of the donor following BSD is an important aspect of organ retrieval. 
This also will influence the outcome of the recipient following successful 
transplantation.  
Therefore understanding the pathophysiology of the BSD and further management of 
the organ donor are the key to successful organ retrieval and transplantation.  
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3. DONOR MANAGEMENT AND HORMONE REPLACEMENT 
THERAPY 
 
 
3.1. Rationale behind donor management 
 
Donor management has unfortunately been most neglected part of thoracic 
transplantation. This is due to the fact that most of the donor work is done away from 
the recipient centres in a new hospital intensive care unit environment and in most 
cases it happens at night time. There is always a shortage of trained practitioners to 
manage an organ donor. However, donor management is the most essential part of 
successful thoracic organ transplantation. 
 
The principles behind donor management involve attention to details on the basic 
physiological parameters (Table-1). Prior to BSD the mean arterial pressure on the 
patient is maintained at higher level in order to achieve adequate cerebral perfusion. 
Once the BSD testing is done and consent for organ donation is available the MAP 
does not need to be very high. Therefore accepting a MAP of 70 mm Hg is adequate 
to maintain end organ perfusion. Achieving adequate pre and after-load along with 
maintaining normal electrolyte, temperature homeostasis and trachea-bronchial 
clearance are the main objectives of donor management. In order to achieve these 
parameters insertion of invasive monitoring lines including pulmonary artery flotation 
catheter (PAFC) is essential. This will help in optimising pre-loads on both right and 
left ventricle and their after load. Performing bronchoscopy will help in airway 
clearance and check the position of the endotracheal tube.   
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Table 3-1- Principles behind donor management 
 
 
• Attention to detail 
• Adequate Mean arterial pressure  
• Optimise pre-load and after-load 
• Meticulous fluid balance 
• Tracheobronchial clearance 
• Maintain normal blood sugar, serum potassium and temperature homeostasis  
• Monitoring haemodynamic performance 
 
 
The role of invasive monitoring and protocol driven donor management could lead to 
increase in number of transplantable donor organs. Wheeldon et al. over 15 years 
ago reported the role of PAFC guided optimisation in transforming unacceptable 
donors to usable ones. They studied 150 donors over 3 year period and found over 
35% (52/150) of donors were outside the criteria for heart transplant suitability. Forty 
four of the 52 donor hearts were suitable at the end of protocol driven donor 
management (Table-2) (63).  
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Table 3-2- Haemodynamic targets used by Wheeldon et al 
 
Mean arterial pressure  >65-70 mmHg 
Central venous pressure  < 12mmHg 
Wedge pressure   <12mmHg 
Cardiac Index   2.5 L.min-1.m-2  
With dopamine use   <5ug/Kg/min  
 
The same group demonstrated using a simple nomogram of protocol driven 
optimisation they could increase their donor organ pool by over 30% (64). Following 
this many authors reported the role of protocol driven donor management in 
increasing potential donor organ pool (65-67). The crystal city consensus conference 
report published in 2002 also recommends the utilisation of PAFC guided donor 
management pathway in maximising the use of organs from the cadaveric donor 
(68).  
 
3.2. Hormone replacement therapy-Thyroid hormone  
3.2.1. Synthesis and release 
The thyroid gland is endodermal in origin and is located in the anterior portion of the 
neck where it lies on either side of the trachea. The functional unit of the thyroid 
gland is the follicle surrounded by a rich capillary plexus. The follicular epithelium 
consists of a single layer of cuboidal cells. The lumen of the follicle is filled with 
hormone containing colloid; this is the major constituent of thyroid mass. This is the 
site of iodination. The major products of the thyroid gland are the iodothyronines. 
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Iodine enters the thyroid follicular cells as inorganic iodide and is transformed in a 
series of steps into the thyroid hormones. T4 and T3 are the two iodothyronines with 
biological activity. The thyroid gland contains 5-8mg of iodide on average. Nearly all 
of this is in the form of iodothyronines. Approximately 1% of this is released from the 
gland per day, 75% as thyroid hormones (TH) and the remainder as free iodide (69).  
 
Active iodide uptake occurs at the basal membrane of the follicular cell. Iodide then 
diffuses along an electric gradient into the lumen. Once within the lumen iodide is 
oxidised by a peroxidase and is incorporated into tyrosine molecules. 
Monoiodotyronine (MIT) and diiodotyronine (DIT) are formed as a result of iodination. 
Two DIT molecules are coupled to form T4 or one DIT and one MIT to form T3 or 
rT3. Once thyroglobulin has been iodinated it is stored as colloid in the follicular 
lumen. Release of T4 and T3 into the circulation requires proteolysis of the 
thyroglobulin. Once T4 and T3 are released into the plasma the vast majority is 
bound to plasma proteins. Thyroxine-binding globulin binds approximately 75% of the 
plasma T4 and almost all (99.5%) of T3. Very small quantities of T4 (0.05%) and T3 
(0.5%) are unbound (free) within the plasma (69).  
 
3.2.2. Regulation of thyroid hormone 
The most important regulator of the thyroid gland is thyroid-stimulating hormone 
(TSH). TSH secreting cells are located within the anterior portion of the pituitary 
gland. Its synthesis is stimulated by hypothalamic thyrotropin-releasing hormone 
(TRH). The secretion of TSH is regulated by two factors. Firstly, TRH increases the 
rate of secretion and secondly, circulating levels of T4 and T3 decrease it as part of a 
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negative feedback loop (Figure 3.1). The regulation of TSH is under a negative 
feedback loop and circulating levels of free T4 and T3 produce feedback to the 
pituitary to decrease TSH production. As levels drop then TSH secretion increases. 
 
            Thermal and caloric signals 
 
 
                                                                                                                    T4/T3 
 
 
TRH 
 
 T4/T3 
 
 
 TSH  
 
 T4/T3 
 
Figure 3-1-Regulation of TSH secretion and negative feedback effects of T3 and 
T4 
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3.2.3. Cardiovascular effects of thyroid hormone 
Thyroid hormone increases the basal metabolic rate, oxygen consumption and heat 
production within the body. It increases the cardiac output and has positive inotropic 
and chronotropic effect on the heart. T3 is the biologically relevant component of 
thyroid hormone in cardiac myocytes. As in other tissues T3 exerts its effects by both 
genomic and non-genomic mechanisms. The predominant mechanism by which T3 
affects myocardial action is by exerting a direct effect in cardiac myocytes by binding 
to nuclear receptor isoforms (70). Secondarily, T3 affects cardiac function by its 
actions on the vascular system, in particular reduction of left ventricular afterload 
(70). The immediate effects are due to the extra-nuclear action of thyroid hormone. It 
increases the oxidative metabolism and increased sensitivity to the circulating 
catecholamines (71). The late effects are due to the genomic action after 6 to 8 hours 
of T3 infusion (72). This increases the protein synthesis and m-RNA expression. It 
also increases the β-adrenergic receptor density (73).  
Reduction in systemic vascular resistance is one of the earliest changes that occur to 
patients on administration of TH. This may in part be due to the release of local 
vasodilators that are liberated as a result of increasing metabolic activity and oxygen 
consumption. This reduction in systemic vascular resistance decreases afterload and 
leads to an increase in cardiac output (70). The subsequent increase in cardiac 
output leads to an increased oxygen delivery to the periphery supporting the 
increased basal metabolic rate and increased oxygen consumption. TH 
administration also leads to an increase in circulating blood volume. This leads to an 
increase in venous return and preload, which further contribute to increased cardiac 
output.  
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3.2.4. Euthyroid sick syndrome 
 
Serum levels of TH drop in response to physical stress such as starvation or illness. 
This can occur rapidly. Most commonly circulating T4 and TSH levels return to 
normal and T3 levels then remain low. This phenomenon is often referred to as the 
“euthyroid sick syndrome” (ESS) on the basis that these patients are not actually 
clinically hypothyroid despite their biochemical profile. It is characterised by low levels 
of total and free T3, low or normal levels of thyroxine, high levels of reverse T3 and 
normal thyroid stimulating hormone (TSH). The reduction in T3 is thought to be 
secondary to a reduction in the peripheral conversion of T4 to rT3. After recovery 
from the precipitating cause thyroid function invariably returns to within normal limits.  
 
3.2.5. Thyroid hormone replacement in multi-organ donors 
 
Brain stem death leads to a rapid decline in serum levels of thyroxine, cortisol and 
insulin. These observations have been confirmed in animal experiments (74). 
However, the changes in thyroid hormone levels following BSD in human organ 
donors are controversial. T3
 
levels are found to be reduced in serum in 85% of 
donors following BSD and the T4
 
levels are found to normal with a low to normal 
levels of TSH and elevated levels of reverse T3
 
(rT3) (32;33). There is abnormal 
peripheral conversion of T4
 
to inactive rT3, all these findings pointing towards 
euthyroid sick syndrome (35;75). The association between low levels of serum T3
 
and myocardial dysfunction and the use of T3
 
in potential organ donors following 
BSD is not confirmed (76). 
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3.2.5.1. Animal studies 
 
Studies on pigs and baboons following experimental brain death have shown rapid 
decline in hormone levels and an increase in anaerobic metabolism. This leads to 
deterioration in cardiac function and depletion of myocardial energy stores and lactic 
acidosis (77). These abnormalities were reversed on administration of T4, cortisol and 
insulin (36;78). However, a load-independent analysis of cardiac function in pigs 
following experimental brain death and T3
 
administration failed to show any 
advantage over the control group in terms of preserving left ventricular function or 
prolonging survival.  
 
Furthermore, marked decreases in myocardial blood flow (MBF) in the T3 group 
versus control group without a significant change in cardiac function was also 
identified. Analysis of endocardial to epicardial flow ratios disclosed no significant 
differences between groups at any time. In summary, animals treated with T3 had a 
greater decline in MBF than the control group at 4 hours, without any benefit to 
cardiac function (79).  
 
3.2.5.2. Retrospective clinical studies 
 
Following BSD same events as described in animal experiments have been observed 
in human organ donors. 85% of BSD patients show low levels of T3
. 
But, the 
presence of T3
 
deficiency and its association between myocardial dysfunction and 
the improvement in haemodynamics following its administration is controversial. 
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There are few prospective studies published in the literature on the use of T3
 
in multi-
organ donors.  
 
A retrospective analysis of all brain dead donors in the United States, from January 
2000 to September 2001, was conducted. The donors were divided to two groups 
depending on whether they received hormone replacement therapy (HRT Group) (T3, 
Methylprednisolone and Vasopressin) or not. Out of 10,292 donors, 701 (6.8%) of 
donors received HRT. On univariate analysis the mean number of organs retrieved 
from HRT group was 22.5% greater than non-HRT group donors (3.1 versus 3.8). On 
multivariate analysis 4.7% increased probability of retrieving heart from the HRT 
group was observed compared to the non-HRT group (80;81). Unfortunately, in this 
study only 47 out of the 701 HRT group donors received T3
 
infusion (0.45%). The 
rest of the 654 donors received T4
. 
It is well known from the above discussion that 
there is a euthyroid sick syndrome status following BSD and the serum levels of T4
 
in 
the donors were found to be normal and abnormal peripheral conversion of T4
 
to rT3
 
has been observed following BSD. Administration of T4
 
will be of no use in these 
donors. The dose, mode, timing (before retrieval) and the duration of administration 
of thyroid hormone in this group of patients was not available. The duration of donor 
management and other management strategy used to stabilize the donor until 
retrieval has not been mentioned.  
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3.2.5.3. Prospective studies 
 
Novitzky et al observed the effects of routine hormone administration on twenty one 
consecutive donors (82) by administering IV T3
 
(0.2µg), cortisol (100mg) and insulin 
(10-30 IU), and repeating the dose hourly. Donors were monitored between 3 to 8 
hours with a mean duration of 5.5 hours. The results were compared with 26 donors 
managed routinely without hormone supplement. They observed a significant 
improvement in mean arterial pressure (MAP), fall in central venous pressure (CVP) 
by 35%, significant reduction in lactate levels and reduction in bicarbonate 
requirement to treat metabolic acidosis compared to the control group. The serum T3
 
levels were initially low in all donors and rose to normal levels following T3
 
replacement.  All 21 hearts were used for transplantation with a good post-operative 
outcome. The study observation confirms the presence of T3
 
deficiency following 
BSD and return to normal levels following replacement therapy. However, the study 
is a non-randomised controlled trial, the donor demographic details are unknown and 
haemodynamics were observed only from the right side of the heart. They continued 
the same observational study to include 116 consecutive donors and found the same 
haemodynamic improvement and decrease in the inotropic support (83).  
 
In an observational study Jeevanandam and colleagues used T3
 
replacement 
therapy in dysfunctional donor hearts that normally might have been considered 
unsuitable for transplantation (High CVP, decreased LVEF <45%, inotrope 
requirement and episodes of cardiac arrest). The donors received 0.2µg bolus of T3
 
repeated hourly to a maximum dose of 0.6µg. The donors were monitored between 
2-3 hours, from the time of administration of drugs to procurement of heart. A 
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significant improvement in the MAP and fall in CVP and left atrial pressure was 
observed following T3
 
administration. All 6 dysfunctional hearts were used for 
transplantation with good post-operative outcome. All the donors in this study were 
young with a mean age of 16.5 years (range of 8-30years). They are unlikely to have 
any coronary artery disease. All donors received 80 mg of frusemide intravenously 
after T3
 
administration. This could have lead to massive diuresis and resulted in fall 
in CVP and LAP. All donors received dopamine infusion between 5 to 10µg/Kg/min 
which might have improved the cardiac contractility and MAP. The study was not a 
randomised controlled trial and apart from filling pressures no other haemodynamic 
and echocardiographic data were available. Serum T3
 
levels were not measured in 
the study group (84;85).  
 
The role of routine use of T3
 
in resuscitating all organ donors was studied in an open 
label non-blinded randomised study by Jeevanandam et al. All donors received bolus 
of 0.6µg of IV T3
. 
All donors were on less than 10µg/kg/min of dopamine. They found 
no difference between the parameters tested in the T3
 
and the control groups (73).  
In a prospective, randomised, controlled study on 25 consecutive organ donors, 
Randell and colleagues used T3
 
and placebo as an infusion to stabilize the organ 
donors. In contrary to the findings observed by Novitzky and Jeevanandam et al, they 
noted no difference in the haemodynamic parameters, inotrope requirement between 
the two groups of donors. They also noticed a worsening metabolic acidosis and 
increase in requirement of bicarbonate infusion in T3
 
group, quite opposite to the 
findings reported by Novitzky and colleagues. The sample size of this study was 
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small and they compared MAP and temperature maintenance between the groups. 
Serum T3
 
levels were not measured before and after treatment (86).  
 
Goarin et al conducted a prospective, randomised, and blinded controlled trial to 
determine the haemodynamic and myocardial effects of T3
 
administration on 37 brain 
dead organ donors. The donors either received 0.2µg bolus of T3
 
or saline placebo. 
All donors were monitored using pulmonary artery catheter and transoesophageal 
echocardiography (TOE). They found very low levels of T3 in
 
85% of donors and 
normal T4
 
levels in all donors. Following administration of T3
 
the serum
 
levels 
returned to normal in all treatment group donors. There was no difference in the 
haemodynamic parameters between the groups. Even in the group with decreased 
fractional axis change (FAC) on TOE T3
 
administration did not improve the function 
and FAC. The study concluded that T3
 
has no important effect on myocardial function 
and haemodynamics of brain dead organ donors (87). 
 
3.3. Hormone replacement therapy-Steroids 
3.3.1. Synthesis and release 
Glucocorticoides are produced from the adrenal glands which lie above both kidneys 
in the retroperitoneum. Adrenal glands are divided into an outer cortex and an inner 
medullary region. The adrenal cortex has 3 further layers called zona glomerulosa 
which produces aldosterone a mineralocorticoide, zona fasciculata which produces 
cortisol and corticosterone or glucocortioides and zona reticularis which produces sex 
hormones. Adrenal medulla produces the catecholamines both adrenaline and nor-
adrenaline. Cortisol is synthesised from cholesterol. The synthesis is stimulated by 
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the adrenocorticotropic hormone (ACTH) which is released from the anterior lobe of 
pituitary gland. ACTH increases the concentration of cholesterol within the 
mitochondria of adrenal cortex. Cholesterol is converted into pregnenolone within the 
adrenal cortex which is the rate limiting step in steroid synthesis. Pregnenolone 
undergoes further hydroxylation process to progesterone, deoxycorticosterone and 
finally to cortisol. Following release from the adrenals cortisol is bound to proteins 
called corticosteroid binding globulin. Most of the cortisol is protein bound and only 
4% of cortisol is available for the receptors. The amount of cortisol available in the 
serum undergoes diurnal variation with the highest levels in the early morning and 
lowest levels present during late evening and at night time. Cortisol is metabolised by 
oxidation in liver by the cytochrome P450 enzyme (88).  
 
3.3.2. Regulation 
Cortisol synthesis is stimulated by ACTH release from anterior lobe of pituitary gland. 
ACTH release is further controlled by a peptide hormone called corticotropin-
releasing hormone (CRH) secreted from the hypothalamus. ACTH increases the 
availability of cholesterol within the adrenal cortex. The released cortisol in turn acts 
as a negative feedback to inhibit release of ACTH and CRH. In the presence of active 
inflammation activated macrophages secrete IL-1 which synergistically increases the 
CRH and ACTH release thereby increasing cortisol and suppression of immune 
response (88).  
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Figure 3-2-Regulation of ACTH and the negative feedback effect of cortisol on 
CRH and ACTH 
                          
  3.3.3. Anti-inflammatory effects of steroids 
 
Glucocorticoides are the hormones released in response to any stress in our body. 
They have various actions including effects on glucose metabolism, collagen loss, 
epithelial fluid transport, and water and sodium re-absorption. However, its effects on 
immune system are of considerable importance. Steroids have been used 
extensively in inflammatory mediated diseases like, multiple sclerosis, rheumatoid 
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arthritis, bronchial asthma and systemic lupus erythematosus. It acts at various levels 
starting from cellular level acting on lymphocytes and neutrophils. At vascular 
endothelium it prevents leucocyte adhesion and aggregation and locally at tissue 
level it stabilises the mast cells and avoids degranulation. It has a potent anti-
inflammatory action by blocking the proliferation of T-lymphocytes. The activated T-
cells secrete IL-2 and produce the T-cell growth factor. Cortisol binds to the IL-2 
receptors thereby prevents activated T-cells responsive to IL-1 stimulation and T-cell 
proliferation (88). Cortisol also has a negative feedback effect on IL-1. In addition 
they exert their anti-inflammatory effect by stabilisation of cellular membranes, 
reduction of HLA antigen up-regulation and inhibition of cytokine elaboration (89). 
Glucocorticoides stimulate the epithelial Na+/K+-channels in alveolar epithelium and 
have an important role in absorption of excessive fluid from the alveolar space (90). 
This particular action is beneficial in early clearance of lung oedema (91;92).  
 
3.3.4. Steroids replacement in multi-organ donors 
The role of steroid administration in multi-organ donors is studied in most trials with 
combination of T3 and vasopressin (80;81). The anti-inflammatory and 
immunosuppressive actions of steroids in post-transplant recipients are well 
established. The role of steroids in organ donor is still in debate. In an experimental 
brain death model both systolic and diastolic heart function was better preserved in 
animals receiving methylprednisolone than in controls and this was associated with a 
significant reduction in inflammatory markers like IL-6, TNF- α and IL-10, 6 hours 
after BSD (93;94). In a sheep model of brain death and heart transplantation the 
measures of left ventricular functions were significantly higher up until 6 hours of 
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transplantation in steroid pre-treated animals. This was also associated with stable 
recovery of transplanted animals than compared with non-steroid group (95). In all 
these animal trials steroids were administered immediately prior to or after BSD. 
However, in clinical studies steroids are usually administered only after confirming 
BSD and consent for organ donation is available. This is usually many hours after 
coning and established BSD. Therefore by the time the steroids are administered the 
inflammatory cascade had well established with elaboration of pro-inflammatory 
cytokines. To achieve the benefits the steroids should be administered as soon as 
possible after clinical signs of coning. But, it is currently unethical in the UK to treat a 
patient as an organ donor prior to the confirmation of BSD and consent for organ 
donation.   
 
In lung transplantation, steroid administration was reported to be associated with 
improved oxygenation and increased lung retrieval rate in a retrospective study (96). 
This improved oxygenation could have been due to its up regulation of alveolar 
epithelial fluid transport (97).  However, there are no prospective randomised trials 
evaluating the role of early steroids administration in potential lung donors.   
 
3.4. Hormone replacement therapy- Vasopressin 
3.4.1. Synthesis and release 
Arginine vasopressin (VP) also called as anti diuretic hormone (ADH) is found in 
most mammals. It is a peptide hormone synthesised as a pre-hormone in the 
hypothalamus and is stored in vesicles in posterior pituitary gland. It is released into 
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the blood stream and also has some direct effects on brain. Vasopressin is released 
into the blood stream in response to the changes in plasma volume and osmolality. 
Whenever there is a reduction in plasma volume activated by the stretch receptors in 
carotid and aortic bodies the posterior pituitary gland releases the hormone. There 
are 3 different types of receptors for VP action. Changes in plasma osmolality and 
plasma volume lead to regulation of its secretion.  
 
3.4.2. Actions of vasopressin 
One of the major functions of VP is to maintain body water content and maintaining 
normal osmolality. Its major action is at the level of the distal convoluting tubules and 
collecting tubules of the kidneys. It concentrates urine by reabsorbing water and 
reducing urine volume. Because of this action it is called anti-diuretic hormone. 
Vasopressin in high concentrations increases peripheral vascular resistance and thus 
increases arterial blood pressure. This effect appears small in healthy individuals; 
however it becomes an important compensatory mechanism for restoring blood 
pressure in hypovolaemic shock. This particular effect is useful in post BSD 
vasoparetic state. 
 
3.4.3. Role of vasopressin therapy in multi-organ donors 
The use of vasopressin (VP) in treatment of post-BSD vasoparesis is well established 
than the other two hormones. Following BSD the serum levels of VP is decreased 
due to the transection of hypothalamo-pituitary axis. This leads to diabetes insipidus 
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and intravascular fluid depletion. Due to this massive fluid shift the donor becomes 
hypotensive and also looses the vascular tone. Blaine et al. reported the effect of 
lack of vasopressin in a BSD animal model and demonstrated that the animal 
becomes hypernatremic and haemoconcentrated. Administration of small dose of VP 
leads to normalisation of plasma osmolality and serum sodium levels (98). Chen and 
colleagues reported the improvement in MAP in organ donors who did not manifest 
diabetes insipidus. This increase in MAP allowed weaning of catecholamines (99). 
The same observation was demonstrated by other authors and has also been shown 
to be safe and not to affect the transplanted kidney function (15;100).   
 
The large fluid shift due to post-BSD diabetes insipidus is treated with crystalloids 
solutions. This could lead to interstitial and intra-cellular oedema and deterioration of 
organ function. Pennefather and colleagues demonstrated the detrimental effect of 
crystalloids transfusion on the arterial oxygen concentration in organ donors (101).  
Use of VP infusion would avoid the need for large volumes of crystalloids infusion. 
Moreover, Post-BSD diabetes insipidus could lead to increased plasma osmolality 
and hypernatraemia, which had been shown to be associated with worse graft 
function following liver transplantation (102). Finally VP use in the management of 
post-BSD vasoplegia has been reported to be associated with reduced pulmonary 
capillary leak, lung oedema and inflammation thereby reduced lung injury (103).  
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4. ECHOCARDIOGRAPHY ON POTENTIAL HEART DONORS 
 
4.1. Transthoracic and transoesophageal echocardiography 
Brain stem death leads to hormonal, inflammatory and haemodynamic changes 
which either directly or indirectly affects the heart function. The average heart 
utilisation after consent for organ donation remains at 30 to 40% (104). This is due to 
the concerns regarding the function of hearts post-transplantation and the risk of 
primary graft dysfunction. Although the failure to use donor hearts is multifactorial, left 
ventricular dysfunction is the commonest single cause and is responsible for 
approximately 26% of the unused organs (105). Heart utilisation rates might be 
improved if techniques were able to select those borderline donor hearts that were 
previously felt to be unsuitable yet could be transplanted with a good outcome. 
Echocardiography is a non-invasive, widely available investigation that is ideally 
suited to the accurate assessment of donor heart function and could guide donor 
optimization. However, usage varies widely, partly because of the limited published 
evidence to support routine echocardiographic assessment of donor hearts. 
 
The potential of transthoracic echocardiography (TTE) as a screening tool for cardiac 
donors was first identified in 1988 (106). Despite the inherent difficulties of imaging 
ventilated subjects, TTE was successfully performed in all but one of 74 potential 
donors. Nine potential donor hearts with grossly abnormal echocardiograms were 
excluded from transplantation (8 hearts with severe left ventricular dysfunction and 1 
heart with severe mitral and tricuspid regurgitation). Of the remaining 64 studied, TTE 
was normal in 46, 9 had pericardial effusions, 5 had mild septal hypokinesis, and 4 
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had possible mitral valve prolapse without significant regurgitation. In the absence of 
TTE, 21 (29%) of these donor hearts would have been excluded on clinical criteria 
(chest trauma, prolonged hypotension, cardiac arrest and prolonged catecholamine 
use). However, transplantation was successful in each case, including those with mild 
abnormalities on TTE. Therefore, TTE screening of donor hearts is feasible. It may 
exclude donor hearts with severe cardiac dysfunction and avoid direct surgical 
inspection. Perhaps more importantly, this study raised the possibility that TTE could 
identify donor hearts that could be used successfully in transplantation despite the 
presence of other clinical factors that would previously have led to exclusion. The 
objectives of echocardiographic assessment of donor heart function are presented in 
Table 4.1. Subsequent studies have helped to define limitations to this early promise 
of standard TTE to distinguish between those donor hearts with ventricular 
dysfunction that could proceed successfully to transplantation and those that could 
not. 
 
There remain however, technical difficulties in performing standard trans-thoracic 
echocardiography (TTE) in brain stem dead (BSD) patients who are intubated and 
mechanically ventilated in the critical care environment, including lack of acoustic 
window, patient positioning, multiple instrumentation, and increased acoustic 
impedance during ventilation. A comparative study of TTE with transoesophageal 
echocardiography (TOE) suggested that TTE assessment may be incomplete in up to 
29%. The yield of abnormal studies was higher with TOE (9/24) compared with TTE 
(3/24) but the study numbers were inadequate to show a difference in outcome 
based on imaging modality (107). TOE may be preferable but a more critical factor 
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may be the availability of adequate experience in the assessment of potential donor 
hearts, particularly given the considerable changes in loading pressures to which the 
hearts are subject (108).  
 
Table 4-1- Established aims of echocardiography in the assessment of donor 
hearts 
 
a. Exclude pre-existing congenital abnormalities 
b. Exclude significant valvular dysfunction 
c. Assessment of the left ventricle: 
a. Size and global function 
b. Regional wall motion abnormalities: 
i. Catecholamine storm 
ii. Regional ischaemia 
iii. Contusion 
c. Response to inotropic and vasodilator therapy 
d. Assessment of the right ventricle: 
a. Size and global function 
b. Effects of pulmonary pressure and volume overload 
c. Response to volume therapy 
e. Detect pericardial effusion and assess haemodynamic 
significance 
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4.2. Resting abnormalities of donor heart function 
The main aim in imaging the donor heart is to select those hearts likely to succeed 
when transplanted and to exclude those that are likely to fail. Unfortunately, current 
standard echocardiographic techniques are not adequate to make this distinction 
without reference to other clinical and invasive haemodynamic markers of outcome. 
Left ventricular (LV) dysfunction is a common finding in patients with intracranial 
pathologies and BSD. In 147 patients with subarachnoid haemorrhage, global or 
regional LV dysfunction was found in 30 (20%) patients on echocardiography. 
Regional wall motion abnormalities tended to cover multiple arterial territories, often 
spares LV apex and occur in the absence of coronary artery disease (109).  
The incidence of LV dysfunction in potential pediatric donors is even higher, with 
abnormalities demonstrable on TTE in over half of the donors. This increase may be 
due to heightened sensitivity to catecholamine storm of young compared to adult 
myocardium (110). These echocardiographic abnormalities do not however 
correspond to any demonstrable pathological abnormality at post-mortem (111). 
More importantly, such abnormalities do not preclude successful transplantation. In 
one study, 9/40 hearts with severe regional wall motion abnormalities (defined as 
diffuse hypokinesis of all segments in a 6 segment model) were successfully 
transplanted with resolution of left ventricular dysfunction 15 months post 
transplantation (112). In a further study of urgent transplantation in sick paediatric 
recipients, the use of donor hearts despite the presence of LV dysfunction (defined 
as LV fractional shortening <28%, mean LV shortening fraction 24.5 ±3%) and mitral 
regurgitation did not result in an increase in 30 day mortality or inotrope requirement 
compared with normal donor hearts. In each case, LV function was normal on 
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echocardiography at 30 days post-transplantation (113). LV abnormalities on TTE 
may be caused by the catecholamine storm that occurs in BSD, a potentially 
transient phenomenon that spares the ventricular apex, (109).  
 
4.3. Limitations to resting echocardiography 
A major disadvantage of standard TTE/TEE assessment of donor ventricular function 
is that the common methods used are load dependant. The ideal index of contractility 
would be sensitive to contractile change, independent of loading conditions, non-
invasive, simple to apply and repeatable (114). The current gold standard method of 
assessment of contractile performance is end-systolic elastance (Ees), as derived 
from conductance catheter techniques (114;115). However, this method is invasive, 
requires special equipment and technical expertise to perform, and is therefore 
unlikely to be used in the routine assessment of donor heart function. A number of 
echocardiographic parameters have been proposed which may give load-
independent information on LV performance, including myocardial performance index 
of Tei (116), isovolumic acceleration on tissue Doppler imaging (117;118). As yet, 
these have not been tested in donor heart assessment and their role is not 
understood.  
 
The role of the myocardial performance (Tei) index in donor assessment has not 
been reported. The Tei index is relatively load-independent, simple to calculate and 
reproducible (116;119). Secondly, tissue doppler examination using isovolumetric 
acceleration (myocardial acceleration during isovolumetric period) (IVA) may provide 
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load-independent assessment of biventricular function (120). IVA is a sensitive index 
of left and right ventricular contractility, which is relatively resistant to physiological 
changes in loading conditions (118;121). Until recently, tissue Doppler has not been 
available on machines with sufficient portability to be used for donor heart 
assessment but this situation has now changed. Although tissue Doppler is easy to 
perform, assessment of IVA needs high frame rates to ensure adequate accuracy 
and also requires trained echocardiographer to acquire and interpret the findings 
 
It is clear that a single snap shot TTE/TEE examination alone is unlikely to provide a 
stand-alone, ‘gold standard’ decision regarding transplantability of the donor heart. 
There are a number of potential alternatives that may provide improvements. Firstly, 
response to stimulation with low dose dobutamine during stress echocardiography 
(DSE) has been studied in a small prospective study of 30 consecutive BSD patients. 
Seven donor hearts were identified with impaired LV function (fractional shortening 
(FS) <30%) and proceeded to DSE. In 3, LV function improved but there was no 
response in the remaining 4. Troponin-t levels were markedly higher in the non-
responsive group compared to the responsive patients (122). Although none of these 
hearts were used for transplantation, the inference is that DSE may identify those 
donor hearts with less myocardial necrosis that could proceed to successful 
transplantation.  The disadvantage of DSE is that this is a demanding technique and 
the skills required may not be readily available at the hours when many donor heart 
evaluations occur.  Secondly, monitoring changes in function using serial 
echocardiography may be more useful than single assessment, since these are more 
likely to detect positive responses to intensive donor management. Serial 
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echocardiography is feasible in these circumstances and detects progressive change 
in donor heart function. In a prospective study of 49 donor hearts with reduced 
ejection fraction (EF<50%) or RWMA sufficient for the organs to be initially rejected, 
prolonged donor management resulted in an improvement in EF or RWMA in 38 
(78%) donors. Serial TTE was successful in identifying this improvement, resulting in 
the successful transplantation of 34 donor hearts (104;123).  
 
In summary echocardiography is an ideally suited non-invasive investigation which 
can identify the presence of major cardiac abnormality and in addition may guide 
during donor management. However, the role of echocardiogram during protocol 
driven donor management with invasive monitoring has not been investigated in a 
prospective study.  
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5. EXTRAVASCULAR LUNG WATER INDEX MEASUREMENT IN 
POTENTIAL LUNG DONORS 
5.1. Thermodilution lung water index measurement 
Extravascular lung water (EVLW) refers to the amount of water in the pulmonary 
interstitium and alveolar spaces. This is an accurate measure of pulmonary oedema 
and it could be measured in number of ways by using double, single dye dilution 
techniques (124;125), radio-isotope labelled dye dilution techniques (126) or nuclear 
magnetic resonance imaging (127). However, these are technically difficult and 
cumbersome methods of estimating EVLW. A well validated method to derive a 
measure of EVLW is pulse-induced contour cardiac output (PiCCO), a single 
thermodilution technique based on the Stewart-Hamilton principle (128).  
PiCCO plus (Pulsion UK Ltd) derives its haemodynamic variables based on injecting 
a known volume of cold saline into SVC through a central venous line and the 
thermistor sensor placed in distal aorta via femoral artery detecting changes in 
temperature. The cold saline distributes within the thorax volumetrically and thermally 
before being detected by the thermistor in distal aorta. Using Stewart-Hamilton 
principle the cardiac output is calculated. From the thermodilution curve the mean 
transit time (MTT-half of the indicator passed detection) and downward slope time 
(DST-exponential down slope time) are calculated (Figure-5.1).  
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Figure 5-1- Estimation of cardiac output using Stewart-Hamilton principle 
 
By multiplying the mean transit time with the cardiac output the entire intra-thoracic 
thermal volume (ITTV) is calculated and downward slope time with cardiac output the 
pulmonary thermal volume (PTV) is measured (Figure-5.2). By subtracting PTV from 
ITTV the volume of blood in all 4 chambers of the heart is calculated. This is called 
the global end-diastolic volume (GEDV) (Figure-5.3) 
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Figure 5-2- Estimation of ITTV and PTV using thermodilution curve 
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Figure 5-3- Estimation of GEDV from ITTV 
52 
 
By multiplying GEDV with a constant value of 1.25, intrathoracic blood volume is 
calculated (ITBV). This consists of blood volume in all 4 chambers of the heart and 
blood volume in the pulmonary circulation excluding the water content in pulmonary 
interstitium. Sakka et al reported the ITBV calculated by single thermodilution 
correlated well with GEDV calculated using double dye dilution technique in 57 
critically ill patients (129). Extravascular lung water is calculated by subtracting ITBV 
from ITTV (Figure-5.4).  
PiCCO_highLevel_V05_04_02_eng.ppt
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Figure 5-4- Estimation of various blood volumes and EVLW using PiCCO plus 
method 
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Extravascular lung water measured by single thermodilution technique has been 
shown to correlate well with double dye dilution technique in critically ill patients 
(129).  
5.2. Validation of thermodilution lung water measurement by gravimetry 
 
The thermodilution EVLW (EVLW-T) has been validated against the gold standard 
gravimetric lung water measurement (EVLW-G). The EVLW-T correlated well with 
EVLW-G in both animal and human studies (130-133) (Figure-5.5).  
PiCCO_highLevel_V05_04_02_eng.ppt
Sturm, In: Practical Applications of Fiberoptics in Critical Care Monitoring, 
Springer Verlag Berlin - Heidelberg - NewYork 1990, pp 129-139
Validation of EVLW (I)
EVLW by indicator dilution compared to gravimetric EVLW measurement 
in brain-dead humans
 
 
Figure 5-5-Validation of EVLW-T with EVLW-G 
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Early data, using a thermal dye double indicator dilution technique in humans 
following BSD suggested that although such techniques over-estimated EVLWI-G, 
they provided a reliable index of lung water content and could be of clinical utility 
(132).  
5.3. Clinical uses of lung water index measurement 
Thermodilution measurement is well validated, simple, reliable and easily available at 
the bedside which gives direct quantification of EVLW. Higher EVLW has been 
shown to negatively correlate with arterial oxygenation (124) and increased mortality. 
In clinical studies higher EVLW was associated with worse outcome, prolonged 
intensive care unit stay and is an independent predictor of  outcome (134;135). 
Mitchell et al managed 101 patients with pulmonary oedema randomised either to 
receive pulmonary artery catheter or indicator dilution measured EVLW. The patients 
fluid management was guided either by wedge pressure measured by PA catheter or 
EVLW. Patients managed with EVLW guided fluid management required significantly 
less number of days of ventilation and their intensive care unit stay was also 
significantly low (136) (Figure-5.6).   
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Figure 5-6- Demonstrates significantly less duration of ventilation and ICU stay 
for patients managed using EVLW measurement 
 
The role of EVLW measurement in a potential lung donor has not been evaluated in 
a prospective study. A properly conducted prospective trial evaluating EVLW with 
protocol driven donor management and its validation by gravimetry will clarify its role 
in managing a potential lung donor. 
56 
 
6. SUMMARY AND OBJECTIVES 
Protocol guided donor management using invasive monitoring is an essential part of 
successful transplantation. The basic principles are simple but require trained 
personnel and equipments to carry out the management. From the available 
evidences we can summarise that there is acute T3
 
deficiency after BSD in most of 
the donors and administration of T3
 
lead to a normal levels in the serum.  However 
there is no evidence to show the association between T3
 
deficiency and myocardial 
dysfunction that follows brain death and also its reversal on T3
 
administration.  
 
The anti-inflammatory properties of steroids are well established, however, its role in 
multi-organ donors needs to be investigated. The role of vasopressin use in treating 
post-BSD vasoplegia and diabetes insipidus is well established. A properly designed 
prospective randomised controlled (blinded) trial using T3 and methylprednisolone 
will clarify the role of routine use of these hormones in resuscitating multi-organ 
donors.  
 
Echocardiography has a significant role to play in donor heart assessment. However, 
with current practice over two thirds of donor hearts are still rejected for 
transplantation. Organ retrieval is costly and labour intensive, and donor heart 
malfunction is the commonest cause for aborted retrieval. Such abortive attempts 
may be reduced by a detailed echocardiographic examination. Studies combining 
echocardiography along with haemodynamic monitoring and protocol driven donor 
management would be required to evaluate the potential role of echocardiography in 
donor assessment.  
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OBJECTIVES 
 
The objectives of this study were following 
1. To evaluate the role of early donor management on donor heart and lung function 
and their retrieval rate for transplantation 
2. To evaluate the role of early hormone replacement therapy with T3 and 
methylprednisolone in a prospective randomised double blind placebo controlled 
trial 
3. To study the effect of hormone replacement therapy on donor heart and lung 
function 
4. To study the effect of hormone replacement therapy on heart and lung retrieval 
rate 
5. To study the role of serial transthoracic echocardiography to assess donor heart 
function during protocol guided donor management in the background of hormone 
replacement therapy 
6. To study the prevalence of post-BSD inflammatory environment, their effect on 
donor heart and lung function and the impact of donor management and hormone 
replacement therapy 
7. To study the prevalence of donor cardiac troponin-I release following BSD and its 
impact on donor heart function 
8.  To study the role of extravascular lung water index measurement using single 
thermodilution technique in evaluating donor lung function 
9. To validate the thermodilution lung water index measurement using gravimetry 
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SECTION 2- METHODS 
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7. CORE METHODOLOGY 
7.1. Introduction 
This study was a prospective, randomized, double blind, factorially designed, placebo 
controlled trial investigating the effect of tri-iodothyronine (T3), methylprednisolone 
(MP) and combination of both T3 and MP in brain stem dead (BSD) potential heart 
and lung donors between January 2004 and April 2006. A diagram of study flow is 
shown in figure 7.1 
BSD confirmation 
 
Consent for organ donation and study 
 
Randomisation 
Research Fellow attendance  
Invasive monitoring lines    protocol driven donor management 
Transthoracic echocardiography   Randomised drug treatment 
Bronchoscopy      
Prospective data collection   
Continued donor management in operating theatre 
  
Assessment of transplant suitability of hearts and lung 
 
Organ retrieval as per protocol 
Figure 7-1-Donor pathway through the study
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7.2. Recruitment 
7.2.1. Patient selection 
All brain stem death confirmed potential multi-organ donors were considered 
recruitment into this study. Following confirmation of brain stem death and consent 
for organ donation the next-of-kin of all suitable donors were approached for lack of 
objection for the study. The donor procurement co-ordinators informed the donors’ 
family regarding the study and a patient information sheet was made available to 
them. Having counselled them and given time to read and discuss about the study, a 
lack of objection was obtained from the donors’ next-of-kin. A separate consent was 
obtained for myocardial biopsy and retrieval of lungs not used for transplantation for 
laboratory research. The study inclusion and exclusion criteria are detailed in Table 
7.1.  
 
Table 7-1-Study inclusion and exclusion criteria 
 
Inclusion criteria      Exclusion criteria 
 
Age >16, <65 years     <16 and >65 years 
Arterial PaO2 >230 mm of Hg   Blunt/penetrating chest trauma 
No evidence of pneumonia    Radiologically confirmed pneumonia 
       History of ischaemic heart disease 
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7.2.2. Ethical approval 
Initially the study was commenced with local research ethics committee approval 
from Birmingham Black Country ethical committee, however to increase the study 
recruitment a multicenter research ethics committee (MREC) approval with no local 
investigator category was obtained. Following this separate approval and permission 
was obtained from the Research & Development department of each hospital 
included in the trial. Some of the hospitals required me to obtain an honorary contract 
to implement the donor management in their intensive care units. We recruited 33 
intensive care units within 100 mile radius of Birmingham heart and lung transplant 
unit within the retrieval zone.    
We also obtained permission from the zonal liver, renal transplant teams and the 
study was supported by the intensive care units within the zone.    
7.3. Randomisation 
 
The donors were randomised according to a computer generated sequence 
allocating to one of 4 treatment groups, T3, placebo, MP and T3 & MP combination. 
Randomisation took place in blocks of 4 (1:1:1:1) without any stratification. All staffs 
involved in organ retrieval and implantation were blinded to the treatment allocation 
by a central randomisation process in which a pre-coded opaque sealed envelope 
containing the notes indicating assignment of a donor to a particular treatment group 
was placed in the theatre office. The donor procurement co-ordinator contacted me 
once a donor was identified and consent for organ donation and study was available. 
The donor’s body weight was informed to the on call operating department 
practitioner (ODP) who was not involved in the trial, was able to pick up the coded 
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envelope from the office. The trial solutions were then prepared as per the nomogram 
by the sister in-charge of the critical care unit and the treatment allocation document 
was signed and counter signed and was placed back in the envelope which was 
returned back to the office. 
7.4. Treatment groups 
7.4.1. Group-1 T3 therapy 
Group-1 received 5% dextrose 20mls as an intravenous bolus (syringe labelled as 
trial drug-B) and T3 (Goldshield pharmaceuticals, UK) 0.8µg.kg-1 IV bolus (made up 
to a volume of 20mls with 5% dextrose, syringe labelled as trial drug-A bolus) 
followed by 0.113µg.kg-1.hr-1 IV infusion (made up to a volume of 60mls using 5% 
dextrose, syringe labelled as trial drug-A infusion, run at 10mls.hr-1). 
7.4.2. Group-2 Placebo therapy 
Group-2 received intravenous bolus of 20mls of 5% dextrose (syringe labelled as trial 
drug-B) and further bolus of 20mls of 5% dextrose (syringe labelled as trial drug-A 
bolus) followed by an intravenous infusion of 5% dextrose at 10mls.hr-1 (syringe 
labelled as trial drug-A infusion). 
7.4.3. Group-3 MP therapy 
Group-3 received 1000mg of methylprednisolone made up to a volume of 20mls 
using 5% dextrose as an intravenous bolus (syringe labelled as trial drug-B) and 
further bolus of 20mls of 5% dextrose (syringe labelled as trial drug-A bolus) followed 
by an intravenous infusion of 5% dextrose at 10mls.hr-1 (syringe labelled as trial drug-
A infusion). 
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7.4.4. Group-4 T3 and MP therapy 
Group-4 received 1000mg of methylprednisolone made up to a volume of 20mls 
using 5% dextrose as an intravenous bolus (syringe labelled as trial drug-B) and T3 
(Goldshield pharmaceuticals, UK) 0.8µg.kg-1 IV bolus (made up to a volume of 20mls 
with 5% dextrose, syringe labelled as trial drug-A bolus) followed by 0.113µg.kg-1.hr-1 
IV infusion (made up to a volume of 60mls using 5% dextrose, syringe labelled as 
trial drug-A infusion, run at 10mls.hr-1). 
7.4.5. Blinding of trial solutions 
To ensure blinding of all personnel involved in organ retrieval the syringes containing 
trial drugs were labelled as ‘Trial Drug-A bolus’ (for T3 iv bolus), ‘Trial drug-A 
infusion’ (for T3 iv infusion) and ‘Trial drug-B’ (for MP iv bolus). The drugs were 
prepared by the sister in-charge of cardiothoracic critical care unit as per the weight 
based nomogram and labelled accordingly.  
 
7.5. Preparation to leave to the donor intensive care units 
 
The donor co-ordinators contacted me regarding the availability of the donor once the 
consent for organ donation and research study was available. I then prepared a 
sterile central line insertion kit along with the pulmonary artery flotation catheter 
(PAFC) sheath and a PAFC - VoLEF catheter (Pulsion Medical UK Ltd) and femoral 
arterial thermodilution catheter (PiCCO, Pulsion Medical UK Ltd). The invasive 
monitoring insertion kit along with the monitors and cables were packed. A 
transthoracic echocardiography (Acuson Cypress, Siemens, USA) portable machine 
and a sterile fibreoptic bronchoscope with light source were also packed. An ice box 
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with all the trial drugs and empty vials to collect the serum sample was prepared and 
finally a cryoflask with liquid nitrogen to snap freeze the left ventricular tru-cut biopsy 
was also packed. All the equipments were carried by me and I drove to the hospital 
to attend the donor as soon as possible following the consent for the study.  
7.6. Donor Management 
 
7.6.1. Insertion of invasive monitoring lines 
Upon arrival to the intensive care unit the donor co-ordinator introduced me to the 
nursing staff looking after the donor. I checked the donor’s case notes for relevant 
history and confirmation of BSD testing and checked the identity of the donor. After 
checking the consent for organ donation and for study the invasive lines were 
inserted. Under aseptic precautions PiCCO thermodilution catheter was inserted in 
the femoral artery. Right femoral artery was preferred if it was unavailable then left 
femoral artery was used. Following that, a PAFC sheath was inserted through the 
right internal jugular vein. If the donor did not have a jugular central line, a quadruple 
lumen central line was also inserted at the same time. A VoLEF pulmonary artery 
catheter was then floated. The monitor was set up and demographic parameters 
were entered. Then baseline haemodynamic parameters were obtained (central 
venous (CVP), mean arterial pressure(MAP), pulmonary capillary wedge pressures 
(PCWP), cardiac index (CI), right and left ventricular stroke work index (RVSWI, 
LVSWI), right ventricular ejection fraction (RVEF), cardiac power output, systemic 
vascular resistance(SVR), extravascular lung water index (EVLWI) (normal 3-8ml.kg-
1), pulmonary vascular permeability index (PVPI) and pulmonary vascular 
resistance(PVR)). 
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7.6.2. Bronchoscopic examination of airways.  
Bronchoscopy was performed to assess anatomy and endotracheal tube placement, 
to aspirate secretions, to detect evidence of active bronchitis or aspiration and to 
obtain a broncho-alveolar lavage (BAL) specimen for culture. The donor FiO2 was 
increased to 100% oxygen with positive end expiratory pressure (PEEP) of 5 cm of 
H2O. After examination of airways and clearing all secretions the bronchoscope was 
wedged into middle lobe bronchus and 20mls of normal saline was used to obtain a 
BAL specimen. The same procedure was repeated on the left side after end 
management prior to retrieval to obtain further BAL specimen. After completion of 
bronchoscopic examination the FiO2 was reduced to maintain arterial oxygen 
concentration of 80mm of Hg and CO2 concentration of 35-55 mm of Hg.  
 
7.6.3. Transthoracic echocardiography  
 
After bronchoscopic examination using Acuson Cypress (Siemens, USA) portable 
machine with second harmonic imaging (3.6 MHz probe) a transthoracic 
echocardiography was performed. The aim was to obtain adequate echo windows to 
interpret left ventricular function (LV). Using M-Mode measurement LV wall thickness 
was calculated. Using standard transthoracic views the LV ejection fraction was 
calculated using fractional shortening formula and LV biplane Simpson’s formula. 
Using 2D-colour doppler any significant valve pathology was excluded. All 
parameters were measured in triplicate and averaged. The left and right myocardial 
performance indices were calculated using standard formulae as described by Tei et 
al. The index was calculated by measuring the mitral closure-to-opening interval at 
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the mitral inflow (a) and ejection time at the LV outflow (b). The sum of isovolumetric 
contraction time (IVCT) and isovolumetric relaxation time (IVRT) was calculated by 
subtracting ‘b’ from ‘a’. The Tei index is calculated by using the formula 
IVCT+IVRT/ejection time (a-b/b). The echocardiographic findings were unavailable to 
recipient centres. Echocardiography was performed by me and I was trained to 
obtain the images only. The accrued images were stored on optical disc and 
analyzed off-line, after removal of patient identifiers and random coding of 
examination timing, by two independent observers blinded to group allocation and 
time order using Cypress viewer software.  
 
7.6.4. Administration of randomised drugs 
 
After obtaining baseline haemodynamic parameters, bronchoscopy and 
echocardiography the trial drugs were administered. The trial drug-A & B bolus was 
given followed by the infusion of Trial drug-A intravenously at 10mls.hr-1. Following 
which the donors were managed according to a strict protocol.  
 
7.6.5. Haemodynamic management 
 
Haemodynamic management directed by the PAFC finding was initiated after 
administration of trial drugs. The main aim is to achieve where possible a CI 
>2.5L.min-1m-2 with CVP and PCWP ≤12mmHg, MAP 70mmHg and SVR 800-1200 
dynes.cm.sec-5. In donors with low pre-load volume replacement was commenced 
using preferably colloids solutions provided the serum sodium level was <160 
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mmol.L-1. Crystalloids were not used for volume replacement unless in donors with 
high serum sodium levels. Vasopressin was commenced in all donors (pitressin 20 
units in 40mls of 5% dextrose) with 1 unit bolus and was started on infusion of 2 units 
per hour. This allowed active weaning of noradrenaline (NA) in all donors (Fig-7.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haemodynamic targets 
Mean arterial pressure  70 mmHg 
Central venous pressure  < 12mmHg 
PAW pressure   <12mmHg 
Cardiac Index   2.5 L.min-1.m-2 
 
Figure 7-2-Managing an organ donor with MAP > 70 mm Hg 
 
MAP> 70 mm Hg 
Accept MAP of 70 mm Hg 
Restrict crystalloids 
Use colloids PRN 
Start vasopressin infusion 
 Reduces fluid shift 
 Reduces urine output 
 Maintains stability 
Wean noradrenaline 
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In donors with high pre-load venesection was commenced using the side arm port of 
PAFC sheath. The blood was collected in a citrated blood bag and was used to make 
up the lung preservative solution (Papworth solution). Donors with adequate CVP 
with low blood pressure due to low cardiac index were treated with inotropes. 
Dopamine was the first line of choice started at 5 µg.kg-1.min-2 (Fig-7.3).  
 
Donor- MAP < 70 mm Hg
Insert PAFC
Check CVP
& PAWP
CVP & PAWP<12 CVP & PAWP >12
Increase Pre-load
Check Serum Na
Na >160 mmol/LNA <160 mmol/L
Use Colloids
Crystalloids
Use 5%-DW
(BM 6-8)
Normal Pre-load
Stop all infusions
-Venesection
Check CI & SVR
Low SVR
Vasopressin
infusion
High SVR
LOW CI
Inotropes
 
 
Figure 7-3- Flow diagram demonstrating management of a hypotensive donor 
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7.6.6. Lung management 
At initial assessment all donors underwent arterial blood gas ABG (mmHg) 
measurement (Fractional inspired oxygen (FiO2) 1.0), positive end-expiratory 
pressure (PEEP) 5cmH2O).  Following baseline ABG and bronchoscopy the FiO2 was 
reduced to maintain PaO2 of >80 mm of Hg. The donor was turned in the bed every 2 
hours and active oral and endotracheal tube suctioning was performed every 2 
hours. Hourly ABG was performed. 
 
7.6.7. Bio-chemical management 
 
During donor management the homeostasis was maintained by keeping normal body 
temperature with the use of warming blankets. Serum potassium (4.5-5.5 mmol.L-1 
and blood glucose (4-6 mmol.L-1) levels were maintained within normal limits. Donors 
with high blood glucose were started on actrapid insulin on a sliding scale to 
normalise the levels.     Haemoglobin was maintained at 10 g.dl-1. 
 
7.7. Intra-Operative assessment of heart and lung function 
 
Donor management was continued in the operating theatre as per the above 
protocol. Following dissection of abdominal organs a median sternotomy was 
performed using handheld saw. After achieving haemostasis the pericardium was 
opened and stay sutures were placed on the pericardial edges. Both pleurae were 
opened widely to assess the lungs for any gross abnormalities. Any collapsed lung 
segments were actively recruited by bagging with 100%oxygen. The heart was 
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assessed for contractility, RV function, hypo/ akinetic segments and any palpable 
coronary artery disease.   The donor was put on 100% FiO2 with PEEP of 5 cm of 
H2O. Arterial blood gas and selective pulmonary venous blood gas sampling were 
performed after 15 minutes of recruitment of collapsed segments. The operative 
findings and blood gas results were conveyed to the recipient centres if the organs 
were accepted for transplantation. If the heart and lungs were suitable for 
transplantation they were retrieved as per the standard procedure.  
 
7.8. Myocardial biopsy technique and retrieval of lungs for gravimetry 
 
Myocardial biopsy was performed immediately prior to the application of cross clamp 
only in donors where the consent was available. Biopsies were full thickness and 
taken from the left ventricular (LV) free wall. LV biopsies were obtained using a 
Trucut biopsy needle (Allegiance Healthcare, McGaw Park, II). Biopsies were 
immediately frozen in liquid nitrogen and stored at -80ºC. The recipient centers were 
informed about the biopsy and the site was used for de-airing the heart after 
implantation. 
Donor lungs accepted for transplantation were flush perfused with single dose of 
antergrade pneumoplegia (Papworth solution- ringer lactate 700mls, human albumin 
(20%) 200mls, 20% mannitol 100mls and heparin 10,000 units along with donor 
blood (300ml), citrate/phosphate/dextrose chelating agent (56mL)) and a single dose 
of epoprostenol (prostacycline) infusion (0.5 mg in 20mls (Flolan, (GlaxoSmithKline, 
UK Ltd)). Donor lungs were retrieved for gravimetric lung water assessment without 
pneumoplegia or prostacycline infusion. Donor lungs were retrieved as a whole block 
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after explanting the donor heart. The trachea was stapled after expansion of both 
lungs. The retrieved lung blocks were transported in cold ringer lactate solution in 3 
plastic bags in 4oC. Donor lungs accepted for transplantation were used in a number 
of UK centres.  
 
7.9. Statistical analysis 
7.9.1. Study design 
This is a randomised double blind factorially designed controlled study of the effects 
of T3 and methylprednisolone (alone or in combination) and an observational study 
to assess the impact of early donor management. 
7.9.2. Hypothesis 
a. The use of T3 in potential heart donors will increase the cardiac index by 0.7 L.min-
1
.m-2.  
b. Early donor management will increase the retrieval rate of both hearts and lungs 
for transplantation. 
7.9.3. Power calculations 
The hypothesis was derived from the previously conducted trial in our institute using 
T3 and glucose insulin potassium solution in coronary artery bypass surgery patients. 
The power calculation was also estimated after analysing data from a pilot study on 
10 donors. The data was analysed without breaking the randomisation code. We 
noted an increase in cardiac index in all donors from baseline to retrieval. Therefore 
we hypothesised that T3 will increase in cardiac index by 0.7 L.min-1.m-2.   
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To detect an increase in cardiac index of 0.7 L.min-1.m-2 between groups at end-
assessment, using a 2×2 factorial design, would require 19 donors in each cell with 
an α of 0.05 and 1-β 0.85. This would lead to 38 donors receiving early T3 and we 
assumed no interaction between T3 and MP. The study was also powered to detect 
an increase in retrieval rate of both hearts and lungs for transplantation by 20% from 
the non-research contemporary cohort of donors. 
7.9.4. Primary outcome measures 
The primary endpoint of the study was the difference in CI between groups at end-
assessment. For a standardized difference of 0.7, using a 2 × 2 factorial design, 19 
donors in each cell were required (α 5%; 1- β 0.85) (i.e. 38 would receive early T3) 
and assumed no interaction between treatments. 
7.9.5. Secondary outcome measures 
Planned statistical analyses were performed for the following secondary outcomes:  
Heart donors: Right and left ventricular stroke work index, cardiac power output, 
systemic vascular resistance, the effect of donor thyroid status on donor heart 
function, impact of donor management on the heart retrieval rate, the effect of donor 
management and noradrenaline (NA) withdrawal on marginal hearts, bio-chemical 
markers in evaluating suitable donor hearts for transplantation and the role of 
cytokines in evaluating donor heart function. 
On lung donors: The effect of T3 and MP administration on lung donors, the impact of 
NA administration on donor lung function, impact of donor management on lung 
retrieval rate, the role of extra-vascular lung water index (EVLWI) measurement in 
potential lung donors, the validation of EVLWI measured by thermodilution with 
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gravimetric lung water measurement and the role of cytokine measurement in 
evaluating donor lung function. 
7.9.6. Data collection and storage 
All data were prospectively collected and stored on a pre designed data sheet. Once 
data acquisition was complete for a patient the data were entered onto a Microsoft 
Access database. Following interrogation of the database, data for analysis were 
electronically transferred to a Microsoft Excel spreadsheet and automatically 
transferred into a statistical package, SPSS version 15.0 software (Chicago, Il) prior 
to performing statistical analysis. 
7.9.7. Data analysis 
Continuous data were assessed for normality and are presented as mean±SD or 
median [25, 75 centiles]. Normally distributed variables were tested using two-way 
ANOVA that included factors for the two treatments given and also their interaction. 
The post-treatment variables were tested using ANCOVA using the pre-treatment 
value as a covariate along with the two treatments given and their interaction. The 
impact of donor management was analysed on the entire cohort of patients using the 
paired sample t-test. Skewed data were tested using non-parametric tests (Mann– 
Whitney and Kruskal–Wallis test). Categorical data were analysed using x2 and 
Fisher’s exact tests. Serial measurements were compared with repeated measures 
ANOVA. Univariate and multivariate analysis (stepwise logistic regression) was used 
to identify factors that predicted suitability for transplantation at end-assessment. 
Receiver operating curves (ROC), sensitivity, specificity and predictive values of 
parameters for heart usability were generated using standard formulae. Kaplan-Meier 
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survival analysis was performed to calculate the recipient outcome and log rank test 
was used to compare the outcome between groups. Statistical significance was 
assigned when P < 0.05 and all tests were two-sided. Further grouping and statistical 
presentation has been described in individual chapters. 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
 
SECTION 3- RESULTS 
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8. A STUDY OF THE HAEMODYNAMIC EFFECTS OF 
ADJUNCTIVE HORMONE THERAPY IN POTENTIAL HEART 
DONORS 
 
8.1- Introduction 
Following brain stem death (BSD), there is commonly a decline in circulating cortisol, 
insulin and thyroxine (T4) (74). Tri-iodothyronine (T3)
 
may also be reduced, 
sometimes with normal T4, low thyroid stimulating hormone (TSH) and elevated 
reverse T3 constituting a “sick euthyroid” syndrome (32;33;35;75). These phenomena 
led to the use of hormonal replacement therapy (HRT) in potential heart donors. 
Retrospective studies suggest that HRT comprising steroid, thyroid hormone and 
vasopressin, enhances retrieval rate with improved post-transplant function (80;81). 
However, while the control of post-BSD vasoparesis using vasopressin (VP) is well 
established (137), the role of T3 and steroids is less clear. Some studies report a 
hemodynamic improvement following T3 administration, while others, suggest T3
 
to 
be either of no benefit or detrimental (83;85-87). Steroids which have a membrane 
stabilising effect and inhibit the elaboration of cytokines (89) may be beneficial in the 
pro-inflammatory post-BSD environment, particularly in lung transplantation (96) but 
an effect on haemodynamic function has not been examined. I therefore investigated 
the individual or combined effects of MP and T3 on donor heart function in potential 
donors in a randomised double blind factorially designed trial.  
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8.2-Methods 
8.2.1-Study design 
In the UK, transplant centres are responsible for heart retrieval within a specified 
zone. Between, January-2004 and April-2006, the next-of-kin of eligible potential 
heart donors in an intensive care unit (ICU) within 2 hours road distance of our 
recipient centre were approached for consent to enter the donor into a prospective, 
double-blind, placebo-controlled, factorially designed randomised trial. The research 
was supported by 33 accessible ICUs and approved by a multi-centre research ethics 
committee, all UK cardiothoracic transplant centres and all zonal liver and kidney 
retrieval teams. The trial was conducted independently of whether donor hearts were 
provisionally accepted for transplantation by any centre. Hearts that were not 
provisionally accepted were not re-offered following management. Consent was 
obtained from the next-of-kin for all participating donors according to the ethical 
approval. 
8.2.2-Initial assessment and management 
As soon as possible following consent to both donation and the study, I attended 
donors, drew blood for thyroid function assessment and inserted a pulmonary artery 
flotation catheter (PAFC - VoLEF catheter-Pulsion Medical UK Ltd) and femoral 
arterial thermodilution catheter (PiCCO, Pulsion Medical UK Ltd). Following 
measurement of central venous (CVP), mean arterial pressure(MAP), pulmonary 
capillary wedge pressures (PCWP), cardiac index (CI), right and left ventricular 
stroke work index (RVSWI, LVSWI), right ventricular ejection fraction (RVEF), cardiac 
power output, systemic vascular resistance(SVR), the study medication was 
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administered. Donors were randomly assigned to receive T3 (0.8µg.kg-1 IV bolus 
followed by 0.113µg.kg-1. hr-1 IV infusion); MP (1000mg as a single IV bolus), both 
drugs or placebo (dextrose 5%) on 1:1:1:1 basis using a computerised model with 
permuted blocks and a sealed envelope system.  The T3 dose was based on reports 
of positive hemodynamic effect following cardiac surgery (138;139). The T3 or 
placebo infusion continued until retrieval. The MP dose was an empirical 
immunosuppressive dose, approximating 15mg.kg-1 for a 70kg donor. The drugs 
were pre-prepared in identical volumes in code-labelled syringes by uninvolved 
recipient centre staff according to a weight-based nomogram. All medical, nursing 
and technical staff involved in the research or donor care remained blinded to 
treatment allocation until analysis. PAFC-directed haemodynamic management then 
commenced according to specific algorithms to achieve where possible a CI 
>2.5L.min-1m-2 with CVP and PCWP ≤12mmHg, MAP 65-85mmHg and SVR 800-
1200 dynes.cm.sec-5 (64). Volume adjustment was restricted to limited blood or 
colloid transfusion to achieve a haemoglobin ≥10g.dL-1 and to maintain filling 
pressures. Any pre-study inotrope and noradrenaline (NA) were weaned and VP 
administered to modulate SVR. Blood sugars were maintained between 4.4-
6.1µmol.L-1 using IV insulin and hypothermia prevented by standard measures. 
Management, continued in the ICU and operating room until retrieval or end-
assessment. The duration of treatment and time of coning (detection of fixed dilated 
pupils and blood pressure surge) were noted. Haemodynamic studies were repeated 
hourly for 3 hours and immediately pre-retrieval. Prior to retrieval repeat blood 
samples were drawn for thyroid function. No donors underwent angiography. Trans-
thoracic echocardiograms were performed but were analysed off-line and were not 
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available at initial assessment. Thus, assessment of left ventricular hypertrophy 
(LVH) and palpable coronary artery disease (CAD) did not occur until after the final 
functional measurements. Recipient 30-day and 1 year survival (100% follow-up) 
were provided by transplant centres. 
8.2.3-Endpoints and statistics 
The primary endpoint of the study was the difference in cardiac index between 
groups at end-assessment. For a standardised difference of 0.7, using a 2x2 factorial 
design, 19 donors in each cell were required (α 5%; 1-β 0.85) (i.e. 38 would receive 
early T3) and assumed no interaction between treatments. Secondary endpoints 
included comparisons of RVSWI and LVSWI and CPO. Post-hoc analyses allowed 
assessment of the response of marginal donor hearts to management, the effects of 
NE withdrawal on donor circulatory function and the impact of initial thyroid functional 
status. Hearts were classified as marginal if the MAP was <70 mm Hg with CVP or 
PCWP >14 mm Hg and CI < 2.4 L.min-1.m-2 at initial assessment or on inotropes 
(dopamine > 5 µg.kg-1.min-2 or adrenaline >0.03 µg.kg-1.min-2) or NA >0.06 µg.Kg-
1
.min-2) (63). When establishing the number of hearts functionally suitable for 
transplantation we set the following criteria; CVP ≤ 12 mm Hg, PCWP ≤ 14 mm Hg, 
CI ≥ 2.5 l.min-1.m-2  on minimal support without gross LVH or palpable CAD on direct 
inspection.  
 
Data were analyzed using SPSS v15.0 (Chicago, IL). Continuous data were 
assessed for normality and are presented as mean ± SD or median (inter-quartile 
range (IQR)). Normally distributed variables were tested using two-way ANOVA that 
included factors for the two treatments given and also their interaction. The post-
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treatment variables were tested using ANCOVA using the pre-treatment value as a 
covariate along with the two treatments given and their interaction. The interaction 
between treatments was not significant and so the p values for the main effects are 
reported for the model without interaction. The impact of donor management was 
analysed on the entire cohort of patients using the paired sample t test.  Skewed data 
were tested using non-parametric tests (Mann-Whitney and Kruskal-Wallis test). 
Categorical data were analyzed using Χ2 and Fisher’s Exact tests. Serial 
measurements of cardiac indices were compared with repeated measures ANOVA.  
 
On the basis of statistical advice received, I included a within subjects factor with 5 
levels for the five repeated measurements of cardiac index (primary outcome 
measure of the study) and the two treatments were entered as between subjects 
factors. I used a full factorial model with type III partitioning of the sums of squares 
and the p values quoted are those obtained after applying the Huynh-Feldt 
correction. The interaction of the within subjects factor and each treatment was used 
to assess whether the treatment had any effect on change in cardiac index.  No 
interaction between treatments was identified and the p values for the main effects 
are reported for the model without interaction.  Statistical significance was assigned 
when p≤0.05 and all tests were two sided. 
8.3-Results  
During the period of recruitment, of 250 zonal donors, 116 were eligible for study. 
Consent was withheld in 36 giving a sample size of 80 (Figure-8.1).  
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Total number of 
donors approached 
(116)
Trial donors
(randomised)
(80)  
No consent to 
study 
(36)
T3 
(20)
Placebo 
(21)
MP 
(19)
T3 and MP 
(20)
Total number of 
zonal donors during 
study period 
(250)
Excluded from study 
(according to exclusion 
criteria (134))
Age (<16, >65)-22
Chest Trauma-2
Myocardial infarction-2
Distance >100 miles-29
Donors within 24 hour period-32
Non-unit participation-47
 
Figure 8-1-CONSORT diagram demonstrating enrolment, exclusion, 
randomisation and number of hearts transplanted 
The donor characteristics of both trial (80) and the non-trial donors (134) are 
presented in Table-8.1.  
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Table 8-1- Characteristics of Trial and non-Trial donors  
 
Parameter   Trial donor (n=80) Non-Trial donor (n=134) p-value 
 
Age      43(36, 55)  44(37, 54)   =0.7 
Donor Cause of death 
Vascular & Tumour   51/80 (64%)  86/134 (64%)   =1 
Traumatic   19/80 (24%)  31/134 (23%)   =1 
Hypoxic   5/80 (6%)  12/134 (9%)   =0.61 
CNS infection   5/80 (6%)  5/134 (4%)   =0.51 
Provisional acceptance 35/80 (44%)  73/134 (54%)   =0.16 
Heart-yield   25/80 (31%)  41/134(31%)   =1 
 
Age is presented as median (25th, 75th centiles) 
CNS- central nervous system 
 
Trial donor demographics (n=80) 
Gender     38 female (48%) 
BMI      25.55±4.67 
Ethnicity     74-Caucasian, 4-Asian and 2-Black-British 
Hypertension     11 donors (14%) 
Diabetes    1 (1.25%) 
Smoking (current)    32 donors (40%) 
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The median age was 43 (IQR 36, 55), 52% were male and 11(14%), 1(1.25%) and 
32(40%) respectively had a history of hypertension, diabetes or smoking. BSD was 
caused by trauma in 19/80(24%), vascular event or tumour in 51/80(64%) and 
hypoxia or infection in 10/80(13%).  
 
Assessment commenced within a median of 2 (IQR 0.5-3.5) hours of consent, within 
12.7±8.3 hours of coning and 6.9±1.3 hours prior to retrieval or end-assessment. 
Study medication was administered for 5.9±1.3 hours prior to retrieval or end-
assessment; the T3 or placebo infusion being continued until OR inspection. 
Between initial and final measurements, donors received 346±344ml of colloid raising 
CVP and PCWP significantly (Table-8.2). In the study population overall, CI, CPO, 
RVSWI and LVSWI all increased (p<0.001) while SVR fell (Table-8.2).   
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Table 8-2-Hemodynamic parameters for the entire Trial cohort  
 
Parameters  Baseline value  Pre-retrieval value  p-value 
 
CVP   8.6 ±4 (7.8-9.6)  11±3.7 (10-11.9)  <0.001 
PCWP  9.4±4.4 (8.4-10.4)  12.6 ±4.1 (11.7-13.6) <0.001 
CI   3.2±1 (2.9-3.5)  3.9 ±1.2 (3.6-4.1)  <0.001 
RVEF   25.6±7.5 (23.8-27.3) 26.5±7.4 (24.8-28.3) =0.09 
LVSWI  40.6±14.5 (37.3-43.9) 46 ±17.8 (41.6-49.7) =0.007 
RVSWI  4.9±3 (4.3-5.6)  7.5 ±4.1 (6.6-8.4)  <0.001 
CPO   1.2±0.5 (1.1-1.3)  1.5 ±0.6 (1.4-1.6)  <0.001 
SVR   1213±506 (1100-1325) 1082±650 (937-1226) =0.001
    
CVP- Central venous pressure, PCWP- Pulmonary capillary wedge pressure, 
CI-cardiac index, RVEF- Right ventricular ejection fraction, LV/RVSWI- Left and 
right ventricular stroke work index, CPO- Cardiac power output, SVR Systemic 
vascular resistance. 
 
Units: CVP and PCWP- mmHg, CI- L.min-1m-2, RVEF- %, LVSWI and RVSWI- g-
m.m-2.beat-1, CPO- Watts, SVR- dyne.cm.sec-5.  
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8.3.1-Donor heart function within the 4 treatment groups of the Trial  
Demographic details, donor heart function and suitability for transplantation for the 4 
treatment groups are summarized in Table 8.3. The administration of T3 and MP 
alone or in combination did not affect CI (Figure-8.2) or any other parameter when 
compared to placebo.  
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Table 8-3-Donor characteristics in the 4 Trial treatment groups  
Parameters T3  
(20) 
MP  
(19) 
T3+MP 
(20) 
Placebo 
(21) 
p-value 
T3 MP MP+T3 
Age 54 (39, 56) 39 (26, 51) 40 (36, 45) 51 (37, 59)    
BSD to treatment 12±6.3 10±6.7  15±9.3  12±10.2    
Donor management    7.5±1.3 6.5±1.2 6.7±1.6 6.7±1.2    
Drug treatment 6.4±1.3 5.6±1.2 5.8±1.6 5.7±1.2 0.14 0.29   0.43 
Hearts suitable 8 10 12 10    
 
Donor heart function (Baseline and post-donor management parameters) 
 
CVP 8.6±4.5 8.7±5 9±3.5 8.2±2.5    
PCWP 9.3±4.8 9.4±3.9 9.9±5.1 9.9±5.4    
CI 3.2±0.9 3±1.1 3.5±1.2 3.2±0.9    
RVEF 26.8±6.8 23.8±7 25.7±10.3 25.4±5.7    
LVSWI 39.4±11.3 35.4±15.2 41.1±15.9 43.7±16    
RVSWI 4.8±2.6 4.7±2.5 5.1±2.9 5.6±3.4    
CPO 1.2±0.4 1.1±0.4 1.4±0.6 1.2±0.5    
SVR 1189±529 1225±405 1175±605 1283±478    
P- CVP 12.1±2.2 10.3±5.1 10.4±2.7 10.9±2.8 0.42   0.02  0.93 
P- PCWP 12.8±3.2 12.6±5.7 11.4±3.9 13.4±3.8 0.40   0.07 
 
0.79 
P- CI 3.7±1.1 3.7±0.9 4.8±1.1 3.8±1 0.25 0.14 0.15 
P-RVEF 26.1±7.5 23.4±6.6 29.4±8.6 27.5±5.5        0.96 0.52  0.05 
P-LVSWI 40±16.6 47.1±19.2 50±16.6 47.8±18.7 0.34 0.14  0.65 
P- RVSWI 6±3.8 7.6±2.8 9.6±3.4 8.6±3.5 0.96 0.09  0.07 
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P-CPO 1.3±0.47 1.6±0.53 1.8±0.68 1.5±0.6 0.88 0.02  0.41 
P-SVR 960±556 1181±423.7 1029±811 1156.6±716 0.38 0.71  0.82 
 
Units as per Table-8.2 
 
Data presented as median (25th, 75th centiles) and mean ± standard deviation. 
Post treatment values were presented with a prefix-P. P-values for T3 and MP 
were generated from ANCOVA analysis for the two main treatment effects after 
removal of the T3 + MP interaction from the model.  
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Figure 8-2- Cardiac index (mean ± 95% confidence interval) between initial (I) 
assessment and end-assessment (E) in the four treatment groups. 
CI improved significantly in the entire cohort (p<0.001) but there was no 
difference between groups (T3 p=0.22; MP p=0.14; MP+T3 p=0.15).  
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8.3.2-Donor heart function according to receipt of T3 or MP 
In a secondary analysis, outcomes in donors according to receipt of T3 (i.e. T3 group 
plus T3 + MP group) or MP (MP group plus T3 +MP group) were compared (Tables-
8.4 and 8.5). T3 administration was not associated with any identifiable beneficial 
haemodynamic effect (Figure-8.3). The receipt of MP did not influence circulatory 
functional changes or retrieval rate (Figure-8.4).  
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Table 8-4-Characteristics of Trial donors according to T3 receipt  
 
     Non-T3 T3 donors Mean Treatment  
     (n=40) (n=40) difference (95% CI) 
Age     44 (37, 54) 45 (30, 56)    
BSD to management (h)  11±8.6 13.5±7.9     
Donor management (h)  6.6±1.2  7.1±1.5     
Randomized treatment (h)  5.6±1.5 6±1.5   
Hearts suitable for transplantation 
    20  20     
Donor heart function (Baseline and post-donor management parameters) 
CVP     8.4±3.8 8.8±3.9    
PCWP    9.9±5.2 9.3±4.3  
CI     3.2±1   3.4±1.1   
RVEF     24±6.4  26±8.6   
LVSWI    40±16  40±14   
RVSWI    5.2±3   5±2.7    
CPO     1.2±0.4  1.3±0.5   
SVR     1254±439  1182±562  
P-CVP    10.6±3.9   11.3±2.6 -0.55 (-1.9, 0.8) 
P-PCWP    13.1±4.7  12.1±3.6 0.56 (-0.8, 1.8) 
P-CI     3.8±0.9  4.2±1.3  -0.23 (-0.63, 0.16)  
P-RVEF    25.7±6.3  27.7±8.1  -0.06 (-2.3, 2.2) 
 
P-LVSWI    47.4±18.7  44.8±17.2 3.3 (-3.7, 10.3)  
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P-RVSWI    8.2±3.2  7.7±4   -0.04 (-1.7, 1.6)  
P-CPO    1.5±0.54  1.6±0.6  -0.02, (-0.2, 0.23)  
P-SVR    1168±585  996±691  115 (-143, 372) 
   
 
Data presented as median (25th, 75th centiles) and mean ± standard deviation 
(95% confidence limits). Post treatment values were presented with a prefix-P.  
Units as per Table 8.2 
The  p values are as for Table-8.3 and were generated from ANCOVA analysis 
for two main treatment effects after the non-significant T3+MP interaction was 
removed from the model. 
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Figure 8-3-Cardiac index (mean ± 95% confidence interval) in donors receiving 
or not receiving T3 (n=40 in each group). 
The x axis denotes time in hours following initial assessment after which T3 or 
placebo was administered. Note the interval between the 3rd hour and end-
assessment was 1 - 2 hours.  Both groups improved cardiac index significantly 
(p<0.001) between baseline and end-assessment. On repeated measure ANOVA 
analysis no significant difference was noted between the groups (T3 p=0.17; 
MP p=0.9; T3+MP p=0.252; T3 and time p=0.56; MP and time p=0.47; T3+MP and 
time p=0.86)  
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Table 8-5-Characteristics of Trial donors according to MP receipt 
  
     Non-MP MP donors Mean treatment 
     (n=41) (n=39) difference (95% CI)
  
Age     53 (38, 56) 39 (29, 47)    
BSD to management (h)  12.3±8.5 13.2±8.2    
Donor management (h)  7.1±1.2  6.6±1.4     
Randomized treatment (h)  5.9±1.2  5.7±1.4     
Hearts suitable for transplantation 
    18  22    
Donor heart function (Baseline and post-donor management parameters) 
CVP     8.4±3.6  8.9±4.2     
PCWP    9.6±5.1  9.6±4.4    
CI     3.2±0.9  3.3±1.2     
RVEF     26±6.2  24±8.9     
LVSWI    42±13.8  39±15.6     
RVSWI    5.2±3   5±2.7      
CPO     1.2±0.4  1.2±0.5     
SVR     1237±505  1187±512    
P-CVP    11.5±2.6  10.3±3.9  1.7 (0.30, 3)   
P-PCWP    13.1±3.5  12±4.8  1.2 (-0.1, 2.5) 
P-CI     3.8±1.1  4.3±1.2  -0.29 (-0.69, 0.1) 
P-RVEF    26.8±6.6  26.6±8.2  0.72 (-2.9, 1.5) 
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P-LVSWI    43.8±17.9  48.6±17.7  -5.2 (-12.2, 1.8) 
P-RVSWI    7.3±3.9  8.7±3.2  -1.4 (-3.1, 0.24) 
P-CPO    1.4±0.5  1.7±0.6  -0.3 (-0.5, -0.05) 
P-SVR    1060±643  1103±648  -49 (-306, 208)
  
 
Data presented as median (25th, 75th centiles) and mean ± standard deviation 
(95% confidence limits). Post treatment values were presented with a prefix-P.  
Analysis by ANCOVA analysis for the main treatment effect after removal of T3 
and MP interaction from the model 
Note the ‘p’ values are the same as in Tables 8.3 and 8.4. Units as per Table 8.3 
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Figure 8-4–Cardiac index (mean ± 95% confidence interval) in donors receiving 
(n=39) or not receiving MP (n=41) in each group. 
 
The x axis denotes time in hours following initial assessment after which MP or 
placebo was administered. Note the interval between the 3rd hour and end-
assessment was 1 - 2 hours.   Both groups improved cardiac index 
significantly (p=0.002) between baseline and end-assessment and treatment 
and time interactions were not significant (p values as per figure 8.3).  
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8.3.3-Donor heart function according to pre-treatment thyroid function 
Further examination of the effect of T3 therapy according to the pre-treatment thyroid 
hormone levels was performed (Table-8.6). Over half the donors (46/80; 58%) had 
low free T3 or free T4 levels initially while only 18 had coexistent low thyroid 
stimulating hormone levels. Of the 46 donors with low T3 or T4 levels, 24 received 
T3, thereby achieving supra-physiological T3 levels. In donors not receiving T3, free 
T3 levels fell significantly (p<0.001).  The change in cardiac index according to initial 
T3/T4 levels and T3 receipt was then compared. Initial cardiac index was not different 
in donors with low T3 or T4 levels. The management protocol improved CI regardless 
of initial T3/T4 levels or T3 administration (Figure-8.5).  
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Table 8-6-Thyroid function changes according to T3 receipt  
 
   Non-T3 Group T3-Group Mean treatment p-value 
    (n=40) (n=40) difference (95% CI)    (T3) 
 
Baseline value 
Free T3 (pmol.L-1)  3.2±1  5.9±6.6     
Free T4 (pmol.L-1)  11.5±3.7  11.4.±4.8   
TSH (mIU.L-1 )  1.1±1.4  1±1.2   
Pre-retrieval value 
Free T3 (pmol.L-1)  3.1±0.9  15.2±3.9 -11.5 (-13.1, -9.9) <0.001 
Free T4 (pmol.L-1)  12.4±4.7  12.3±5.2 -0.23 (-1.1, 0.64) 0.59 
TSH (mIU.L-1)  1.4±1.4  1.3±1.5 -0.1 (-0.37, 0.17) 0.45 
 
Data presented as mean ± standard deviation.  The reference laboratory ranges 
are free T3 (3.3-7.5 pmol.L-1), free T4(11-26 pmol.L-1) and TSH (0.4-6.3 mIU.L-1). 
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Figure 8-5-Cardiac index (mean ± 95% confidence interval) between initial (I) 
assessment and end-assessment (E) in biochemically euthyroid or low T3 or T4 
donors receiving or not receiving T3 during donor management. 
Cardiac index improved in the entire cohort (p<0.001). Administration of T3 
(p=0.13), the pre-treatment thyroid status (p=0.27) or the interaction between 
the thyroid status and T3 administration (p=0.158) did not affect the cardiac 
index 
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8.3.4-Donor heart function and noradrenaline administration 
Within the data, an apparent association between NA withdrawal and cardiac 
functional improvement was noted and further post-hoc analysis performed. At 
assessment, 7 donors were on inotropes and 48/80 (60%) were receiving NA 
(0.2±0.3 µg.kg-1.min-1). None were receiving VP. Thirty six out of 48 donors were 
receiving >0.06 µg.kg-1.min-1 of NA support at the time of baseline measurement of 
parameters. Their baseline LVSWI (43.5±14.9 vs 36.6±13.5 (p=0.03)) and CPO 
(1.3±0.52 vs 1.0±0.42 (p=0.03)) were significantly lower when compared to those not 
receiving NA support. VP was introduced in 60/80, allowing NA to be withdrawn 
(26/48) or reduced to 0.06±0.16 µg.kg-1.min-1 (p<0.001). NA reduction was 
accompanied by a rise in CI from 3.18±1.1 to 3.72±1.5 L.min-1m-2 (p<0.001) and a fall 
in SVR from1190±572 to 964±381 (p=0.001). 
 
8.3.5-Marginal and non-marginal donor hearts, transplant suitability and 
outcomes 
At initial assessment, half of the donor hearts met the functional criteria of suitability 
for transplantation. Of these, 26/40 remained suitable at the end-assessment and 
15/26 hearts were transplanted. The reasons for rejection or non-use are detailed in 
Figure 8.6. Of 40/80 of the donor hearts with initial marginal status, 14/40 (35%) 
attained the functional suitability criteria at end-assessment and 10 (25%) were 
transplanted with no recipient 30 day mortality. Administration of T3 and MP alone or 
in combination did not influence the hemodynamic parameters or transplant rate.   
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Twenty donors (25%; median age 55 (range 48-57)) had palpable coronary artery 
disease on direct inspection, despite a negative medical history and 7/20 donors with 
CAD also had LVH. At end-assessment 20 further hearts were deemed unsuitable for 
transplant on the basis of inadequate function or macroscopic right (n=11) or left 
(n=9) heart dysfunction. Thus, from 80 potential donors assessed, 40 hearts (50%) 
were ultimately suitable for transplant and 25 (31%) were actually transplanted. As 15 
additional hearts, not provisionally accepted for transplantation, fulfilled the suitability 
criteria, the actual percentage of potentially usable hearts was 50%. Of these 15, 5 
had been rejected for reasons of donor age ≥60 (n=3), history of hypotension (n=1) 
or inotrope use (n=1) and 10 were rejected due to an inability to identify suitable 
recipients. They were not re-offered at end-management. Following transplantation, 
24/25 recipients survived beyond 30-days (96%) and 1-year survival was 88%. The 
early death was unrelated to graft function.   
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Figure 8-6-Organisation chart of donor heart outcomes within the study 
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8.4-Discussion  
Active donor management improves circulatory function and has the capacity to 
increase the yield of suitable hearts from the existing pool of potential donors. Neither 
T3
 
nor MP, alone or in combination appear fundamental to this improvement.  
The clinical relevance and management of post-BSD thyroid dysfunction remains an 
area of controversy (32;67;76;140-142). In experimental studies of BSD, rapid falls of 
T3 have been documented. This led to supplementation of T3 in the human donor 
with salutary results compared to historical controls. Observational studies with 
limited hemodynamic assessment then showed a general beneficial effect of T3 
(83;143). In a report of 6 dysfunctional donor hearts (mean age 16.5 years) with high 
CVP, LVEF <45%, inotrope requirement and episodes of cardiac arrest, T3 
administration was followed by an increase in mean arterial pressure, a fall in filling 
pressures and successful transplantation (85) . However, the donors also received 
furosemide and dopamine which may have been responsible for the fall in pre-load 
and increased MAP (84;85). Thereafter T3 was used in management regimes that 
incorporated PAFC-guided manipulation of pre-load, afterload and inotropy (63). 
These measures led to improved cardiovascular performance and increased 
donation rates but as HRT was administered to all, a specific beneficial effect of T3 
could not be evaluated (144). High dose T4 therapy has also been reported to reduce 
catecholamine requirements but does not change cardiac output and actually 
increases oxygen consumption and base deficit (84). In this study and previous 
randomised studies, low T3 levels were not associated with worse haemodynamics 
and T3 administration did not affect retrieval rate or haemodynamics beyond that 
achieved by the other components of management (73;86;87). This suggests that T3 
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reduction is not the mechanism of donor circulatory dysfunction.  Low T3 levels were 
found in >50% of donors in the current study and all T3 recipients achieved T3 levels 
above the upper reference limit.  The change in CI was not different regardless of 
initial T3/T4 levels or T3 administration. Additionally, T3 donors received the drug for 
a longer period than reported previously and our weight-based nomogram provided 
slightly higher dosages which have previously been shown to improve post- coronary 
artery bypass surgery haemodynamics without increasing oxygen consumption (139).  
The reasons for these discrepant findings are unclear. T3 has been found to 
ameliorate post-ischaemic cardiac dysfunction (138;139), to improve contractile 
performance after excessive catecholamine stimulation (145) and to stabilise pressor 
requirements following brain death (146;147). I suspect that the reasons relate to 
vascular resistance modulation with vasopressin. Vasopressin levels fall profoundly 
following BSD (99;146) in parallel with the progressive vasoparesis. Administration of 
vasopressin, reverses this phenomenon, stabilising blood pressure and reducing 
catecholamine requirements as in this study (99;148;149). Vasopressin 
administration, which was not used in the early observational studies that suggested 
improvement with T3, therefore appears to have a more fundamental role in donor 
management than T3.     
In a large retrospective survey, HRT was associated with an increased retrieval rate 
of the heart and other organs.  However, only 701/10,292 (6.8%) donors received 
HRT and only 47/701 (<0.5%) received T3. The remainder received T4 which may be 
preferentially converted to the inactive r-T3 in the ‘sick euthyroid’ state and be 
thereby clinically ineffective. Donors receiving HRT were significantly younger and 
less likely to have died from cerebrovascular accidents or have diabetes, 
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hypertension or renal dysfunction; factors predictive of a lower yield of hearts for 
transplantation. Moreover, although donors that received HRT had a statistically 
higher thoracic organ donation rate, this is intuitive as only donors under active 
consideration for heart donation may have been prescribed T3 or T4 (80). A second 
retrospective report from the same database suggested that triple HRT (i.e. T3 or T4, 
steroids and vasopressin) reduced recipient mortality and the incidence of early graft 
dysfunction. Duration of therapy was not reported but non-HRT hearts had longer 
ischemic times and non-HRT recipients had a higher incidence of congenital heart 
disease, ventilator dependency and female donor-to-male recipient matching; factors 
predictive of worse post-transplant outcome. Only a triple HRT combination was 
associated with a beneficial effect, the administration of T3 or T4 alone was not 
beneficial. Thus, the investigation of the individual roles of the hormonal agents 
remains relevant.  
The current study suggests that neither T3 nor a T3/MP combination lead to an 
additional improvement in donor circulatory function beyond that achieved by active 
management. Their routine use for this indication remains, therefore, an area of 
debate. 
Noradrenaline (NA) is known to be cardiotoxic and a coronary vasoconstrictor (150). 
NA accelerates cardiovascular decline in the vasoparetic phase that follows the 
catecholamine storm (15).and has been associated with reduced right ventricular 
contractility and worse heart recipient survival (151;152). This association between 
NA and reduced function was confirmed in the post hoc analyses in the current study 
and NA withdrawal and substitution with vasopressin was associated with improved 
function, attributable at least in part to normalisation of systemic vascular resistance 
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and vasopressin’s lack of cardiotoxicity; a finding consistent with previous reports 
(15;31;153).  Despite these adverse effects, NA remains the most commonly used 
pressor agent in hypotensive organ donors. The study data supports the view that 
the use of NA infusions for post-BSD pressor support should be abandoned and 
vasopressin utilised in preference. In conjunction with invasive cardiac functional 
assessment, this allows manipulation of pre-load and afterload and discrimination 
between those donor hearts that can be resuscitated from those that cannot.  
The sample size, although larger than previously reported, reflects the logistical 
difficulties of undertaking such prospective, randomised, blinded and controlled 
studies in this population. It remains relatively numerically small and thereby under-
powered to confidently exclude some positive haemodynamic effects of multi-
hormone therapy particularly in donors with initially low T3 or T4 levels or an 
advantageous post-ischemic effect following recipient implantation. The 
randomisation process permitted age differences to occur in the trial treatment 
groups but this does not, we believe, significantly alter the interpretation of the data. 
Although we have not reported recipient outcomes in detail, overall graft survival 
appears satisfactory regardless of HRT use. The donor age reported in this study 
reflects a typical change in the donor population observed world-wide. The incidence 
of coronary artery disease (CAD) is of concern, particularly as coronary angiographic 
screening is not available in many countries and alternative methods of screening to 
rule out CAD in donors need to be identified. 
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8.5-Conclusion 
The study demonstrates that not only may donor circulatory status be improved by 
active management but that also there is the potential to increase the yield of 
transplantable hearts if decisions on organ acceptance are deferred until a period of 
resuscitation and assessment is complete. Active donor management with PAFC 
monitoring is the cornerstone of this objective but this has implications for planning 
donor retrieval services. The simple introduction of hormone therapy is not a 
substitute for the detailed hemodynamic assessment and management of the 
potential heart donor. 
 
107 
 
9. A STUDY OF PRO-INFLAMMATORY ENVIRONMENT IN 
POTENTIAL HEART AND LUNG DONORS AND IMPACT OF 
DONOR MANAGEMENT AND HORMONAL THERAPY 
 
9.1-Introduction 
Brain stem death (BSD) generates a pro-inflammatory environment, promoting pro-
inflammatory cytokine m-RNA gene expression (38;154;155), leading to elevated 
plasma levels of interleukins-1 and 6 (IL-1 & IL-6) and tumour necrosis factor-alpha 
(TNF- α). In heart transplantation, high tissue and plasma levels of these cytokines 
have been associated with worse donor heart function (39-41;48) and post-
transplantation graft outcome (11;43;154). C-reactive protein (CRP) and procalcitonin 
(PCT), a precursor of the hormone calcitonin, are also markers of inflammation and 
abnormal levels of both have been observed following BSD and high levels may be 
predictive of adverse heart transplantation recipient outcome (49;50). Thus, the pro-
inflammatory environment which exists in the prospective organ donor may be a 
target for therapeutic intervention which could potentially improve organ function and 
yield.  
In light of the known propensity of the organ donor to have diminished circulating 
thyroid hormone levels, tri-iodothyronine (T3) is commonly administered to heart 
donors as a putative optimising agent. Its effect on the pro-inflammatory environment 
is unknown. 
The administration of steroids may be beneficial in the post-BSD environment by 
virtue of their anti-inflammatory effects involving stabilization of cellular membranes, 
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reduction of HLA antigen up-regulation and inhibition of cytokine elaboration (89). In 
experimental animal studies, post-BSD elevations of IL-6 and TNF- α levels have 
been diminished by steroid administration and this reduction is paralleled by better 
maintenance of heart function (93;94). This effect has not been confirmed in humans. 
In clinical lung transplantation, the early administration of steroids has been reported 
to improve oxygenation and organ yield and to attenuate lung water accumulation 
(97;156). It is not known if these observations reflect an anti-inflammatory effect, 
modification of alveolar fluid clearance or other phenomena. We hypothesised that 
donor hormonal treatment would reduce inflammatory marker levels. Thus, the 
objectives of this study were to (i) prospectively evaluate the prevalence of elevated 
inflammatory markers in potential heart and lung donors, (ii) to evaluate the impact of 
T3 and steroids administered during donor management, (iii) to correlate the 
presence of biomarker levels with donor heart and lung function and (iv) to explore 
the value of these biomarkers in predicting donor organ outcome.  
9.2-Methods 
9.2.1-Study design 
This study reports the cytokine analyses, a secondary outcome measure, of the main 
trial. The clinical outcomes have been previously reported (156;157). In brief, donors 
were randomized to receive T3 (0.8µg.kg-1 IV bolus followed by 0.113µg.kg-1. hr-1 IV 
infusion); MP (1000mg as a single IV bolus), bothT3 and MP or placebo (dextrose 
5%) following an initial comprehensive assessment of cardiopulmonary function. The 
T3 or placebo infusion continued until retrieval. The details of recruitment have been 
explained previously. Following donor identification and consent, I conducted the 
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study. Blood samples were collected prior to the initiation of donor management. The 
samples were initially stored on ice and then transferred to a core laboratory where 
they were centrifuged and stored at -70°C until batch analysis. Following initial 
sampling, invasive monitoring lines were inserted as described previously. Following 
hemodynamic and blood gas measurements and an echocardiogram (for off-line 
assessment of left ventricular ejection fraction (LVEF)), donors were randomly 
assigned to hormonal treatment groups. Hemodynamic management of the donor, 
directed by the PAFC monitoring, then commenced according to specific algorithm.  
Following volume adjustment, any pre-study inotropes were weaned if possible. In 
donors receiving noradrenaline (NA), this was actively weaned and substituted with 
vasopressin (VP).  Lung management comprised initial bronchoscopic sputum 
clearance, alveolar recruitment manoeuvres and fluid limitation. The duration of 
treatment and time of coning (detection of fixed dilated pupils and blood pressure 
surge) and white cell count on the day of retrieval were noted. Hemodynamic studies 
were repeated hourly for 3 hours and immediately pre-retrieval. Prior to retrieval 
blood gases were repeated. Blood samples were drawn for repeat cytokine 
measurement after 4 hours of initial sampling.  
For the purpose of this study, marginal donor hearts were pre-defined as those with 
initial higher filling pressures CVP and/or PAWP >14 mm Hg), and CI ≤2.4 L.min-1.m-
2) ± inotropes or NA >0.06µg.kg-1.min-1. Marginal donor lungs were pre-defined as 
those with an initial PaO2/FiO2 ratio >230 but ≤320 at initial assessment (156). Heart 
suitability for transplantation at end-assessment was defined as CI >2.4L.min-1m-2 
with CVP and PCWP ≤12mmHg in the absence of palpable coronary artery disease 
during direct inspection. Lung suitability was defined as a PaO2/FO2 of ≥300 
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(marginal = <300) in the absence of lung contusion, aspiration, infection, or non-
recruitable atelectasis during the direct assessment at end-management. The 
number of organs transplanted was noted together with their 30-day survival. 
Information on primary organ function was not available.  
9.2.2-Serum immunoassay 
Serum measurement of IL-1, IL-6 and TNF-α were performed from the serum with 
commercially available immunoassay kits (Human Quantikine HS, R & D systems, 
Oxford, UK). PCT was measured using flash chemiluminescence (Liaison® Flash 
chemiluminescence), repeat measurements were not performed in light of PCT’s 
known longer plasma half-life. C-reactive protein (CRP) measurement was performed 
using standard bio-assay kits. Coefficients of variation for each assay were <10%. All 
the measurements were performed in Aston University, Birmingham. 
9.2.3-Statistical analysis 
The study was powered to detect a standardised difference of 1.0 (α=0.05; 1-β=0.85) 
in biomarker levels post-therapy. Data were analyzed using SPSS v15.0 (Chicago, 
IL). Continuous data were assessed for normality and are presented as mean± SD or 
median (inter-quartile range (IQR)). Normally distributed variables were tested using 
two-way ANOVA that included factors for the two treatments given and also their 
interaction. The post-treatment variables were tested using ANCOVA using the pre-
treatment value as a covariate along with the two treatments given and their 
interaction.   However, throughout the analysis we found the T3+MP interaction did 
not affect any of the measured biomarkers, therefore the interaction was removed 
from the analysis and the main effects were tested. Categorical data were analyzed 
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using Χ2 and Fisher’s Exact tests. Receiver operating curves, sensitivity, specificity 
and predictive values of procalcitonin as a predictor of heart usability were generated 
using standard formulae. Statistical significance was assigned when p≤0.05 and all 
tests were two sided. 
9.3-Results 
Eighty potential heart donors (60 were eligible for lung donation) were recruited into 
the study. No donors were pyrexial and none had received steroids prior to the study. 
Study blood samples were drawn in all but one (positive hepatitis C) donor. A 
Consort diagram demonstrating the study exclusion and randomisation has been 
presented in Figure-9.1. Demographic details for the 79 study donors are presented 
in Table-9.1. The median donor age was 45 (range 36-56) years and 38 were female 
(48%). The mean time to initiation of donor management from the time of clinical 
coning was 12.2±8.3 hours. The donors were managed for a mean period of 6.9±1.4 
and the randomized hormonal treatment administered 5.9±1.4 hours prior to final 
functional assessment.  
 
112 
 
Table 9-1- Donor demographic parameters 
 
Age (years)       45 (36, 56) 
Sex (Female)      38/79 (48%) 
Donor cause of death (no) 
Vascular     51/79 (65%) 
Trauma     19/79 (24%) 
Hypoxic brain damage   4/79 (5%) 
CNS infection    5/79 (6%) 
Time to donor management after coning (hours) 12.2±8.3 
Duration of donor management (h)   6.9±1.4  
Duration of drug treatment (h)    5.9±1.4  
White cell count (×109.L-1)     13.1±5.9  
 
Values presented as median (25, 75 centiles) or mean±SD 
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Total number of 
donors approached 
(116)
Trial donors
(randomised)
(80)  
No consent to 
study 
(36)
T3 
(20)
Placebo 
(20)
MP 
(19)
T3 and MP 
(20)
Total number of 
zonal donors during 
study period 
(250)
Excluded from study 
(according to exclusion 
criteria (134))
Age (<16, >65)-22
Chest Trauma-2
Myocardial infarction-2
Distance >100 miles-29
Donors within 24 hour period-32
Non-unit participation-47
Sample not collected 
Hepatitis-C positive Donor
(1)
 
Figure 9-1–Consort diagram showing the donor inclusion, exclusion and 
allocation to randomised treatment groups 
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 9.3.1-The prevalence of a pro-inflammatory environment 
Interleukin-1 (mean 2.3±4.1pg.mL-1; upper reference limit (URL) 9 pg.mL-1) was 
above URL in 13/79(16%) donors while IL-6(mean 91.9±28.2; URL 4.5pg.mL-1) was 
elevated in all and was >10x URL in 70/79 donors. Tumour necrosis factor-α (mean 
8±2.3; URL 20pg.mL-1) levels were above URL in 22/79(28%).  C-reactive protein 
(mean 113±63) levels were >5mg.L-1(URL) in 78/79(98%) donors (mean 113±63) and 
procalcitonin levels (mean 5.2±15.3) were >0.1ng.mL-1(URL) in 69/79(87%). Thus, all 
donors had evidence of a pro-inflammatory environment manifest predominantly as 
elevation of IL-6, CRP and PCT levels.  
 
9.3.2-The effect of donor management and hormonal therapy 
Table-9.2 reports the initial and final biomarker levels according to treatment groups 
and their interaction. There was no difference in final biomarker levels (IL-1, IL-6, 
TNF-α and CRP) according to treatment allocation and any change detected was not 
dependent on the time-interval of treatment. 
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Table 9-2-Baseline and pre-retrieval inflammatory marker levels in 79 donors 
according to 4 treatment groups 
 
Parameter T3  
(20) 
MP  
(19) 
T3+MP 
(20) 
Placebo 
(20) 
p-value 
T3 MP T3+MP 
CRP 127±4 91±54 90±70  101±55    
CRP-P 124±7 119.6±42 105±86 111±51 0.62    0.56  0.55 
IL-1 2.2±3.8 1.8±2.3 2.1±3.4 2.8±5.7    
IL-1-P 1.5±2.3 3.9±7.6 2.2±3.6 2.2±6.1 0.53 0.19 0.46 
IL-6 96±29 102±20 88±30 87±26    
IL-6-P 98±24 103±20 90±32 100±24 0.12 0.35  0.79 
TNF- α  7.9±1.8 8.2±2.3 7.4±2.5 8.4±2.9    
TNF- α-P 7.8±2.2 7.7±2.4 7.8±2.1 7.7±2.9 0.23 0.75  0.79 
PCT 3.3±7.2 1.6±2.9 2.4±4.7 8.4±19.3    
PCT-P 3.6±7.9 1.8±2.3 2.9±4.5 22.9±63.5 0.32 0.8  0.69 
 
Comparison of treatment effects post-management using ANCOVA analysis 
with initial biomarker value as co-variate, P-values for T3 and MP were 
generated from ANCOVA analysis for the two main treatment effects after 
removal of the T3 + MP interaction from the model. Results presented as 
mean±SD. CRP =C-reactive protein, IL =Interleukin, TNF =-tumour necrosis 
factor and PCT-procalcitonin. IL-1, IL-6 and TNF- α expressed in pcg.ml-1.PCT 
expressed in ng.ml-1 and CRP in mg.L-1. The suffix -P identifies the post-
management, pre-retrieval value.  
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The factorial design of the study allowed comparison of biomarker change according 
to the receipt of T3 or steroids. Thirty-nine donors received MP (±T3) and 40 no-MP 
(±T3) and similarly 40 received T3 (±MP) and 39 no-T3 (±MP) following initial 
assessment. Within these groupings we compared the post-treatment biomarker 
levels using ANCOVA with baseline value as a co-factor.  Administration of neither 
T3 nor MP affected the marker levels when compared to no-T3 (±MP) or no-MP 
(±T3) groups (Tables-9.3 and 9.4). 
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Table 9-3-Baseline and pre-retrieval cytokine levels in donors receiving 
methylprednisolone compared to non-MP donors 
 
Parameters  non-MP donors MP donors  Mean difference  
(n=40)   (n=39) (95%confidence intervals)
  
 
CRP   114±66  91±62     
IL-1   2.5±4.8  2.0±2.9   
IL-6   91±27   95±26   
TNF- α   8.1±2.4  7.8±2.4   
PCT   5.8±14.6  2.1±3.9  
CRP-P  119±60  112±69  -5.6 (-22.8, 11.7)  
IL-1-P   1.8±4.2  2.9±5.7  -1.7 (-4.1, 0.71)  
IL-6-P   98±23   96±28   +4.1 (-4.5, 12.7)  
TNF-α-P  7.8±2.5  7.8±2.2  -0.21 (-1.4, 0.97)  
PCT-P  11.8±41.8  2.4±3.3  +0.7 (-5.1, 6.5) 
   
 
Value presented in mean±SD. CRP-C-reactive protein, IL-Interleukin, TNF-
tumour necrosis factor and PCT-procalcitonin. The suffix -P identifies the post-
management, pre-retrieval value. The  p values are as for Table-9.2 and were 
generated from ANCOVA analysis for two main treatment effects after the non-
significant T3+MP interaction was removed from the model. 
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Table 9-4-Baseline and pre-retrieval cytokine levels in donors receiving T3 
compared to non-T3 donors 
 
Parameters  non-T3 donors T3 donors  Mean difference 
   (n=39)   (n=40) (95%confidence intervals)
  
CRP   96±54   109±74     
IL-1   2.3±4.4  2.2±3.6 
IL-6   94±24   92±29 
TNF- α   8.3±2.6  7.6±2.1 
PCT   5.2±14.4  2.8±6.0 
CRP-P  115±46  116±75  +4.8 (-12.4, 21.9)  
IL-1-P   3±6.8   1.8±2.9  +0.48 (-1.5, 3.2)  
IL-6-P   101±22  94±27   +6.6 (-2, 15.1) 
TNF-α-P  7.7±2.7  7.8±2.1  -0.7 (-1.8, 0.49) 
PCT-P  14.4±49.2  3.4±7   +2.4 (-3.3, 8.1) 
 
Value presented in mean±SD. IL-1, IL-6 and TNF- α expressed in pcg.ml-1.PCT 
expressed in ng.ml-1 and CRP in mg.L-1. The suffix -P identifies the post-
management, pre-retrieval value. The  p values are as for Table-9.2 and were 
generated from ANCOVA analysis for two main treatment effects after the non-
significant T3+MP interaction was removed from the model. 
119 
 
9.3.3-Initial biomarker levels and donor organ function 
In post-hoc analyses relationship between initial marker levels, donor diagnostic 
category, time from coning, white cell count and donor organ function was explored. 
There was no difference in biomarker levels according to donor cause of death and 
no correlation with time from coning or white cell count.  There was no correlation 
between IL-1, IL-6, TNF- α and CRP levels and CI, L or RVEF or left ventricular 
stroke work index (LVSWI). However, baseline PCT level correlated inversely with 
LVEF (p=0.045 Spearman rank coefficient r=-0.297) and RVEF (p<0.001 Spearman 
rank coefficient r=-0.494). To illustrate this effect, we arranged the data into tertiles 
grouping of donor PCT levels (Figure-9.2).   
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Figure 9-2-The relationship of CI, LVEF and RVEF with procalcitonin levels 
On the x-axis donor procalcitonin levels (ng.ml-1) are presented as tertiles (0 – 
0.3 n=26, 0.31 - 1.3 n=26, ≥1.3 n=27). Higher PCT levels were associated with 
significantly, incrementally worse CI (p=0.04), LVEF (p=0.02 and RVEF 
(p<0.001). N.B. for presentation the cardiac index is multiplied by 101.  
Note RVEF was calculated by pulmonary catheter while LVEF using 
echocardiography. 
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Previous studies have suggested a PCT cut-off of 2ng.ml-1, above which donor 
hearts have a higher risk of dysfunction (50). On univariate analysis, a PCT level 
>2ng.ml-1 was noted to be associated with significantly worse donor cardiac index, 
stroke work index and bi-ventricular ejection fractions and appeared less able to 
increase cardiac index with donor management (Table-9.5).  
 
Table 9-5-Initial and change in heart function in donors with low and high 
baseline PCT level 
 
Parameter     PCT <2 ng.ml-1      PCT >2 ng.ml-1  p value 
          (n=62)    (n=17) 
Initial CI (L.min-1m-2)  3.5±0.98  2.9±1.1  0.037 
LVEF (%)    66.1±17.1  53.8±19.3  0.026 
RVEF (%)     28.6±6.6  20.8±7.9  <0.001 
LVSWI (g-m.m-2.beat-1)  44.8±12.9  35.1±14.9  0.003 
RVSWI (g-m.m-2.beat-1)  5.1±2.7  4.6±3.9  0.55 
∆-CI (L.min-1m-2)   0.75±0.9  0.11±0.6  0.013 
 
Value presented in mean±SD. PCT- procalcitonin, CI – cardiac index, LVEF- left 
ventricular ejection fraction, RVEF- right ventricular ejection fraction, LVSWI- 
left ventricular stroke work index, RVSWI- right ventricular stroke work index. 
∆-CI represents the change in cardiac index following donor management (final 
CI – initial CI) 
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Using the pre-determined definition of heart marginality (vide supra) 27/79 hearts 
were marginal at initial assessment. In marginal heart donors, TNF-α (8.7±2.9 versus 
7.5±1.9pg.mL-1; p=0.044) and PCT (6.1±16.2 versus 2.9±6.6ng.mL-1; p=0.02) levels 
were higher than in non-marginal donors but IL-1 (2.6±5.1 versus 2.0±3.2pg.mL-
1;p=0.5), IL-6(93.2±28 versus 92±27pg.mL-1; p=0.8) and CRP(95±67 versus 
105±63mg.mL-1; p=0.55) were not different. In the 60 potential lung donors, 
biomarker levels showed no correlation with initial pO2/FiO2 ratio or extravascular 
lung water index (EVLWI) and were none were higher in those with marginal initial 
pO2/FiO2 ratio.    
 
9.3.4-Biomarker levels and heart and lung suitability for transplantation 
As I had detected no effect of treatment on biomarker levels, further assessment was 
performed whether initial marker levels predicted the end-assessment and 
management suitability of organs for transplantation. As the initial PCT level 
significantly correlated with the donor heart function we performed ROC analysis of 
baseline PCT level predicting the subsequent transplant suitability of the donor heart. 
It demonstrated that baseline PCT was a potentially useful tool in predicting the end-
management heart usability for transplantation (Area under the curve=0.668; 
SE=0.06; p=0.01) (Figure-9.3). Baseline PCT level ≤ 2ng.ml-1 had a sensitivity of 
88%, specificity of 31%, positive predictive value of 57% and a negative predictive 
value of 71% in detecting subsequent heart suitability for transplantation. Despite, 
this 5/17 hearts with initial PCT >2ng.mL-1 were suitable. Overall, at end-
management 40/79 hearts and 60/120 possible lungs met the pre-defined functional 
and patho-anatomical suitability criteria. Apart from PCT marker levels were not 
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different between those suitable or unsuitable for either organ (data not shown). 
Twenty-five donor hearts and 48 donor lungs (21bilateral and 6 single lung 
transplantations) were transplanted and the 30-day survival for both hearts and lungs 
transplanted was 96%.  
PCT ≤2ng.ml-1
A=0.668± (SE)0.06, p=0.01 
 
 
Figure 9-3-Receiver operating characteristic curve demonstrating the 
relationship between sensitivity and 1-specificity in determining the predictive 
value of initial PCT level in identifying subsequent heart usability for 
transplantation 
The area under ROC curve (A) ± SE is reported 
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9.4-Discussion 
There is a very high prevalence of a pro-inflammatory response in potential heart and 
lung donors predominantly manifest as elevated IL-6, CRP and procalcitonin. The 
response is unrelated to factors such as donor cause of death or time from coning. 
The pro-inflammatory response is potentially detrimental to the heart and other 
organs and provides a target for intervention during optimisation. However, the donor 
management strategy and hormonal treatment did not affect biomarker 
concentrations. 
Over 25% of donors display elevated levels of the cardiotoxic cytokine, TNF-α. TNF-α 
mRNA is expressed in the failing or stressed nucleated myocyte generating and 
releasing TNF-α (46). In patients with heart failure,  serum TNF- α levels correlate 
with disease severity and are predictive of mortality (11;37;42;47). In heart donors, 
myocardial upregulation of TNF-α mRNA and elevated serum TNF-α levels have 
been reported previously and the greatest increase has been found in donor hearts 
rejected for transplantation due to of poor function (38;39;48). In these donors, TNF-α 
levels exceed those seen in patients with advanced heart failure (39). These findings 
are also replicated for interleukin-6 (IL-6), a promoter of myocyte hypertrophy and a 
negative inotrope (39). In this study IL-6 levels were >URL in all donors but levels 
were not associated with marginal function. Although higher TNF-α levels were noted 
in the initially marginal category, neither initial IL-6 nor TNF-α level predicted whether 
a heart was functionally suitable for transplantation at end-assessment.  
Similarly other inflammatory markers, procalcitonin and C-reactive protein, which is 
prognostically valuable in heart failure, have also been predictive of primary graft 
failure and graft dysfunction following heart transplantation (49-51). Wagner et al. 
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retrospectively analyzed the serum levels of PCT and CRP in 79 donors. They 
grouped the donor hearts into two, based on the post-transplant mortality related to 
graft dysfunction. Assessment of donor heart function was limited and ischemic times 
were significantly greater in the high PCT donors. They reported that higher PCT 
levels were associated with significantly elevated graft failure-related mortality and 
that a PCT >2ng.ml-1 had 96% specificity and 50% sensitivity for predicting post-
transplant mortality (50). In the current study, I found an important inverse 
relationship between PCT levels and donor heart function which potentially explains 
these previous observations. I also found that donor hearts with PCT levels >2ng.ml-1 
may not augment cardiac index with management. However, as the change in 
cardiac index is less than the measurement error for the thermodilution method, this 
finding should be viewed with caution. With the exception of PCT, no marker was 
predictive of ultimate suitability for transplantation of either hearts or lungs. As some 
hearts with elevated PCT and TNF-α were successfully transplanted with satisfactory 
recipient survival, this suggests that while PCT and TNF-α may be surrogate indices 
of donor heart function; their presence may not preclude successful optimisation. 
This observation should be viewed with caution as numbers transplanted were small 
and the finding requires corroboration by larger studies.  
One of the study hypothesis was, that hormone replacement therapy, particularly 
methylprednisolone because of its anti-inflammatory properties, might favourably 
influence biomarker levels. In an experimental brain death model both systolic and 
diastolic heart function was better preserved in animals receiving methylprednisolone 
than in controls and this was associated with a significant reduction in IL-6, TNF- α 
and IL-10, 6 hours after BSD (93;94). This finding was not corroborated in the current 
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clinical study in which MP failed to influence any biomarker concentration at 4 hours 
and this, therefore could represent a sampling time effect. The discrepancy could 
also be related to a varying time interval of initial sampling following coning (1.2 to 
37.5 hours) but this is unlikely as no time-dependent effect was observed. Future 
appropriately powered studies, with earlier administration of steroids post-BSD and a 
longer observation period might yield an effect.  
Steroid administration has been reported to increase donor lung yield and improve 
function but the mechanism of this effect is unclear (96). The failure of MP to 
attenuate the cytokine response, in this study, suggests that this is not the 
mechanism of action. An alternative explanation may be the effect of steroids on 
enhancing alveolar fluid clearance; a finding demonstrated experimentally (97) and in 
human lung donors (156). It is also possible that other cytokines e.g. IL-8 may be 
both more relevant in lung transplantation and more steroid responsive.  
9.5-Conclusion 
This study has implications for clinical cardiac donor management. Elevated levels of 
TNF-α and PCT may identify donors with cardiac dysfunction which, if left 
unrecognised and unmanaged may worsen recipient outcome (48;50). Their 
measurement may therefore alert transplant teams to adopt an aggressive 
optimization management to restore donor hearts to a transplant-suitable status. 
Biomarker assessment might thus become a prompt for more intensive management 
and evaluation rather than organ rejection. It is also possible that additional 
biomarkers of cardiac ischemia, injury or stress may add discrimination in assessing 
the suitability of the donor heart. Thus, larger studies assessing an array of 
127 
 
biomarkers, including inflammatory probes, analyzed singly or in combination may 
facilitate donor heart assessment and better predict recipient outcomes.  
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10. A STUDY INTO THE MEASUREMENT OF CARDIAC 
TROPONIN-I IN POTENTIAL HEART DONORS AS A 
BIOCHEMICAL SURROGATE OF FUNCTION 
 
10.1-Introduction 
Although donor heart assessment remains a critical factor in determining post-
transplant outcome, the criteria for donor heart selection are ill-defined and some 
hearts that appear unacceptable on initial data may in fact become satisfactory for 
transplantation.  Brain-stem death (BSD) may cause myocardial injury if undetected 
may lead to primary graft dysfunction (PGD) and death of the recipient (67). Despite 
best attempts to match the donor to the recipient, PGD remains the major cause for 
30 day mortality (158). In an attempt to stratify, the suitability of donor hearts for 
transplantation a number of biomarkers have been studied (39;48). Among these are 
cardiac troponins, markers of myocardial injury or infarction and an important 
prognostic index in ischaemic heart disease and advanced heart failure (159). 
Elevated troponins have been correlated with donor heart dysfunction and may 
predict adverse recipient outcome, being associated in some studies with increased 
risk of early graft failure and increased rates of inotrope requirement post-
transplantation and post-transplant rejection (49;56-59) However, this association 
remains controversial as equivalent outcomes have been achieved in other studies 
with no increased risk of rejection (60-62). The objectives of this study were to 
evaluate the prevalence of cTnI elevation in heart donors, its relationship to donor 
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heart function and time from coning, its predictive value of donor heart suitability and 
post-transplant recipient outcome in a prospective study. 
10.2-Materials and methods 
10.2.1-Donor management and data collection 
This report represents serum troponin-I measurement, one of the secondary outcome 
measures, of the main trial. The study population was previously discussed. As soon 
as feasible following identification, I attended the donors. Blood samples were 
collected prior to the initiation of donor management, initially stored on ice and within 
8 hours were centrifuged, serum collected and stored at -70°C for later core 
laboratory batch analysis. Following initial sampling, invasive monitoring lines were 
inserted as previously discussed. Haemodynamic measurements an echocardiogram 
for off-line assessment of left ventricular ejection fraction (LVEF), fractional 
shortening, wall motion score and the LV Tei index were obtained. Donors were 
randomly assigned to hormonal treatment groups and haemodynamic management 
of the donor, directed by the PAFC monitoring was then commenced according to 
specific algorithm.  Following volume adjustment, any pre-study inotropes were 
weaned if possible. In donors receiving noradrenaline (NA), this was actively weaned 
and substituted with vasopressin (VP).  This management, continued in the intensive 
care unit and operating room until retrieval or end-assessment. Changes in donor 
organ function were conveyed to the recipient centers, which had provisionally 
accepted organs for transplantation. The duration of treatment and time of coning 
(detection of fixed dilated pupils and blood pressure surge) were noted. 
Hemodynamic studies were repeated hourly for 3 hours and immediately pre-retrieval 
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or direct inspection. Dysfunctional donor hearts were defined as those hearts with 
initial higher filling pressures CVP and/or PAWP >14 mm Hg), and CI<2.4 L.min-1.m-
2) ± inotropes or NA >0.06µg.kg-1.min-1. 
10.2.2-Recipient data collection 
The recipient demographic data, ischaemic time, length of hospitalization, use of 
post-operative mechanical support, 30 day and 1 year outcome were obtained from 
the UK Cardiothoracic Transplantation Audit (UKCTA) database.  
10.2.3-Statistical analysis 
Data was analyzed using SPSS v15.0 (Chicago, IL). Continuous data were assessed 
for normality and are presented as mean± SD or median (inter-quartile range (IQR)). 
Normally distributed variables were tested using independent sample t test. Skewed 
data were tested using non-parametric tests (Mann-Whitney and Kruskal-Wallis test). 
Categorical data were analyzed using Χ2 and Fisher’s Exact test. Spearman rank 
correlation, regression and receiver operating curve (ROC) analyses of cTnI levels 
with parameters of cardiac function were performed.  As previous studies (61) have 
found a cut-off value of cTnI of 1µg.L-1,  to be discriminant we also compared 
functional and outcome parameters for donor hearts with serum cTnI ≤1 µg.L-1 and 
cTnI > 1 µg.L-1. Recipient survival was reported using Kaplan-Meier analysis and the 
inter-group comparison was analysed using the log rank test. Statistical significance 
was assigned to p value ≤0.05. Univariate and multivariate analysis (stepwise logistic 
regression) was used to identify factors that predicted suitability for transplant at the 
end assessment. 
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10.3-Results 
10.3.1-Donor demographics 
Eighty potential heart donors were recruited into the study. Study blood samples 
were drawn in all but one (positive hepatitis C) donor. The median donor age was 45 
(range 36 to 56) years and 38 (48%) were female. The median time to initiation of 
donor management from the time of clinical coning was 9.8 (25, 75 centiles 6.5-16.1) 
hours. The donors were managed for a mean period of 6.9±1.4hours and the 
randomized hormonal treatment administered 5.9±1.4 hours prior to final functional 
assessment. The laboratory upper reference limit (URL) for cTnI was 0.01 µg.L-1 and 
all 79 donors exceeded this URL with a median value of 0.25µg.L-1 (0.03 to 3.1). The 
distribution of cTnI levels is shown in Figure-10.1.  
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Figure 10-1-Distribution of CTnI levels in the entire donor cohort 
 
Serum cTnI was >1 µg.L-1 in 29/79 (37%) donors and was greater than 10µg.L-1 in 
5/29(17%).  There was no difference in any of the donor demographic parameters 
between donors with cTnI ≤1 µg.L-1 or cTnI > 1 µg.L-1 groups (Table-10.1) with the 
exception of the time from clinical coning to blood sampling. This time duration was 
significantly shorter in the cTnI >1 µg.L-1 group (8.5±5.4 versus 14.5±9.1 (p=0.006) 
hours).  
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Table 10-1-Donor demographic parameters 
 
Parameter           CTnI ≤ 1 µg.L-1       CTnI > 1 µg.L-1  p-value 
(n=50)  (n=29) 
Age      44.1 (37-55)  42.5 (37-55) =0.59 
Sex (Female)    21(42%)  17(59%) =0.17 
Donor cause of death 
Vascular (n)     31 (62%)  20 (69%) =0.62 
Trauma (n)     13 (26%)  6 (21%) =0.78 
Hypoxic brain damage (n)   3 (6%)  1 (3%) =0.99 
CNS infection (n)    3 (6%)  2 (7%) =0.99 
Time to donor management (hours (h) 14.7±9.1  8.5±5.4 =0.006 
Received tri-iodothyronine   27 (54%)  13 (45%) =0.49 
Received methylprednisolone  24 (48%)  15 (52%) =0.82 
Duration of donor management (h) 6.9±1.5  6.6±1.2 =0.32  
Duration of drug treatment (h)  5.9±1.5  5.7±1.1 =0.26  
Noradrenaline therapy   32(64 %)  17(59%) =0.06  
  
 
Values presented as median (25 and 75 centiles), mean±SD or number 
(percentage) 
CNS-central nervous system 
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10.3.2-Donor haemodynamic parameters  
LVEF measurement by transthoracic echocardiography was available in 47/79 (59%), 
LV Tei index in 64/79 (81%), wall motion score 48/79 (61%), CI in 79/79 and 
thermodilution RVEF in 79/79. A strong negative correlation was found between 
baseline donor cardiac functional parameters and cTnI levels; LVEF (Spearman’s 
correlation r=-0.487, p=0.001) (Figure-10.2a), CI (Spearman’s correlation r=-0.335, 
p=0.003) (Figure-10.3a) and RVEF (Spearman’s correlation r=-0.414, p<0.001). 
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Figure 10-2-a-Correlation between left ventricular ejection fraction and CTnI 
levels in 79 heart donors. 10-2-b- ROC curve demonstrating the relationship 
between sensitivity and 1-specificity in determining the predictive value of 
cTnI>1µg.L-1 for identifying decreased donor LV ejection fraction (LVEF <50%)  
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Figure 10-3-a-Correlation between baseline cardiac index and cTnI levels 10-3-
b-ROC curve demonstrating the relationship between sensitivity and 1-
specificity in determining the predictive value of CTnI>1µg.L-1 for identifying 
decreased donor cardiac index  
 
The area under ROC±SD (or SE) (A) is reported.  
 
The donor LV-Tei index (Spearman’s correlation r=0.336, p=0.008 (Figure-10.4) 
positively correlated with cTnI level indicative of worse myocardial performance with 
increased cTnI. 
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Figure 10-4-Correlation between LV-Tei index and cTnI levels in 79 donor 
hearts  
(Spearman’s correlation r=0.336, p=0.008). Normal LV-Tei index is 0.39±0.05. 
There was a strong positive correlation between the cTnI level and LV-Tei index 
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Of the 47 donors with measurable LVEF, this was <50% in 15/47 (32%) donors. In 
these 15 donors, cTnI was significantly higher than in those donors with normal LVEF 
(LVEF >50%) (4.5±3.7 µg.L-1, 1.4±0.54 µg.L-1, p=0.005).  A ROC curve analysis was 
performed to evaluate the role of a pre-assessment cTnI level >1 µg.L-1 in predicting 
donor hearts with decreased LVEF (<50%) and baseline CI <2.4 L.m-2.min-1. It 
demonstrated that cTnI was an accurate tool in predicting decreased donor LVEF 
(A=0.794±0.075, p=0.002) (Figure-10.2b) and decreased baseline CI (2.4 L.min-
2
.min-1) (A=0.821±0.06, p<0.001) (Figure-10.3b).  
The baseline haemodynamic and echocardiographic parameters were significantly 
worse in 29 donors with cTnI > 1 µg.L-1 than the donors with cTnI < 1 µg.L-1 (Table-
10.2). In addition donors with cTnI > 1 µg.L-1 were receiving higher doses of 
inotropes and noradrenaline. Following the protocol-driven donor management, 
haemodynamic parameters improved significantly (160) and the change in donor 
parameters did not differ between the cTnI groups (Table-10.2). Administration of 
hormone replacement alone or in combination did not affect any of the parameters. 
138 
 
Table 10-2-Donor parameters between the CTnI groups 
 
 
Parameter           CTnI ≤ 1 µg.L-1        CTnI > 1 µg.L-1 p-value 
      (n=50)   (n=29) 
 
Central venous pressure (CVP)  7.9±2.9  10±5.1  =0.026 
Pulmonary artery wedge pressure (PAWP) 8.1±3.1  12±5.4  =0.002 
Cardiac Index  (CI)    3.6±0.9  2.7±1.1 =0.001 
LV-stroke work index (LVSWI)  45.6±12.3  31±14.1 <0.001 
Fractional shortening (FS) (%)  32.6±9.4  20.4±11.2 =0.001 
Ejection fraction (EF) (%)   67.7±13.7  46.7±20.1 =0.001 
LV-Tei index     0.41±0.15  0.62±0.29 =0.002 
Wall motion score    1.4±0.51  2.3±0.58 <0.001  
∆-CVP      2.8±3.1  1.7±4.4 =0.17 
∆-PAWP     3.4±3.1  2.8±3.5 =0.46 
∆-CI      0.74±0.9  0.5±0.9 =0.28 
∆-LVSWI     4.9±16.5  5.1±16.1 =0.95 
∆-FS      3.3±8.9  -1±6.5  =0.17 
∆-EF      4.8±11.5  -2.8±12.9 =0.08 
∆-LV-Tei index    0.04±0.2  -0.02±0.2 =0.29
 
∆-Wall motion score    1.9±8.2  3.5±11.1 =0.58 
Value presented in mean ± SD-(∆-value is derived by subtracting the pre-retrieval 
value from the baseline value)-Units: CVP and PCWP- mmHg, CI- L.min-1m-2, RVEF- 
%, LVSWI - g-m.m-2.beat-1 Tei index is calculated by pulse wave Doppler across the 
right and left ventricular inflow and outflow tracts. The following formula is used to 
calculate the index: Tei=IVCT+IVRT/ET (IVCT-isovolumetric contraction time, IVRT- 
isovolumetric relaxation time and ET-ejection time) 
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10.3.3-The relationship of cTnI and function with the time between coning and 
assessment 
As the time from clinical coning to blood sampling was significantly lower in the cTnI 
group >1 µg.L-1 the relationship between coning time and cTnI was analysed. There 
was a significant inverse correlation between the two, demonstrating falling cTnI level 
with increase in coning time (Spearman’s correlation r=-0.26 p=0.025). The donor 
parameters CI (Spearman correlation r= -0.261 p=0.02) and wall motion score 
(Spearman’s correlation r= -0.25 p=0.04) were higher after a longer period since 
coning.  
10.3.4-Suitability for transplantation 
Twenty five out of 79 (32%) donor hearts were ultimately retrieved for transplantation. 
An additional 15 of the remaining 54 (28%) hearts were found to meet the suitability 
criteria at the end of donor management but were not transplanted. Of these 15, 5 
had been rejected for reasons of donor age ≥60 (n=3), history of hypotension (n=1) 
or inotrope use (n=1) and 10 were rejected due to an inability to identify suitable 
recipients. They were not re-offered at end-management.  The remaining 39 donor 
hearts were not retrieved for transplantation due to the presence of coronary artery 
disease (n=20), left heart dysfunction (n=9) and right heart dilatation and failure 
(n=10). I used baseline CI, fractional shortening, CTnI≤1µg.L-1, cTnI>1µg.L-1, T3 and 
MP group to identify factors that predicted suitability for transplant at the end 
assessment.   On univariate analysis baseline cardiac index (p=0.009), CTnI≤1µg.L-1 
(p=0.01) predicted suitability of hearts for transplantation (Table-10.3). On stepwise 
logistic regression analysis none of the factors significantly predicted the ultimate 
heart suitability. (Baseline CI (odds ratio (OR), 1.9; 95% CL, 0.98, 3.7 p=0.058). 
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Table 10-3-Comparison of donor variables between suitable and unsuitable 
hearts for transplantation 
 
Variable  Unsuitable hearts         Suitable hearts p-value 
    (n=40)   (n=40) 
Baseline CI   2.9±1.2   3.5±0.85  =0.009 
Baseline FS   23.9_13.7   30.8±8.9  =0.06 
CTnI≤ 1 µg.L-1  19/40 (48%)   31/40 (78%)  =0.01 
 CTnI > 1 µg.L-1  20/40 (50%)   9/40 (23%)  =0.01 
T3-positive   19/40 (48%)   21/40 (52%)  =0.82 
MP-positive   17/40 (43%)   22/40 (56%)  =0.37 
 
Value (age) presented in median (25 and 75 centiles) or mean±SD 
10.3.5-Recipient parameters 
Nineteen/50 cTnI≤1µg.L-1 and 6/29 cTnI>1µg.L-1 hearts were transplanted (p=0.137). 
Recipient demographic and outcome parameters were not different (Table-10.4) and 
30 day (95%, 100%) and the 1 year survival (89%, 83%) were similar (p=0.252) 
(Figure-10.5).   
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Table 10-4-Recipient parameters between the CTnI groups 
 
Parameter    CTnI ≤ 1 µg.L-1 CTnI > 1 µg.L-1 p-value 
          (n=19)      (n=6) 
 
Age     46.4 (40-57)  40.3 (41.5-56) =0.35  
Sex (Female)   3/19 (16%)  3/6 (50%)  =0.125 
Donor triiodothyronine  9 (47%)  2 (33%)  =0.66 
Donor methylprednisolone  14 (73%)  3 (50%)  =0.34 
Ischaemic time (min)  205±79  188±75  =0.66 
Mechanical support   2/19 (11%)  2/6 (33%)  =0.23 
ITU stay (days)   6.4±9.1  8.2±5.2  =0.67 
Hospital stay (days)   23±10.7  21.8±4.7  =0.65 
30 day survival   18/19 (95%)  6/6 (100%)  =1 
1 year survival   17/19 (89%)  5/6 (83%)  =1 
 
Value (age) presented in median (25 and 75 centiles) or mean±SD 
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Figure 10-5--Kaplan-Meier survival curve demonstrating early recipient 
outcome following transplantation  
Log rank test showed no difference in outcome between the CTnI groups in 
early recipient outcome (p=0.252) 
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10.4-Discussion 
In this prospective study, serum cTnI was found to be above the upper reference limit 
in all donors and correlated strongly and negatively with haemodynamic and 
echocardiographic parameters of cardiac function. Thus, cTnI appears to be a useful 
surrogate index of cardiac function and may indicate which donors require intensive 
evaluation and management to assure their transplant suitability.  
Troponin-I and troponin-T of the tropomyosin complex, are proteins present in the 
thin filament of the cardiac myofibril. They are released into the blood during 
episodes of myocyte injury and cell death (53;54). Circulating serum cTnI is a highly 
sensitive and specific marker of myocardial injury and is potentially useful tool in 
determining the quality of donor hearts. Troponin release into the recipient’s blood 
post-transplantation has been previously evaluated as a marker of rejection (161). 
Cardiac troponin I elevation has also been observed in patients with subarachnoid 
haemorrhage and in this setting is associated with increased LV dysfunction, 
pulmonary oedema, hypotension requiring inotropic support and is predictive of 
worse outcome (55). 
Riou et al. measured cardiac troponin-T and LV ejection fraction using 
transoesophageal echocardiography in 100 donors. They observed an LV ejection 
fraction <50% in 39% of donors and 14% had a LVEF <30%. Troponin-T level was 
significantly elevated in donors with LVEF <30% versus donors with normal LVEF 
and cTnT was found to be a significant predictor of severe LV dysfunction (56). 
However, they did not report the actual number of hearts retrieved for transplantation 
from these groups or their post-transplant outcome. Khush et al., in a retrospective 
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study measured cTnI in 263 heart donors, of which 139 hearts were utilised for 
transplantation (61). They found the cTnI level was >1µg.L-1 in 43/139 donors but in 
contrast to the present study, they did not find any difference in non-invasive 
haemodynamic parameters between groups. They noted that the post-transplant 30 
day and one year outcome were similar in the recipients. In a further study of 159 
donor hearts, cTnI levels were found to be significantly higher in donor hearts with 
ejection fraction <50% and worse wall motion abnormalities but again recipient 
outcome appeared unaffected by the donor cTnI levels (62). In the current study, 
although a cTnI >1µg.L-1 was associated with significantly worse baseline donor 
heart function, this did not preclude improvement with optimisation or successful 
transplantation. However, the numbers transplanted were small and this finding 
needs to be corroborated by larger studies.  
An important and novel finding of the current study is the relationship of cTnI levels 
and functional parameters with the duration of the time-period between coning and 
initial assessment. The higher cTnI and worse function observed in donors with 
shorter post-coning period offers an attractive pathophysiological hypothesis of a 
time-dependent myocardial stunning phenomenon, the severity of which diminishes 
with time. This raises the possibility of extending periods of donor management until 
the donor heart is in a recovery phase and has obvious implications for the logistical 
coordination of heart transplantation retrieval services. This finding corroborates the 
observation that wall motion abnormalities observed in the cardiac donor or 
subarachnoid haemorrhage victim may improve over time (104;109).  In addition, in 
the current study, the functional improvement in donor hearts subjected to active 
management did not differ by cTnI level; an indication of the recovery potential of this 
145 
 
stunning phenomenon and further, recipient outcome was similar although there was 
a suggestion of a higher need for mechanical support in the cTnI >1µg.L-1 group.. 
This observation should be viewed with caution as the number of transplants in the 
cTnI>1µg.L-1 group was small and our finding needs corroboration by larger studies.  
There is also a possibility that greater myocyte injury in the donor may increase the 
risk of rejection and graft vasculopathy in the recipient; again larger studies are 
required to investigate this. The impact of time on post-BSD cardiac function requires 
further studies to investigate whether this phenomenon of an apparent time-
dependent recovery is a real effect which could ultimately be utilised to determine 
best donor care and the optimal timing of retrieval. One caveat to this approach, 
however, is the contrasting observation in lung donors where longer time from coning 
is predictive of worse donor lung function (156).  
10.5-Conclusion 
The use of cTnI as a surrogate index of donor heart function represents an attractive, 
non-invasive assessment tool for donor evaluation. It can aid in identifying donor 
hearts with dysfunction where the targeted donor management could lead to 
successful optimisation and increased heart utilisation without compromising 
recipient outcome. The combination of cTnI measurement with other biomarkers that 
have been demonstrated to have predictive value of either function or outcome may 
ultimately become a useful point-of-care assessment. Further, large prospective 
studies are required test this hypothesis.  
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11. A STUDY OF SERIAL ECHOCARDIOGRAPHY IN THE 
POTENTIAL   HEART DONORS AND THE IMPACT OF DONOR 
MANAGEMENT AND HORMONAL THERAPY 
11.1. Introduction 
Many patients listed for heart transplantation die awaiting a satisfactory donor heart. 
The shortfall in hearts obliges centres to consider ‘marginal’ organs with less assured 
outcomes (158) but the proportion of hearts ultimately retrieved for heart 
transplantation remains low (105).  
The best way to assess the donor heart is debated. Consensus guidelines 
recommend an initial echocardiogram with progression to more invasive, pulmonary 
artery catheter (PAFC) investigations if subnormal LV echocardiographic systolic 
function (E-function) is identified (68). However, in some organ procurement 
networks, including the UK, that have a low availability of echocardiography, there is 
reliance on PAFC–guided assessment and management of hearts provisionally 
accepted for heart transplantation (63). No studies have systematically examined the 
relationship between these two different modes of assessment. 
If echocardiography is used, subnormal E-function even in the absence of a prior 
history of heart disease is the most common cause for rejecting a heart for 
transplantation (67). However, although a normal LV ejection fraction (LVEF) may 
predict heart usage and satisfactory recipient outcome, subnormal E-function does 
not necessarily preclude successful heart transplantation  as the dysfunction may be 
reversible either within the donor or in the recipient following implantation (162). 
Thus, the utility of echocardiography in donor heart assessment has been questioned 
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as adherence to strict limits of E-function may inappropriately exclude hearts that 
could be used successfully. Conversely, failure to perform echocardiography as an 
entry investigation may lead to arbitrary rejection of hearts on “soft” clinical criteria 
and non-progression to formal PAFC-guided assessment e.g. a heart from an older 
potential donor with a history of hypertension and some inotrope requirement may be 
rejected for further assessment on the basis of presumed left ventricular hypertrophy 
(LVH) and dysfunction when in fact the heart has no or minimal LVH and is receiving 
inotropic support inappropriately for hypovolaemia and vasodilatation. 
Echocardiographic studies to-date have been limited to single snap shot assessment 
of E-function (106;111), whereas the phenomenon of reversibility suggests that serial 
studies may have better discriminative value (123). The best measure of E-function 
to predict heart transplant usability is not known.  
Hormonal manipulation of the organ donor using tri-iodothyronine (T3), steroids and 
vasopressin is believed to augment cardiac function and improve yield (80) but its 
effects on haemodynamic function (H-function) and E-function are debated. In this 
prospective study, I had the opportunity to assess both and therefore sought to 
evaluate (a) the association between haemodynamic parameters and 
echocardiography (b) whether measurement of echocardiographic parameters 
performed at the initiation of donor management predicted functional suitability for 
heart transplantation; (c) whether repeat TTE might track changes that improved 
prediction of outcome and (d) the impact of donor management and hormonal 
manipulation on E-function. 
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11.2-Materials and methods 
This report represents the echocardiographic assessment, a secondary outcome 
measure, of the main trial.  At the time of the study, the provision of 
echocardiography at the donor hospital was rarely available and heart assessment 
was primarily based upon the results of PAFC-acquired pressure and cardiac output 
studies followed by direct inspection of the organ. Between, January-2004 and April-
2006, the next-of-kin of eligible potential heart donors were approached for consent 
to enter the donor into the study independently of whether the donor heart was 
provisionally accepted for transplantation by any centre. The presumed time of 
coning was identified as the time of the first recorded observation of fixed dilated 
pupils accompanied by a blood pressure surge. Consent was obtained from the next-
of-kin for all participating donors according to the ethical approval. 
11.2.1-Initial assessment and management 
As soon as possible following consent, I attended the donor and drew blood for 
thyroid function and inserted invasive monitoring lines as discussed previously. I then 
undertook TTE imaging. Coronary angiography was not performed as this is an 
exceptional investigation of donor hearts in the UK. Active algorithm-based, donor 
management was then instituted as per algorithm guided by the invasive monitoring. 
Pre-load was adjusted using either colloid administration or venesection, and after-
load modulated by pressor therapy. The SVR was manipulated to a target range of 
800-1200 dynes.cm.sec-5. Pre-management noradrenaline (NA) was actively 
substituted with vasopressin. This management continued in the ICU and OR until 
final heart inspection, assessment and retrieval. Each heart was finally inspected in 
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the operating room to assess macroscopic right and left ventricular function, LVH and 
the presence of palpable coronary artery disease.  
11.2.2-Echocardiography 
The trans-thoracic echocardiography (TTE) was for image acquisition not 
interpretative reporting and was performed using an Acuson Cypress (Siemens, 
USA) portable machine with second harmonic imaging (3.6 MHz probe). Images 
were repeated after 4 hours of management and stored on optical disc. Repeat 
echocardiography was performed specifically to look at the changes in myocardial 
function during intensive management and weaning of vasoconstrictors. After 
removal of patient identifiers and random coding of examination timing, studies were 
analysed by two observers (Dr Rick Steeds and I) who remained blinded to group 
allocation and time order using Cypress viewer software. E-function parameters were 
measured in triplicate and averaged, with LVEF (%) measured by Simpson’s biplane. 
LV fractional shortening (LVFS), LV and RV ventricular myocardial performance (Tei) 
indices were calculated as previously described (116). As I accrued but did not 
interpret the images, echocardiographic findings were not conveyed to centres 
considering hearts for transplantation. Thus, echocardiographic findings did not 
influence the decision-making process of organ acceptance, which was still based on 
PAC measurements and direct inspection. 
11.2.3-Endpoints and statistics 
In this observational study I assessed the frequency of satisfactory initial and repeat 
TTE image accrual and the inter-class correlation between the reporting observers. 
Donor LVH, assessed using M-mode measurements of interventricular and/or 
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posterior wall thickness, was categorized as mild (1.2-1.3cm), moderate (1.4-1.7 cm) 
or severe (>1.7 cm) (163). Severe LVH is considered a contra-indication to heart 
donation and if detected prospectively would have precluded further management 
towards heart donation. In view of this, donors with severe LVH were withdrawn from 
subsequent analyses.  Thus, the study cohort submitted to further analysis comprised 
those donors with satisfactory acoustic windows for at least initial image accrual who 
did not have severe LVH. 
The incidence of echocardiographic abnormalities was noted and the correlation 
between initial E-function and H-function and the effect of hormonal treatment 
allocation on E-function assessed.  Further analyses allowed assessment of 
echocardiographic response to management in donors with initially subnormal LV 
systolic E-function and the impact of initial thyroid functional status on 
echocardiographic function. For the purpose of this study, the echocardiographic 
criteria of normality were LVEF ≥50%, LVFS ≥30% and LV Tei index ≤0.45. 
Subnormal E-function was defined as either an LVEF <50%, an LVFS <30% or LV 
Tei index > 0.45. To be categorized as having normal E-function, donor hearts had to 
have no subnormal values in the measured parameters. Thus, a heart with a LV Tei 
<0.45 was designated normal E-function even if images allowing LVEF and LVFS 
assessment were unobtainable. Echocardiographic improvement in function was pre-
defined as an increase in LVEF or LVFS of ≥5% or a fall in LV-Tei index of 0.2 (1 
standard deviation). Data were analyzed using SPSS v12.0 (Chicago, IL). 
Continuous data were assessed for normality and are presented as mean± standard 
deviation or median (inter-quartile range). Normally distributed variables were tested 
using two-way ANOVA that included factors for the two treatments given and also 
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their interaction. The post-treatment variables were tested using ANCOVA using the 
pre-treatment value as a covariate along with the two treatments given and their 
interaction. As no interaction between T3 and MP was identified, the interaction was 
excluded from the model when reporting significance levels for the separate effects of 
T3 and MP.  Skewed data were tested using non-parametric tests (Mann-Whitney 
and Kruskal-Wallis test). Categorical data were analyzed using Χ2 and Fisher’s Exact 
tests and correlations using Spearman rank analysis. Observer variability was tested 
using interclass correlation co-efficient. Sensitivity, specificity, positive and negative 
predictive values of E-function variables in detecting hearts functionally suitable for 
transplantation at end-assessment was calculated using standard formulae. 
Statistical significance was assigned when p≤0.05 and all tests were two sided. 
 
11.3-Results 
Trial recruitment, TTE image acquisition and repeatability are demonstrated in Figure 
11.1.  
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Total number of donors 
approached (n=116)
Donors with initial 
echocardiographic data 
available (n=70)
Excluded (n=36)
No consent to study
Total number of zonal donors 
during study period (n=250)
Excluded from study on initial  
exclusion criteria (n=134)
Age (<16, >65) -22
Chest Trauma -2
Myocardial infarction -2
Distance >100 miles -29
Donors within 24 hour period- 32
Non-unit participation -47
T3 
(n=19)
Placebo 
(n=17)
MP 
(n=13)
T3 and MP 
(n=17)
Withdrawn from 
echo study 
(n=10)
Poor acoustic window
Total number of donors in 
hemodynamic study (n=80)
Donors with echocardiographic 
data without severe LVH (n=66)
Withdrawn from 
echo study (n=4)
Severe LVH 
(wall thickness 1.7cm)
 
 
Figure 11-1-Consort diagram of donor inclusion, exclusion and recruitment into 
the trial and withdrawal from the echocardiographic study with allocation to the 
four randomized treatment groups 
 
Of 80 donors within the trial, 70(87.5%) had acoustic windows sufficient to assess at 
least one initial measure of E-function, thus overall, LVEF, LVFS, LV Tei and RV Tei 
could be assessed in 59%, 59%, 80% and 50% respectively. The interclass 
correlation co-efficient between observers was 0.99 (95% (CI) confidence intervals 
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0.99-0.991); p<0.001. Seven donors were found to have LVH; mild n=1, moderate n= 
2 or severe n=4 (6%). Hearts with severe LVH were withdrawn from further analyses 
leaving a study cohort of 66 donors. In this cohort, LVEF (mean 59±19%) was 
assessable in 44/66 and was <50% in 15/44(34%; mean 36±11%). LVFS (mean 
28±12%) could be assessed in 44/66 and was <30% in 23/44 (52%; mean 18±7%). 
The LV Tei index (mean 0.48+0.23) could be assessed in 60/66 donors and was 
abnormal in 26/60 (43%; mean 0.68±0.21). The RV Tei index (mean 0.48+0.21) 
could be assessed in 36/66 and was abnormal in 18/36 (50%; mean 0.63±0.18).  No 
donor hearts were found to have significant valvular heart disease (more than mild 
stenosis or regurgitation of any valve). Overall, the incidence of sub-normal E-
function by any measure was 44%. 
 
The study cohort’s median age was 43 (IQR 35, 56), 54% were male and 11(16%), 
1(1.4%) and 27 (39%) respectively had a history of hypertension, diabetes or 
smoking. BSD was caused by trauma in 18/70 (26%), vascular event or tumour in 
44/70 (63%) and hypoxia or infection in 8/70 (11%).  
Assessment commenced within a median of 2 (IQR 1.5-2.0) hours of consent, within 
12.4±8.1 hours of coning and 6.8±1.7 hours prior to retrieval or end-assessment. 
Study medication was administered for 5.8±1.6 hours prior to retrieval or end-
assessment; the T3 or placebo infusion being continued until OR inspection. 
11.3.1-Echocardiographic correlation with haemodynamic measurements  
In the 66 donor study cohort, baseline LVEF (Figure-11-2) , LVFS and LV Tei index 
(Figure-11.3) correlated as expected with initially measured cardiac index but neither 
initially normal E-function nor conversely, satisfactory initial H-function, clearly 
154 
 
defined hearts that were haemodynamically or echocardiographically suboptimal 
(Table 11.1) 
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Figure 11-2-Scattergram and correlation of left ventricular ejection fraction with 
cardiac index  
(L.min-1m-2) (r=0.56, p<0.001) 
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Figure 11-3-Scattergram and correlation of left ventricular Tei index with 
cardiac index  
(L.min-1m-2) (r= -0.49, p<0.001) 
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Table 11-1-Echocardiographic parameters LVEF, LVFS and LV Tei index versus 
cardiac index at initial assessment 
 
Echo parameter CI >2.4L.min-1m-2 (n) CI<2.4L.min-1m-2 (n) Total 
 
LVEF≥50%   28    1   29 
LVEF<50%   7    8   15 
Total    35    9   44 
 
LVFS≥30%   21    0   21 
LVFS<30%   14    9   23 
Total    35    9   44 
 
LV-Tei≤0.45   30    3   33 
LV-Tei>0.45   15    11   26 
Total    45    14   59 
 
157 
 
On the pre-defined criteria, 29/66 (44%) hearts had initially subnormal LV systolic E-
function. Donor hearts with times from coning above the median value of 11 hours 
were observed to have significantly better LV and RV systolic E-function (LVEF 
65±13.3% vs 53±23% p=0.03; RV-Tei index 0.39 ±0.14 vs 0.52 ±0.22 p=0.03).  
11.3.2-Initial echocardiographic function and thyroid functional status 
Thirty-six of 66 study donors had subnormal T3 or thyroxine levels (157). Initial LVEF 
(57±21% vs. 62±18%; p=0.41), LVFS (26.4±12% vs. 29±11.3%; p=0.45), LV Tei 
index (0.43±0.22 vs. 0.53±0.24; p=0.09) and RV Tei index (0.43±0.16 vs. 0.53±0.24; 
p=0.12) were not statistically significantly different between those donors with 
subnormal or normal thyroid hormone levels. 
11.3.3-Hormonal treatment and echocardiographic changes 
There was no difference in any initial LV E-function parameter between those 
randomised to T3 and MP, alone or in combination (Table-11.2). Fifty-two donors 
underwent repeat echocardiographic assessment but echocardiographic parameters 
did not change in any treatment group with the exception of the RV Tei index which 
improved in T3 but not T3+MP donors (p=0.04). No interaction between T3 and MP 
was identified.  
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Table 11-2-Echocardiographic parameters of initial and post-management 
ventricular function by treatment group 
 
 
Parameter Placebo 
(17) 
T3 
(9) 
MP 
(13) 
T3+MP 
(17) 
p-value 
T3 MP T3+MP 
LVFS  29±10(10) 32±12(14) 20±9(11) 30±11(12)    
LVEF  62±16(10) 65±18(14) 46±19(11) 63±18(12)    
LV-Tei  0.44±0.2(16) 0.51±0.2(18) 0.59±0.3(13) 0.45±0.2(17)    
RV-Tei 0.38±0.1(8) 0.53±0.1(14) 0.54±0.2(8) 0.44±0.3(10)    
WMS  1.8±0.7(17) 1.7±0.7(19) 2.0±0.6(14) 1.7±0.8(17)    
P-LVFS (%) 36±11 33±12 24±8 31±11 0.52   0.63       0.39      
P-LVEF (%) 71±18  67±20 55±15 65±17 0.57   0.77     0.65 
P-LV-Tei 0.45±0.2 0.45±0.2 0.58±0.2 0.46±0.2 0.66   0.12     0.91 
P-RV-Tei 0.49±0.2 0.36±0.1 0.61±0.2 0.34±0.2 0.04   0.08     0.99 
 
 
Data are presented as mean±SD (number of donors with available repeat 
measurements in each group).  The repeat value after 4 hours of management 
is represented by a prefix-P. P-values for T3 and MP were generated from 
ANCOVA analysis for the two main treatment effects after removal of the T3 + 
MP interaction from the model. LVFS-left ventricular fractional shortening (%), 
LVEF-left ventricular ejection fraction (%) 
159 
 
11.3.4-Repeat echocardiographic assessment  
At least one repeated measure of E-function could be obtained in 52/66(79%) of 
hearts. Repeat measurements could be more frequently obtained using the Doppler-
based LV-Tei index (50/66) than using 2D Simpson biplane estimation of LVEF or 
LVFS (36/70; p = 0.01).  The reasons for being unable to repeat echocardiography 
were donor haemodynamic deterioration requiring urgent transfer to theatre for 
retrieval of abdominal organs (n= 5) and other technical and logistic difficulties 
precluding repeat assessment (n=9).   
Of the 52 hearts with repeat assessment, 33 had normal initial E-function. At end-
assessment, this was retained in 30. Cardiac index changed from 3.8±0.8 to 
4.3±1.2L.min-1m-2; p=0.002 and 24/33 met the H-function criteria for transplant. 
Following donor management 10/19 (53%) hearts with initial subnormal LV systolic 
E-function improved echocardiographically on the pre-defined criteria (Figure-11.4). 
Improvement was accompanied by a change in CI from 3.4±0.9 to 4.1±0.82L.min-1m-
2
, p=0.03. The remaining 9/19 hearts failed to improve echocardiographically but 
nevertheless CI increased from 2.5±0.8 to 3.6±1.32L.min-1m-2, p=0.004. Eight of 10 
echocardiographic improvers and 8/9 non-improvers achieved functional suitability at 
end-assessment. Thus, neither initial subnormal LV E-function nor a failure to 
improve echocardiographically precluded hemodynamic augmentation or attainment 
of the H-function suitability criteria for transplant. 
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Trial donors with baseline 
echocardiographic data available 
without severe LVH (n=66)
Donor hearts with initial 
normal LV E-function (n=37)
Donor hearts with initial 
subnormal LV E-function (n=29)
Repeat 
echocardiography not 
possible (n=4)
Retained normal 
LV systolic function  
(n=30)
Deteriorating
LV systolic function 
(n=3)
Repeat 
echocardiography 
possible (n=33)
Repeat 
echocardiography not 
possible (n=10)
Repeat 
echocardiography  
possible (n=19)
Improved 
LV systolic function  
(n=10)
Non-improved or 
deteriorating LV
systolic function  (n=9)
End-assessment
H-function suitability(43)  
End-assessment 
H-function non-suitability(9)  
n=8
n=24 n=1
n=2
n=8
n=6n=3
 
 
Figure 11-4-Flow diagram in donors in which repeat assessment of LV 
echocardiographic function was possible (n=52).  
Twenty-seven of 33 donors with initially normal LV echocardiographic (E) 
function attained hemodynamic functional suitability criteria.  Sixteen donors 
with subnormal LV E-function improved to suitability which was not dependent 
on E-function change.  
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The echocardiographic and hemodynamic change in hearts with subnormal function, 
according to the degree of LV impairment is shown for LVEF and LV-Tei index in 
Figure-11.5 & 11.6. LVFS changes paralleled those of LVEF. No hearts with an initial 
LVEF<30% improved to H-function suitability but above this threshold and for LV–Tei 
indices, no degree of LV dysfunction precluded hemodynamic ± echocardiographic 
improvement.  
Achieved H-function criteria 
Improved LVEF n=5
Improved LVEF 
Did not achieve H-function criteria 
n=2
Achieved H-function criteria 
Failed to improve LVEF n=3
Failed to improve LVEF 
Did not achieve H-function criteria 
n=4
LVEF <30%
n=4
LVEF 30-40%
n=4
LVEF 40-50%
n=6
 
 
Figure 11-5-Echocardiographic and haemodynamic change in donors with 
subnormal LVEF according to degree of LV impairment, where repeat 
measurement was available (n=14).  
Each arrow denotes a single donor. Eight of 14 donors attained hemodynamic 
suitability.  
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Achieved H-function criteria 
Improved LV-Tei n=5
Did not achieve H-function criteria 
Improved LV-Tei n=0
Achieved H-function criteria 
Failed to improve LV-Tei n=10
Did not achieve H-function criteria 
Failed to improve LV-Tei n=2
LV-Tei 
>0.6-0.85
n=5
LV-Tei 
>0.45-0.60
n=9
LV-Tei 
>0.85
n=4
 
 
Figure 11-6-Echocardiographic and hemodynamic change in donors with 
abnormal LV-Tei index where repeat measurement was available (n=18).  
 
Each arrow denotes a single donor. Fifteen of 18 donors attained 
hemodynamic suitability. Numbers are slightly different to Figure-11.3 which 
included all modes of LV E-function assessment and some donors had both 
LVEF and LV-Tei indices assessed. 
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11.3.5-Predictors of end-assessment functional suitability  
Within the 66 donor study cohort, 37 had initially normal LV E-function and 28/37 of 
these had H-function suitable for transplant at end-assessment. In the 29(44%) 
hearts with initial subnormal LV systolic E-function, 17/29 achieved the H-function 
suitability criteria at end-assessment; a total of 45/66(68%) of investigated hearts 
achieving the H-function criteria (Figure11-7).  
 
To assess whether the initially measured E-function parameters, LVEF, LVFS and LV 
Tei index predicted end-assessment H-function suitability, initial LVEF, LVFS, LV 
index were compared as continuous variables by univariate and multivariate analysis, 
along with donor age, time from coning, receipt of T3 and MP including all cases with 
missing data. On univariate analysis baseline higher initial LVFS (p=0.02) and LVEF 
(p=0.006, lower LV-Tei index (p=0.03) and a longer time after coning (p=0.01) 
predicted subsequent heart usability. The sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) for normal E-function are shown in 
Table-11.3.  
On stepwise logistic regression analysis, baseline LVEF (Odds ratio=1.05; 95%CL 
1.007, 1.088; p=0.021) independently predicted ultimate functional suitability of 
hearts for transplantation. The sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) for normal E-function (by any or all parameters) 
in predicting end-assessment functional suitability were 62%, 66%, 70% and 58% 
respectively. 
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Trial donors with baseline 
echocardiographic data available 
without severe LVH(n=66)  
Donor hearts with initial 
normal LV E-function(n=37)  
Donor hearts with initial 
subnormal LV E-function(n=29)  
Initial hemodynamic 
non-suitability  (n=15)
Initial hemodynamic 
suitability  (n=22)
Initial hemodynamic 
non-suitability  (n=19)
Initial hemodynamic 
suitability  (n=10)
End-assessment  
hemodynamic 
suitability  (n=28)
End-assessment  
hemodynamic 
non-suitability  (n=9)
End-assessment  
hemodynamic 
non-suitability  (n=12)
End-assessment  
hemodynamic 
suitability  (n=17)
n=17
n=5 n=11
n=4 n=11
n=8
n=1 n=9
Transplanted (n=16)
Non-transplanted (n=12)
Donor history (3)
No recipient (4)
Donor CAD(5)
Transplanted (n=2) Ŧ
Non-transplanted (n=7)
No recipient* (2)
Donor CAD(5)
Transplanted (n=0)
Non-transplanted (n=12)
No recipient* (1)
Donor LHD/RHD (11)
Transplanted (n=6)
Non-transplanted (n=11)
Donor history (1)
No recipient (2)
Donor CAD (5)
Donor LHD/RHD (3)
 
Figure 11-7-Flow diagram in the 66 donors with initial echocardiographic 
functional assessment showing outcome towards hemodynamic functional 
suitability for transplantation 
Two heartsŦ below H-function criteria were transplanted, one had a lower mean 
arterial pressure and one a high pulmonary capillary wedge pressure while all 
other criteria were attained.   Three hearts* not achieving hemodynamic 
function suitability had been  declined for transplant prior to full assessment 
due to no suitable recipients identified. Ten hearts, functionally suitable were 
rejected due to palpable coronary artery disease.  
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CAD -coronary artery disease, L-HD and R-RHD – left- or right- heart 
dysfunction 
 
Table 11-3-Demonstrating normal E-function predicting suitable hearts fro 
transplantation 
 
Parameter Sensitivity Specificity PPV NPV 
 
LVEF>50% 
LVFS>30% 
Normal LV systolic function 
85% 
56% 
62% 
65% 
65% 
66% 
79% 
71% 
70% 
73% 
48% 
58% 
LV Tei index ≤0.45 62% 50% 62% 50% 
11.3.6-Findings at operating room inspection, transplantation outcome 
Regardless of provisional acceptance for transplantation, each echocardiographically 
assessed heart was inspected in the operating room. LVH was notable in the 4 (wall 
thickness>1.7 cm) hearts subsequently confirmed to have severe echocardiographic 
LVH and in each of these there was concomitant palpable coronary artery disease 
(CAD). Palpable coronary artery disease (CAD) was also found in a further 15 donor 
hearts and in the absence of coronary angiography these hearts were rejected for 
transplantation. Neither demographic descriptors nor echocardiographic parameters 
were different in these 15 donors.  
The outcomes for the 66 hearts are described in Figure 5. Twenty-four hearts were 
retrieved and transplanted with 100% graft and patient survival at 30 days and no 
166 
 
hearts required mechanical assistance. Thirteen functionally suitable hearts were not 
retrieved due to inability to identify suitable recipients (n=9) or non-acceptance due to 
adverse donor history (n=4). Each of the remaining 14 donor hearts that did not 
achieve functional suitability had macroscopic right or left heart dysfunction on direct 
inspection.  
 
11.4-Discussion 
The accrual of echocardiographic images without immediate interpretation in this 
study provides a unique insight into the inter-relationship of echocardiography and 
haemodynamic assessment in potential heart donors. The two methods of 
investigation appear complimentary. Echocardiography can identify structural valve 
abnormalities and ventricular hypertrophy (10% in this study) as well as providing an 
initial ventricular function assessment which, if normal, is predictive that functional 
suitability will be attained. PAFC–guided donor assessment can confirm the 
functional suitability of echocardiographically normal hearts and guide the 
optimisation of those hearts with either subnormal echocardiographic function or sub-
optimal haemodynamic findings to suitable status. This dual investigational approach 
should be considered in all potential heart donors. 
Although normal E-function at initial assessment is predictive of post-management 
functional suitability, specificity is poor and with optimisation, a significant number of 
hearts with initially abnormal echocardiographic function could improve their H-
function and achieve transplantable status even if E-function does not change. This 
confirms that subnormal echocardiographic LV systolic function does not preclude 
successful transplantation (112;122;162), provided that other risk factors for early 
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graft failure are not disregarded (164-166).  Only hearts with an initial LVEF <30% 
failed to improve with management and baseline LVEF independently predicted the 
subsequent heart usability for transplantation.  
From a practical perspective, LVEF, LVFS and LV Tei are relatively easily-acquired 
objective assessments of LV systolic function. Of these, LV Tei index was obtained 
most frequently during donor assessment. The LV Tei index is a Doppler-derived 
index which, although requiring correct alignment, does not demand the same high 
image quality as biplane LVEF. It correlates closely with invasive measures of both 
systolic (+dP/dt) and diastolic function (-dP/dt and Tau), and is independent of heart 
rate and of LV geometry (116). Thus, although the Tei index is not load-independent, 
it is less dependent than volumetric LVEF, which is particularly sensitive to the large 
variations in loading, common in the cardiac donor (167). Previous data have 
documented that the Tei index has incremental prognostic significance beyond 
volumetric LVEF in a number of other clinical situations (168-170). 
Despite the inherent difficulties of TTE in BSD patients who are intubated, 
mechanically ventilated and have relatively fixed supine positioning, image 
acquisition was possible in 87.5% of the trial cohort and repeat examination was 
feasible in 79% of these. Serial echocardiography in donor heart assessment has 
only previously been reported in smaller studies (104;123) but has demonstrated the 
capacity for E-function to improve. Our study corroborates this finding, demonstrating 
the potential for both echocardiographic and hemodynamic improvement. H-function 
improvement, to a level permitting heart transplantation may occur independently of 
E-function change and thus repeat echocardiography seems unnecessary in 
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determining the response to management provided that haemodynamic optimisation 
is achieved.   
The use of hormonal therapy, particularly T3 in potential heart donors remains 
controversial. Several observational studies have suggested that T3 therapy may 
improve donor heart function but a number of randomized studies have found T3 to 
be of no benefit (86;157). In this study, neither initial thyroid functional status, nor T3 
or MP therapy affected any parameter of LV function or predicted end-assessment 
functional suitability. In patients receiving T3, there was a significant improvement in 
the RV Tei index. This effect should be viewed with caution as numbers are small 
and we have previously reported that thermodilution RVEF does not change with 
management (157). However, as the right is potentially the more compromised 
ventricle following BSD a possible beneficial effect of T3 on RV dysfunction in both 
donor and recipient should be investigated further. 
The association of better E-function with longer time from coning is concordant with 
the findings of haemodynamic and cardiac troponin studies and is consistent with the 
hypothesis that BSD generates a time-dependent reversible stunning phenomenon 
within some donor hearts (168). If corroborated, this finding has implications for 
donor management inferring that a longer period of donor observation and 
management following BSD may lead to more donor hearts becoming utilizable for 
transplantation and allowing exclusion of those hearts destined to fail to respond to 
therapy.  
The study has several limitations. The pragmatic study design assessing all possible 
donors meant that there were a large number of changing variables that could 
influence detectable changes on echocardiography between the first and second 
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study e.g. loading conditions, inotrope and noradrenaline usage and time from 
coning.  Echocardiographic contrast to optimise border detection and accuracy was 
not used and might improve prediction (169). Also, Doppler data on cardiac output 
from velocity-time integral data were not collected, which would have been useful to 
attempt to correlate changes in echocardiographic parameters with invasive data. 
Importantly, we were not able to assess E-function in recipients as these were 
dispersed nationwide. However, the 100% 30-day survival indicates that initial donor 
heart function remained satisfactory without early graft failure; indicative of the 
appropriateness of the H-function criteria used. Additionally, the study remains 
numerically small and this reflects the logistical difficulties of undertaking such 
investigations in multiple intensive care units in the setting of BSD. Further studies 
are required to determine if there is a cut-off in LV systolic function below which 
attempted donor resuscitation is futile.  
The third component of donor heart assessment is inspection in the operating room.  
This allows further assessment of LVH and allows visual inspection of, particularly 
the right ventricle, potentially the most vulnerable part of the donor heart. In this study 
only those hearts not attaining the haemodynamic functional criteria displayed 
macroscopic LV or RV dysfunction on inspection.  
If donor coronary arteriography is unavailable, there is a reliance on direct inspection 
and palpation to detect CAD which, if present, usually leads to rejection of the heart 
for transplantation. Any relationship between subjective CAD assessment, based on 
inspection and palpation, and haemodynamically significant CAD assessed 
objectively using coronary angiography remains undefined. Palpable CAD was the 
cause for heart rejection in 15 functionally suitable donors in this study. 
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Unfortunately, explantation and bench angiography to assess the relevance of this 
finding was not available. It is quite possible that some donor hearts with palpable 
CAD will not have flow-limiting lesions and could be safely utilised for transplantation. 
Conversely, in view of the ubiquitous nature of coronary atheroma, it is also likely that 
significant CAD could go undetected. At a time when donor numbers are diminishing, 
there is a need to increase the availability of coronary arteriography or other objective 
investigations both to further explore the possible yield from the existing donor pool 
and to exclude hearts with covert but extensive disease (68).   
Finally, TTE has limitation in image acquisition due to lack of acoustic windows in 
supine, intubated, ventilated organ donor. Smaller TOE probes, with portable 
echocardiography consoles incorporated with tissue doppler facilities are more 
preferable in an organ donor.  This will increase the image acquisition and 
repeatability during donor management. Studies using TOE analysis of donor heart 
function during management will help to address this issue in the future.  
11.5-Conclusion 
TTE is possible in the majority of potential heart donors. Normal LV systolic function 
is a strong predictor that hearts will be functionally suitable for transplantation but 
subnormal function does not preclude haemodynamic improvement. Serial 
echocardiography is feasible but does not improve prediction of post-optimisation 
functional suitability. Neither initial thyroid functional status, nor T3±MP therapy affect 
E-function. The study leads me to recommend that both echocardiography and PAC-
guided assessment and management should be standard approaches to the 
potential heart donor.  
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12. A STUDY INTO THE IMPACT OF EARLY DONOR 
MANAGEMENT AND HORMONE REPLACEMENT THERAPY IN 
INCREASING THE RETRIEVAL RATE OF LUNGS FOR 
TRANSPLANTATION 
 
12.1-Introduction 
Lung transplantation is increasing (171) but demand outweighs supply with a 
significant waiting list mortality (172). Only approximately 20% of post-brainstem 
death (BSD) cadaveric donor lungs are ultimately used for transplantation and there 
is a need to investigate whether this utilisation rate can be increased without 
jeopardizing outcome. Lung donation may be compromised by lung injury, which may 
occur before and after BSD due to trauma, aspiration, infection, fluid overload and 
ventilatory barotrauma. Also, during BSD, hemodynamic shear forces and pro-
oedematous hydrostatic pressures may cause direct injury. Each of these modes of 
injury may be exacerbated by a pro-inflammatory post-BSD environment 
(16;45;173;174).  Steroids may stabilise cellular membranes, reduce up-regulation of 
HLA antigens (175), inhibit or prevent alterations in cytokines (89) and upregulate 
alveolar fluid clearance (AFC) (92;97). A retrospective study reported increased yield 
and improved donor lung function after early methylprednisolone (MP) administration 
(96).  However, the effect of MP has not been investigated prospectively. Tri-
iodothyronine (T3) is commonly used to putatively improve donor heart function.  
Improved cardiac function, with reduced hydrostatic pressures might limit lung water 
accumulation and in addition, T3 increases AFC (97). I therefore investigated the 
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effects of MP and T3 (administered early following consent for organ donation) on 
heart and lung function in potential heart and lung donors in a randomized trial. 
Within this Trial, in addition to receiving hormone therapy, potential donors were 
actively managed to try and maintain organ function. As combination, MP, T3 and 
vasopressin (VP) therapy has been associated with higher organ retrieval rates (80) 
and as active management of marginal lung donors is reported to increase retrieval 
rate (176-179), I additionally compared lung yield between the Trial donors and a 
contemporary cohort of non-Trial donors.   
12.2-Materials and methods 
12.2.1-Study design 
Between, January-2004 and April-2006, I accrued data on potential lung donors 
within our zone. Study inclusion and exclusion criteria are already discussed. 
Marginal organs were defined as a PaO2/FiO2 ratio <320 but >230 at referral.  The 
lungs of all such donors were offered to transplant units via donor procurement 
coordinators (DPCs) and accepted or rejected on the basis of size, blood group, 
chest x-ray findings, arterial blood gases (ABG), the presence of endotracheal 
secretions and medical history.  Within this cohort, we approached the next of kin for 
consent to enter into a prospective, double-blind, placebo-controlled, randomized 
trial. Consent was obtained from the next-of-kin for all participating donors according 
to the MREC approval. The Trial was conducted independent of whether donor lungs 
were provisionally accepted for lung transplantation. Lungs previously declined were 
not re-offered following management.  
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12.2.2-Assessment and management of non-Trial donors 
Non-Trial donors were managed using a standard protocol by DPCs in collaboration 
with local ITU staff with the aims of maintaining haemodynamic stability, limiting fluid 
overload and substituting noradrenaline (NA) with VP in donors provisionally 
accepted for cardiac transplantation. In non-trial donors, PAFC insertion, 
bronchoscopy and hormone replacement therapy with MP and T3 only occurs in 
accepted heart or lung donors following transfer to the operating room (OR) for the 
retrieval procedure several hours following initial assessment. EVLWI measurement 
would not be routinely undertaken in this cohort.  
12.2.3- Assessment and management of trial donors 
Trial donors were attended on the ICU by me as soon as feasible, following donation 
and study consent. At initial assessment they underwent ABG (mmHg) measurement 
(Fractional inspired oxygen (FiO2) 1.0), Positive end-expiratory pressure (PEEP) 
5cmH2O). This was followed by insertion of invasive monitoring lines as describe 
previously. In addition to all haemodynamic parameters, extravascular lung water 
index (EVLWI) (normal 3-7ml.kg-1), pulmonary vascular permeability index (PVPI) 
and pulmonary vascular resistance (PVR) were measured. The underlying principles 
and analysis of lung water assessment have been previously reported (128). 
Following initial assessment, bronchoscopy was performed to assess anatomy and 
endotracheal tube placement, to aspirate secretions, to detect evidence of active 
bronchitis or aspiration and to obtain a broncho-alveolar lavage (BAL) specimen for 
culture. Thereafter, lung management protocol was followed as described previously.    
Trial medication was then administered; T3 (0.8µg.kg-1 IV bolus followed by 
0.113µg.kg-1. hr-1 IV infusion); MP (1000mg IV) as a single dose; both drugs or 
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placebo (dextrose 5%) and the T3/placebo infusion continued until retrieval.  All 
medical, nursing and technical staff involved in the research or donor care remained 
blinded to treatment allocation until study completion.  
Active hemodynamic management was simultaneously commenced according to 
specific algorithm. Systemic vascular resistance was maintained in the range 800-
1200 dynes.cm.sec-5 by actively substituting VP for NE. Crystalloid infusions were not 
used to replace urine output except in hypernatremic donors (n=3).  
Management, continued in the ICU and OR until retrieval.  Changes in lung function 
and bronchoscopy findings were conveyed to the recipient centers which had 
provisionally accepted lungs for transplantation.  The duration of treatment and time 
of coning (detection of fixed dilated pupils and BP surge) were noted. 
Hemodynamic studies, PaO2/FiO2 ratio at FiO2 1.0, EVLWI, PVPI and PVR were 
performed at baseline and repeated after initial bronchoscopic examination, 1 hour 
thereafter and immediately pre-retrieval. Pre-retrieval ABG measurements were 
performed after direct inspection and manual inflation to recruit atelectatic lung 
segments where possible. After each measurement, FiO2 was reduced, as after initial 
assessment. 
12.2.4-Endpoints and statistics 
The pre-planned primary Trial end-point was a difference in PaO2/FiO2 of one 
standard deviation (SD)) between groups at end-management. The Trial had 80% 
power (α = 0.05) to detect this with recruitment of 4 groups of 24 allowing for multiple 
comparisons. Actual recruitment did not reach this target but the study remained 
powered to allow satisfactory comparison of this end-point in donors receiving MP or 
no MP or T3 or no T3. The Trial was also initially powered to detect a 20% absolute 
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increase in the number of lungs transplanted versus a historical or non-Trial cohort. 
Secondary Trial end-points included other functional data, the effect of NA 
administration in donors and the transplant suitability at the end-management. 
Suitability was defined as a PaO2/FiO2 ≥300 without identifying lung trauma, 
aspiration, infection or non-recruitable atelectasis during assessment and at direct 
inspection. Data were analyzed using SPSS v12.0 (Chicago, IL). Continuous data 
were assessed for normality and are presented as mean± SD (95% confidence limits 
(CL)) or median (inter-quartile range (IQR)). Normally distributed variables were 
tested using independent or paired sample t tests. Skewed data were tested using 
non-parametric test (Mann-Whitney and Kruskal-Wallis test). Categorical data were 
analyzed using Χ2 and Fisher’s Exact testing. Serial measurements were compared 
using repeated measures ANOVA. Statistical significance was assigned when 
p≤0.05. Univariate and multivariate analysis (stepwise logistic regression) was used 
to identify factors that predicted suitability for transplant at end-assessment. 
 
12.3-Results  
Study enrolment is summarized in Figure-12.1.  During the period of Trial 
recruitment, there were a total of 254 donors, of which 182 fulfilled the study inclusion 
criteria with consent to lung donation. Of these 118 were within the specified distance 
for inclusion into the Trial. Thirty could not be considered for logistical reasons and 
study consent was withheld in 28 giving a Trial group (T) of n=60 and a consent rate 
of 68%. The non-Trial (non-T) group (n= 122) comprised those donors outside the 
specified inclusion distance, those excluded for logistical reasons and those in whom 
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consent was obtained for donation but not the Trial.  Twenty of the overall 254 
donors were only eligible for the cardiac study and are excluded from the analyses.  
177 
 
Total number of potential Trial 
donors (182)
Total number of donors 
approached (88)
Unable to run 2 studies 
within 24 hours period (30)
Excluded due to non unit 
participation or distance 
>100 miles (64)
Trial donors(60)(randomized)
(Lungs = 120)
No consent to Trial (28)
Non-Trial donors (122) (not 
randomized) (Lungs=244)
Lungs retrieved 
(22/62) 35.5%
Lungs retrieved 
(26/58) 44.8%
Group-1
T3 (17)
Group-2
Placebo (14)
Group-3
MP (15)
Group-4
T3 and MP (14)
Non-MP donors(31)
(Lungs= 62)
MP donors (29)
(Lungs= 58)
Total number of zonal donors 
during study period (254)
Lungs transplanted (48/120) 40%
Included in cardiac 
component of study only (20)
Lungs transplanted (66/244) 27%
Excluded from study 
(according to exclusion criteria (72)
p=0.016
Donors not
recruited to Trial
 
 
Figure 12-1-CONSORT diagram demonstrating study enrolment, exclusion, 
allocation to treatment groups and number of lungs transplanted from Trial and 
non-Trial cohorts.   
Donor numbers are in bold and donor lungs in bold italics. The proportion of 
lungs transplanted was higher in the Trial cohort (p=0.0061) 
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The median age, mean PaO2/FiO2 ratio, donor cause of death, percentage 
provisional acceptance for transplantation and fraction of marginal donors between T 
and non-T were not different (Table-12.1)  
 
 
Table 12-1-Characteristics of Trial and non-Trial donors 
 
Parameter   Trial donor  Non-Trial donor  p-value 
Age      47(36, 56)  45(37, 53)   =0.65 
Baseline PaO2/FIO2 ratio 396±79 (377-418) 394±102 (375-412)  =0. 85 
Donor Cause of death 
Vascular & Tumour  83/122 (68%) 40/60 (67%)   =0.98 
Traumatic   28 (23%)  14/60 (23%)   =0.89 
Hypoxic   8/122 (6.5%)  3/60 (5%)   =0.93 
CNS infection   3/122 (2.5%)  3/60 (5%)   =0.64 
Provisional acceptance and marginal fraction of donor lungs 
Provisional acceptance 64/120 (53%) 128/244 (52.5%)  =0.96 
Marginal donors   15/60 (25%)  33/122 (27%)  =0.9 
  
Characteristics of Trial and non-Trial donors  
Values are presented as median (25, 75 centiles), mean ± SD (95%CL) and 
numerator/ denominator (percentage). CNS = central nervous system 
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Within the Trial, management commenced within a median of 2 (IQR 0.5-3.5) hours 
of consent, within a mean of 12.5±8.1 (95%CL10.3-14.6) hours of coning and 
continued for 6.9±1.2 (95%CL6.6-7.3) hours. Trial drugs were commenced 5.9±1.2 
(95%CL5.7-6.3) hours prior to retrieval or end-assessment. There was no difference 
in these variables between treatment groups.  During the management period Trial 
donors received 376ml (95%CL289-463) of colloid to maintain CVP/PCWP and 27m l 
(95%CL4-50) of crystalloid. Bronchoscopy revealed abnormalities in 20 donors, 
including endotracheal tube malposition (7), evidence consistent with aspiration (4), 
edema (2) and excessive purulent secretions (7). Malposition was corrected and 
secretions cleared. Broncho-alveolar lavage yielded positive cultures in 31 donors 
(5/7 with excessive secretions). Organisms cultured included staphylococcal aureus 
(10), streptococcus pneumoniae (6), Gram positive anaerobes (1), Serratia spp. (3), 
Escherichia coli (3), Pseudomonas spp. (2), Klebsiella pneumoniae (4) and Candida 
albicans (2).  
12.3.1-Donor lung function within the treatment groups of the Trial  
Demographic details, suitability and donor lung function for the 4 treatment groups 
are summarized in Table-12.2. Baseline lung function did not differ and the 
administration of MP and T3, alone or in combination, did not affect the PaO2/FiO2 
ratio or any other parameter compared to placebo.  
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Table 12-2-Donor parameters between the four Trial treatment groups 
Parameters   T3
 
Group MP Group T3+MP Placebo p-value 
    (n=17)  (n=15)  Group (n=14)    (n=14) 
Demographics 
Age    55(40, 56) 41(38, 47) 34(26, 53) 52(35, 56) 0.15 
Hospital stay (days)   2(1, 3)  1(0, 2)  2(0, 4)  2(0, 4)  0.56 
Duration of ventilation  1(0, 2)  1(0, 2)  2(0, 4)  2(1, 3)  0.2 
BSD to treatment (h)  12.4±6.6 10.3±6.5) 13.4±7.6 14.1±11.2 0.81 
Duration of treatment (h) 7.5±1.2 6.6±1.1 6.7±1.2 7±1.1  0.44 
Drug treatment duration (h) 6.3±1.3 5.7±1.2 5.9±1.1 6±1.1  0.19 
Lung suitable for transplantation 
    18  18  12  12  0.09 
Donor lung function 
Baseline PaO2/FIO2 ratio 398±79 392±70 383± 85 413± 87 0.78 
Baseline EVLWI  9± 5.2  9.9± 4.3 9.5±4.2 9.9± 3.7 0.78 
Baseline PVPI   2.2± 0.7 2.4± 0.9 2.6±1.4 2.4±0.8 0.67 
Baseline PVR   151± 159 117± 73 106±65 111± 67 0.65 
Baseline PCWP  9.2± 5.1 6.7±4.5 8.3±3.5 9.4±6.1 0.43 
∆- PaO2/FIO2 ratio  50± 125 29± 113 35± 157 37± 132 0.98 
 ∆-EVLWI   2.3±2.8 -0.6±3.9 0.5±2.1 1.5±2.3 0.06 
 ∆-PVPI   0.6± 1.2 0.04± 0.4 0.08± 0.8 0.1± 0.9 0.21 
 ∆-PVR   8.5±123 2.2± 24 -35±114 -23.9± 87 0.58 
Demographic and pulmonary function parameters in the 4 treatment groups of 
the Trial values are presented as median (25, 75 centiles) or mean ± SD. EVLWI 
as ml.kg-1 and PVR as dyne.sec.cm-5. Changes in PaO2/FiO2 ratio, EVLWI, PVPI 
and PVR are presented as ∆-(Baseline value-pre-retrieval value) 
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12.3.2-Donor lung function according to receipt of hormonal therapy 
In the post hoc analysis I compared outcomes in donors receiving or not receiving 
MP (±T3) or T3 (±MP). MP donors were younger (p=0.036) (Table-12.3).  MP 
administration did not affect any absolute parameter (Figure 12-2) although it was 
associated with a reduced accumulation of EVLWI (p=0.009) and a lower pre-
retrieval PCWP (p=0.03). T3 administration did not affect any parameter. 
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Table 12-3-Parameters in Trial donors receiving or not receiving 
methylprednisolone 
    Non-MP donors (n=31) MP donors (n=29) p-value 
Donor demographics 
Age     53(38, 56)  39(30, 48)  0.027 
Hospital stay (d)   2(0, 4)   1(0, 2)   0.36 
Duration of ventilation (d)   2(1, 3)   1(0, 2)   0.4 
BSD to treatment(h)    13.2±9 (9.8-16.6) 11.7±7 (8.9-14.5) 0.53 
Duration of donor management (h) 7.2±1.2 (6.8-7.7) 6.7±1.2 (6.2-7.7) 0.15 
Duration of drug administration (h) 6.2±1.2 (5.7-6.6) 5.8±1.1 (5.3-6.2) 0.07 
Lungs suitable for transplantation 
30   30   1 
Donor lung function 
Baseline PaO2/FIO2 ratio  407± 81 (377-437) 388±77 (359-417) 0.35 
Baseline EVLWI   9.4±4.6 (7.7-11.1) 9.8±4.1 (8.2-11.4) 0.47 
Baseline PVPI    2.3±0.7 (2.0-2.6) 2.5±1.1 (2.1-2.9) 0.17 
Baseline PVR    133±126 (87-180) 114±68 (87-141) 0.38 
Baseline PCWP   9.3± (7.3-11.3) 7.4± (5.8-9.1)  0.15 
∆- PaO2/FIO2 ratio   44±126 (-4-,91) 32±133 (-19-83) 0.73 
∆-EVLWI    1.9±2.6 (1.0-2.9) 0.03±3.1 (-1.1-1.2)  0.009 
∆-PVPI    0.4± 1.1 (0.02-0.9) 0.1±0.6 (-0.1-0.3) 0.25 
∆-PVR     -6±107 (-45-33) -15±80 (-47-17) 0.65 
∆-PCWP    -2.9± 6.3 (-5.2- -0.6) -2.4±2.7 (-3.5- -1.3) 0.74 
Pre-retrieval PaO2/FIO2 ratio  361±124 (315-408) 356±115 (312-399) 0.85 
Pre-retrieval EVLWI   11.4±5.9 (9.2-13.4) 10.2±4.4 (8.5-11.9) 0.37 
Pre-retrieval PVPI   2.7±1.4 (2.2-3.2) 2.7±1.1 (2.2-3.1) 0.93 
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Pre-retrieval PVR   139±109 (99-179.4) 126±99 (86-166) 0.64 
Pre-retrieval PCWP   12.2±4 (10.7-13.6) 9.8±4.2 (8.1-11.5) 0.03 
Characteristics and pulmonary function parameters in Trial donors according 
to receipt of methylprednisolone (MP) Values are presented as mean± SD (95% 
CL) or median (25, 75centiles). EVLWI presented as ml.kg-1 and PVR as 
dyne.sec.cm-5. Changes in PaO2/FiO2 ratio, EVLWI, PVPI and PVR are presented 
as ∆ (Baseline value-pre-retrieval value). 
 
12.3.3-Observations in the whole Trial population  
In the 60 Trial donors, between baseline assessment and retrieval, lung function 
deteriorated significantly (Table-12.4). PaO2/FiO2 fell while EVLWI and PVPI both 
increased, PVR remained unchanged. PaO2/FiO2 rose following lung inspection and 
recruitment of atelectatic segments (Figure-12.2) 
 
184 
 
200
250
300
350
400
450
500
non-MP donors MP-donors
PaO2/FiO2- 1 PaO2/FiO2- 3PaO2/FiO2- 2 PaO2/FiO2- 4
Pa
O
2/F
iO
2 
ra
tio
‡ ‡
* #
Figure 12-2-Changes in PaO2/FiO2 ratio ± 95% confidence intervals in donors 
receiving (MP n=29) or not receiving (non-MP n=31) methylprednisolone 
PaO2/FiO2-1 was measured before initial bronchoscopic examination and 
hemodynamic studies. PaO2/FiO2-2 was measured following bronchoscopy and 
PaO2/FiO2-3 was measured one hour after the 2nd measurement. PaO2/FiO2-4 
was measured at end-assessment in the OR after inspection of the donor 
lungs. The mean time between PaO2/FiO2-1 and end-assessment PaO2/FiO2 was 
6.9 hours. Note the y axis does not commence at zero. There was a significant 
deterioration between baseline and PaO2/FiO2-3(p<0.001) in both groups but 
improvement following inspection and recruitment of atelectatic segments 
(non-MP* p=0.005; MP# p=0.0135). There was no difference between groups 
(p=0.969).  
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Table 12-4-Overall parameters of lung function within Trial donors (n=60) 
 
Parameter  Baseline value  Pre-retrieval value  p-value 
 
PaO2/FIO2 ratio 397±78 (376- 417)  359±126 (328-390)  =0.028 
EVLWI  9.7±4.5 (8.6-10.9)  10.8± 5.2 (9.4-12.2)  =0.009 
PVPI   2.4±0.9 (2.2-2.7)  2.7±1.2 (2.4-3.0)   =0.025 
PVR   123±103 (96-151)  133±104 (106-161)  =0.50 
  
Changes in pulmonary function observed in all Trial donors (n=60).  
Values are presented as mean± SD (95% CL). EVLWI presented as ml.kg-1 and 
PVR as dyne.sec.cm-5. 
 
At initial assessment 35/60 (58%) of Trial donors were receiving NA. By adding VP, it 
was possible to withdraw NA completely in 21/35(60%) and reduce NA from 
0.25±0.3µg.kg-1min-1 (95%CL0.13-0.36) to 0.11±0.27µg.kg-1min-1(95%CL0.01-0.2) in 
the remainder (p<0.001).  In donors receiving NA at initial assessment, PaO2/FiO2 
ratio deteriorated (p=0.038) from 398± 84(95%CL368-427) to 350±131 (95%CL304-
396) compared to 395±73 (95%CL364-425) and 370±100 (95%CL328-412) in non-
NA donors (p=0.35). EVLWI also increased (p=0.04) in NA donors from 10.1±5.2 
(95% CL8.3-11.9) to 11.4±6.2ml.kg-1(95%CL 9.3-13.4). These changes were not 
influenced by the ability to withdraw NA.  
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12.3.4-Suitability of lungs for transplantation and transplant outcomes 
More donors yielded lungs for transplantation in the Trial cohort (26/60 versus 
35/122; p=0.054) and the number of lungs transplanted was significantly higher 
(p=0.016) in the Trial cohort (48/120; 43%) than the non-Trial cohort (66/244; 27%) 
(Fishers Exact test) (Figure-12.1). Although 48/120 Trial donor lungs were 
transplanted, a further 12 lungs (not provisionally accepted for transplantation) were 
also found to be suitable for transplantation at end-management.  
Sixty lungs were deemed unsuitable due to deteriorating PaO2/FiO2 or hemodynamic 
features (n=30), abnormality on inspection (bullous disease, adhesions, intractable 
atelectasis (n=16), marginal PaO2/FiO2 ratio ± excessive secretions in conjunction 
with adverse donor history (age >60 years, mild asthma and smoking) (n=10) and 
hepatitis C positivity (n=4). In marginal Trial donors (n=15), PaO2/FiO2 increased 
slightly (292±34 (95%CL273-311) to 331±152 (95%CL247-416) although this change 
was not significant (p=0.34). Administration of methylprednisolone in these marginal 
lung donors did not influence the change in EVLWI (p=0.15) during management.  
Four of 30 marginal lungs were transplanted and 8/30 lungs met suitability criteria. 
On univariate analysis, lower baseline EVLWI, particularly EVLWI <10ml.kg-1 and 
shorter time from coning, predicted suitability for transplant at end-management 
(Table-12.5).  
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Table 12-5-Comparison of (Trial) donor parameters between suitable and non-
suitable lungs for transplantation (Univariate analysis) 
 
Parameter   Unsuitable lungs   Suitable lungs p-value 
            (n=60)          (n=60) 
     
Donor age   48(30, 55)   45(37, 56)  =0.89 
Time from coning (h) 12±8.6 (0.75-23.25)  8.5±6.3 (2-15) =0.02 
Baseline PaO2/FIO2 ratio  377±90 (342- 412)  416±64 (393-440) =0.09 
Baseline EVLWI  11.2±5.6 (8.9-13.3)  8.4±2.9 (7.4-9.6) =0.02 
Baseline PVPI  2.6±0.8 (2.2-2.9)  2.3±0.9 (1.9-2.6) =0.13  
∆- PaO2/FIO2 ratio  66±146 (10-123)  12±107 (-28-+53) =0.1 
∆-EVLWI    -1.1±3.8 (-2.5, +0.5)  -0.9±1.9 (-1.6, -0.2) =0.73  
∆-PVPI   -0.4±0.7 (-0.6, -0.04) -0.08±0.6 (-0.3, 0. 2)=0.09  
MP positive    30/60 (50%)   30/60 (50%)  =1 
NA positive   30/60 (50%)   38/60 (63%)  =0.3 
Baseline- EVLWI  34/60 (56%)   54/60 (90%)  =0.019 
<10ml.kg-1 
 
Univariate comparison of (Trial) donor factors between suitable (n=60) and 
non-suitable (n=60) lungs for transplantation. Values presented as median (25, 
75 centiles), mean±SD (95%CL) or numerator/ denominator (percentage). 
EVLWI presented in ml.kg-1. MP-positive=donor receiving methylprednisolone. 
NA-positive=donor receiving noradrenaline at initial assessment. 
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On stepwise logistic regression analysis higher baseline PaO2/FiO2 ratio (Odds ratio 
(OR) =1.014(95%CL1.0-1.025); p=0.01 and lower ∆-EVLWI (OR=1.66(95%CL1.13-
2.5); p=0.01, independently predicted suitability. These data were not available in 
non-Trial donors preventing further analysis. The 30-day and 1 year survivals for Trial 
and non-Trial lung transplant recipients were 96.3% versus 92.1% (p=0.636) and 
77.8% versus 76.3% respectively (p=1).  
 
12.3.5. Effect of Trial management on other solid organ retrieval 
Within the Trial, 25 hearts, 57 livers and 118 kidneys were transplanted. Non-use of 
these organs was based upon intrinsic abnormality or failure to identify suitable 
recipients.  In 4 donors, the study assessment identified poor heart function and 
hemodynamic decline despite maintained MAP. In these, cardiothoracic organ 
offering was abandoned allowing rapid procurement of liver and kidneys.  
 
12.4-Discussion 
Active and early donor management, as undertaken in the Trial cohort, increased the 
yield of transplantable lungs from the existing donor pool with equivalent recipient 
outcomes and without jeopardizing other organ retrieval.  
A third of donors with normal chest X-ray have bronchoscopic abnormalities that may 
be correctable (180). Bronchoscopy, by clearance of secretions and blood clots and 
correction of endotracheal tube malposition may improve lung function. It may also 
identify factors precluding lung donation and may thereby avoid delay in retrieving 
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other organs.  Limited crystalloid administration also appears important and may 
maintain better gas exchange (101).   
Combination of both MP±T3 might improve donor lung function via their effects on 
the heart, endothelium and lung epithelium.  T3 had no effect but MP attenuated the 
accumulation of EVLWI, supporting its use in lung donors. Despite such active 
management, PaO2/FiO2 deteriorated with rising EVLWI and PVPI suggesting 
increasing permeability. The deterioration of PaO2/FiO2 ratio was not affected by MP 
or T3.  Early MP (15 mg.kg-1) administration has been associated with improved lung 
yield in a retrospective report but in this report, MP-treated donors were actively 
managed for a longer period which may have contributed to the observed changes. 
The study may have been under-powered to corroborate these findings but suggests 
that MP use in isolation is not a substitute for active management. Neither T3 nor MP 
administration was associated with worsening lung function and a beneficial post-
transplantation effect cannot be excluded.  Moreover, MP administration took place 
12.5hours after coning was recognized and earlier administration may be necessary 
to realise any beneficial effect.  
Vasoparetic hypotension post-BSD is commonly treated by NA, a potent but 
cardiotoxic α-adrenergic agonist (150). In the Trial, PaO2/FiO2 ratio and EVLWI 
deteriorated in donors receiving NA and this was not prevented by NA withdrawal. 
The reason for the association between NA and lung dysfunction is unclear. NA 
requirement may reflect greater cardiac dysfunction, a greater pro-inflammatory 
response or a deleterious effect on pulmonary endothelium. Donor pressor support 
with NA has been associated but worse prognosis in heart and lung transplantation 
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(152) and inferior post-transplant gas exchange (181)., Although NA usage did not 
affect yield in this study its use in potential lung or heart donors may be inadvisable.  
EVLWI is a validated index of pulmonary oedema and may be elevated before 
changes in gas exchange, clinical status or chest X-ray (182;183).  On univariate 
analysis, a normal EVLWI (<10ml/.kg-1) and on multivariate analysis, a lower ∆-
EVLWI and higher baseline PaO2/FiO2 predicted the eventual suitability of lungs for 
transplantation. AFC, the capacity to remove alveolar water by active ion transport, 
remains normal in most donor lungs, even those rejected for transplantation 
(184;185) and normal AFC hastens resolution of post-transplantation edema (91). As 
increased AFC, in response to steroids and β-adrenergic stimulation has been 
documented in experimental neurogenic pulmonary oedema and human acute lung 
injury this may be the mechanism for the reduced ∆-EVLWI observed with MP. Thus, 
measurement and manipulation of lung water may become important in the 
assessment and management of potential lung donors (186;187).  
On univariate analysis, a shorter time from coning predicted transplant suitability.  
This may reflect less time for secondary lung injury to occur due to fluid overload, 
aspiration, ventilatory barotrauma and nosocomial colonisation and a shorter duration 
of lung exposure to a hostile hemodynamic and pro-inflammatory environment. 
Earlier truncation of this exposure may retain better lung function.  
 
Although, prospective, randomized, blinded and controlled, this Trial remains 
numerically small and as recruitment did not reach the intended sample size, it is 
under-powered to detect differences between individual therapy groups. However, as 
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both Trial and non-Trial donor cohorts had similar ages, initial PaO2/FiO2 ratios, 
proportions with marginal PaO2/FiO2 ratios and provisional acceptance rates, the 
study demonstrates the importance of donor management in increasing yield 
especially as Trial lungs were not re-offered following initial rejection.  Although non-
Trial donor care was based on a similar management protocol albeit without 
bronchoscopy or invasive monitoring, management was overseen by DPCs who are 
simultaneously engaged in a logistical process including acquisition of consent, 
donor family support, offering of organs to recipient centers, arranging the multi-
organ retrieval procedure and transportation of organs and tissue. In contrast, I was 
wholly dedicated to the donor management and I would suggest that this dedicated 
donor management role is fundamental to maximize yield and this could be increased 
further if repeat offering of lungs improving post-management occur.  
 
12.5-Conclusion 
Lung transplant availability can be increased by better management of lung donors. 
Early steroid administration is a component part of this management but is not a 
substitute for intensive donor care.  
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13. A STUDY OF MEASUREMENT OF EXTRAVASCULAR LUNG 
WATER IN POTENTIAL LUNG DONORS 
 
13.1. Introduction 
Extra-vascular lung water (EVLW) may increase in brain-stem dead potential lung 
donors for a number of reasons, particularly over-zealous crystalloid fluid 
replacement, direct lung injury associated with the cardiovascular events of coning 
(16) and secondary effects related to the pro-inflammatory response or cardiac 
dysfunction (45;174). In these circumstances, lung water measurement may have 
clinical utility. EVLW can be measured in different ways (124;125) and but a widely 
validated method to derive a measure of EVLW is pulse-induced contour cardiac 
output (PiCCO), a single thermodilution technique based on the Stewart-Hamilton 
principle (128). The EVLW may be indexed to body weight and has a normal range of 
3-7ml.kg-1. Experimentally, EVLWI measured using this thermodilution method 
(EVLWI-T) has been shown to correlate well with lung water measured by gravimetry 
(EVLW-G) (133;188).  Early data, using a thermal dye double indicator dilution 
technique in humans following BSD suggested that although such techniques over-
estimated EVLWI-G, they provided a reliable index of lung water content and could 
be of clinical utility (132). 
 
EVLWI elevation precedes clinical, radiological and oxygenation manifestations of 
lung oedema (182;183) and is a predictor of outcome in a critically ill patients with 
acute pulmonary oedema and acute respiratory distress syndrome (134).  
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In vivo assessment of the donor lung is currently reliant on donor history, chest-X-ray 
evaluation, arterial and pulmonary venous blood gas measurement, bronchoscopy 
and direct inspection. Despite best efforts during assessment, retrieval and 
transplantation, there is a disturbing incidence of lung injury manifest as primary graft 
dysfunction with impaired gas exchange and pulmonary infiltrates. In view of this, 
estimation of lung water content may enhance the assessment process of the donor 
lung. The aims of this observational study were to present the EVLWI findings in 
potential lung donors and to validate this measurement in lungs not used for 
transplantation. We also evaluated the role of EVLWI measurement during protocol 
guided donor management, assessed the changes in EVLWI in response to 
administration of methylprednisolone, its role in predicting lungs suitable for 
transplantation and recipient outcome following transplantation.  
 
13.2. Methods 
 
13.2.1. Study design 
Between, January-2004 and April-2006, contemporaneous PiCCO EVLWI and 
arterial blood gas measurement (ABG) was performed in 60 potential lung donors 
recruited into a prospective study on early donor management and hormonal therapy. 
Additional consent was obtained when possible to retain lungs rejected for 
transplantation for gravimetric lung water assessment.  
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13.2.2. Donor management 
At initial assessment all donors underwent ABG (mmHg) measurement at a fractional 
inspired oxygen (FiO2) 1.0 and 5cmH2O positive end-expiratory pressure (PEEP). 
Invasive monitoring lines were inserted as previously described for measurement of 
hemodynamic parameters, EVLWI (normal range 3-7ml.kg-1) and pulmonary vascular 
permeability index (PVPI). The underlying principles and analysis of lung water 
assessment have been previously reported (128;129). The PVPI is the EVLW/ 
pulmonary blood volume ratio. Elevated EVLW with low PVPI implies hydrostatic 
edema whereas a high EVLW and PVPI imply permeability edema.  Following initial 
assessment, bronchoscopy was performed to assess anatomy and endotracheal 
tube placement, to aspirate secretions, to detect evidence of active bronchitis or 
aspiration and to obtain a broncho-alveolar lavage (BAL) specimen for culture. 
Donors were then randomized to receive either T3 (0.8µg.kg-1 IV bolus followed by 
0.113µg.kg-1. hr-1 IV infusion); MP (1000mg IV) as a single dose; both T3 and MP or 
placebo (dextrose 5%) and the T3/placebo infusion continued until retrieval. The 
duration of treatment and time of coning (detection of fixed dilated pupils and BP 
surge) were noted. All medical, nursing and technical staff involved in the research or 
donor care remained blinded to treatment allocation until study completion. The 
donors were managed according to a strict protocol. Management, continued in the 
ICU and OR until retrieval.   
 
13.2.3. Retrieval of donor lungs 
Donor lungs accepted for transplantation were flush perfused with single dose of 
antergrade pneumoplegia (Papworth solution- ringer lactate 700mls, human albumin 
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(20%) 200mls, 20% mannitol 100mls and heparin 10,000 units along with donor 
blood (300ml), citrate/phosphate/dextrose chelating agent (56mL)) and a single dose 
of epoprostenol (prostacycline) infusion (0.5 mg in 20mls (Flolan, (GlaxoSmithKline, 
UK Ltd)).  Donor lungs were retrieved for gravimetric lung water assessment without 
pneumoplegia or prostacycline infusion. Donor lungs were retrieved as a whole block 
after explanting the donor heart. The trachea was stapled after expansion of both 
lungs. The retrieved lung blocks were transported in cold ringer lactate solution in 3 
plastic bags in 4 degree C.  
 
13.2.4. Gravimetric measurement of lung water 
Gravimetric analysis of lung water was calculated in the laboratory by the Holcroft 
and Trunkey modification of the Pearce method (189;190).  This method is based on 
the comparison between the wet and dry weight of the lungs, which gives the total 
pulmonary water content. The lung blood volume is calculated by determining the 
haemoglobin in the lung tissue and systemic circulation. The lung blood weight is 
then subtracted from the total lung water to give gravimetric extravascular lung water.  
 
10mls of terminal pulmonary venous effluent blood was collected prior to retrieval of 
lungs along with venous blood sample in EDTA bottle for haemoglobin estimation. 
Lungs were retrieved in a standard manner and transported at 4ºC in Ringer lactate 
solution in an inflated state. Within 8 hours of retrieval, lungs were split on table and 
were weighed. Lung samples from upper and lower lobes were weighed and then 
homogenised with a known amount of distilled water and centrifuged at 12,000 rpm 
for 30 minutes at 4oC. The wet weights of supernatant, lung sediments and the 
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pulmonary venous blood were obtained. Haemoglobin levels from the pulmonary 
venous effluent blood and supernatant samples were measured. Supernatant, blood 
and the lung sediments were then freeze dried for 72 hours and were weighed again 
to obtain their dry weight. EVLW was calculated according to the formula described 
by Holcroft and Trunkey.   
 
13.2.5. Endpoints and Statistics 
All hemodynamic and lung function parameters including EVLWI and PVPI was 
measured at baseline and repeated after initial bronchoscopic examination, 1 hour 
thereafter and immediately pre-retrieval. Data were analyzed using SPSS v15.0 
(Chicago, IL). Continuous data were assessed for normality and are presented as 
mean± SD (95% confidence limits (CL)) or median (inter-quartile range (IQR)). 
Normally distributed variables were tested using independent or paired sample t 
tests. Skewed data were tested using non-parametric test (Mann-Whitney and 
Kruskal-Wallis test). Comparison between gravimetry and thermodilution was 
performed using spearman’s correlation and Bland-Altman analysis. Categorical data 
were analyzed using Χ2 and Fisher’s Exact testing. Recipient survival was compared 
using log-rank test according to EVLWI dichotomised at 10ml.kg-1 and Kaplan-Meier 
survival.  Statistical significance was assigned when p≤0.05.  
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13.3. Results 
13.3.1. Donor demographics 
The demographic details of all 60 donors are described in Table-13.1. The donor 
management commenced within a median of 2 (IQR 0.5-3.5) hours of consent, within 
a mean of 12.5±8.1 (95%CL10.3-14.6) hours of clinical coning and continued for 
6.9±1.2 (95%CL6.6-7.3) hours. During management the donors received 376ml 
(95%CL289-463) of colloid to maintain CVP/PCWP and 27m l (95%CL4-50) of 
crystalloid. 
Table 13-1- Donor demographic data 
 
Parameter     n=60  
Age        47(36, 56)   
Sex (Female: Male)    31: 29   
Baseline PaO2/FIO2 ratio   396±79 (377-418)  
Donor Cause of death 
Vascular & Tumour    40/60 (67%)    
Traumatic     14/60 (23%)   
Hypoxic     3/60 (5%)    
CNS infection     3/60 (5%)  
Duration of ventilation (hours)  24 (24, 48) 
Hospital stay (d)     2 (1, 2) 
 
Data are presented in mean ± standard deviation or median (25, 75 centiles).  
CNS- central nervous system 
198 
 
13.3.2. Baseline parameters 
 
The mean overall initial EVLWI-T was 9.7±4.5. In 39/60 it was >7ml.Kg-1 and 
>10ml.kg-1 16/60. Baseline EVLWI values of ≤7, 7-10 and >10ml.kg-1 corresponded 
to arterial pO2/FiO2 ratios to 359±71.1, 413±71 and 428±83 respectively.PaO2Fio2 
ratios in donors with EVLWI >10ml.kg-1 were only slightly higher that lower than 
values ≤10ml.kg (387±75 versus 428±83; p=0.08).There was no correlation initial 
EVLWI and PaO2/FiO2 ratio measurements. Baseline PVPI was mean 2.4±0.9 and it 
significantly correlated with initial EVLWI (r=0.8, p<0.001). Donors with EVLWI-T 
>7ml.kg-1, had significantly higher PVPI values (2.8±1 vs 1.9±0.4; p=0.003) 
suggesting increased permeability as a contributor to lung water excess. 
 
13.3.3. Pre-retrieval parameters 
 
In the whole cohort EVLWI and PVPI increased significantly from 9.7±4.5 to 
10.8±5.2; p=0.009 and 2.4±0.9 to 2.7±1.2 (p=0.025) respectively while the. 
PaO2:FiO2 ratio fell (397±78 to 359±126 (p=0.028)) suggesting increasing oedema 
and pulmonary permeability. The final EVLWI was >10 in 22 donors. On univariate 
analysis initial EVLWI, initial PVPI, duration from coning were each higher in lungs 
with an end-EVLWI >10ml.kg-1 and significantly lower number of lungs were 
ultimately suitable for transplantation (Table-13.2).    
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Table 13-2- Univariate analysis of parameters in donors with end-assessment 
EVLWI<10ml.kg-1 and 10ml.kg-1 
 
   End-EVLWI<10ml.kg-1   End-EVLWI>10ml.kg-1 p-value 
(n=38)    (n=22) 
 
Age    45.5±12.1   41.8±14.5  =0.32 
Duration from coning (h) 11.1±6.1   16.5±9.5   =0.03 
Baseline PO2 (mm Hg) 386±82   418±71  =0.12 
Duration of ventilation (h) 45±43    61±59   =0.09 
Baseline EVLWI (ml.kg-1) 7.8±2.4   13.1±5.4  <0.001 
Baseline PVPI  2.1±0.4   3±1.2   <0.001 
Lungs suitability  24/38 (63%)   6/22 (27%)  <0.001 
 
 
 
13.3.4. Noradrenaline use and extravascular lung water index 
 
At initial assessment 35/60 (58%) of Trial donors were receiving noradrenaline (NA). 
By adding vasopressin (VP), it was possible to withdraw NA completely in 
21/35(60%) and reduce NA from 0.25±0.3µg.kg-1min-1 to 0.11±0.27µg.kg-1min-1 in the 
remainder (p<0.001).  In donors receiving NA at > 0.06 µg.kg-1min-1 dose at initial 
assessment, the EVLWI (8.5±3.2 vs 11.6±5.7; p=0.011) and PVPI (2.1±0.5 vs 
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2.8±1.2; p=0.01) were significantly higher. These changes were not influenced by the 
ability to withdraw NA.  
 
13.3.5. Extravascular lung water index and suitability of lungs for 
transplantation 
 
Lung suitability for transplantation in this study was defined as a PaO2/FiO2 ≥300 
without identifying lung trauma, aspiration, infection or non-recruitable atelectasis 
during assessment and at direct inspection. Initial EVLWI was lower in suitable lungs 
(8.4±2.9 versus; 11.2±5.6 p=0.02) and on univariate analysis an initial EVLWI ≤10 
ml.Kg-1 was predictive of suitability (p=0.019). We undertook receiver operating 
characteristic curve analysis for both initial pO2 and EVLWI as a guide to ultimate 
lung transplant suitability. It demonstrated both baseline PO2 (A=0.66± (SE) 0.07 
(95% CI 0.52, 0.8), p=0.03) (Figure-13.1) and baseline EVLWI (A= 0.67± (SE) 0.07 
(95% CI 0.53, 0.81); p=0.025) predicted end-assessment lung suitability for 
transplantation (Figure-13.2). 
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Po2-300 mm Hg
 
Figure 13-1- ROC curve demonstrating the relationship between sensitivity and 
1-specificity in determining the predictive value of baseline PaO2 in identifying 
lungs suitable for transplantation  
 
The area under ROC curve (A) ± SE is reported 
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EVLWI-10 ml.kg-1
 
Figure 13-2- ROC curve demonstrating the relationship between sensitivity and 
1-specificity in determining the predictive value of baseline EVLWI for 
identifying lungs suitable for transplantation 
 
The area under ROC curve (A) ± SE is reported.  
 
13.3.6. Recipient outcome after transplantation 
Twenty six out of 60 donor lung pairs were retrieved for transplantation.  However, 6 
single lung transplantation and 21 bilateral lung transplantation were performed. The 
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overall 30 day and 1 year mortality following transplantation was 96% and 74%. 
However, recipients who received lungs from donors with baseline EVLWI >10 ml.kg-
1
 performed significantly worse after transplantation. The peri-operative mortality was 
significantly higher (p=0.03) and their long term outcome was also inferior compared 
to recipients who had received lungs from donors with EVLWI<10 ml.kg-1 (p=0.03) 
(Figure-13.3).    
 
p=0.03
 
Figure 13-3-Kaplan-Meier survival curve demonstrating early recipient outcome 
following transplantation 
Log rank test showed significantly worse outcome for recipients who had 
received lungs from donors with elevated baseline EVLWI > 10 ml.kg-1.   
204 
 
13.3.7. Lung water index validation 
 
Twenty donor lungs not accepted for transplantation were removed for research 
analysis (9 bilateral lungs and 2 single lungs). EVLWI measured by thermodilution 
using single cold saline indicator correlated well with gravimetric lung water 
measurement (r=0.7; Spearman’s correlation p=0.002) (Figure-13.4). On regression 
analysis a relationship between the two measurements was noted (EVLW-T= 
3.04+0.85 × EVLW-G). The thermodilution method over-predicted the EVLWI 
compared with gravimetry with a mean difference (positive bias) between EVLWI-T 
and EVLWI-G on Bland-Altmann analysis of 1.6±2.14 ml.kg-1. The upper and lower 
limits of agreement (± 2 standard deviations) were 5.8 and -2.6 ml.Kg-1 respectively 
(Figure-13.5). Positive bias increased with higher EVLWI.  
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Figure 13-4-Correlation between EVLWI measurement by thermodilution and 
gravimetry (r=0.7; Spearman’s correlation p=0.002) 
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Figure 13-5-Bland-Altman plot demonstrating limits of agreement between 
EVLWI measurement by thermodilution and gravimetry 
 
EVLWI-T over predicted the EVLWI-G and there was a positive bias which 
increased with higher EVLWI-T. However the limits of agreement vales lie 
between the 2 standard deviation 
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13.4. Discussion 
This prospective observational study demonstrated that EVLWI is elevated in majority 
of the potential lung donors, its measurement predicted the suitability of lungs for 
transplantation and also recipient outcome. Lung water may increase in donor lungs 
by various mechanisms of injury like trauma, aspiration, infection, fluid overload and 
ventilatory barotrauma. These may occur before or after BSD.  Also, during BSD, 
hemodynamic shear forces and pro-oedematous hydrostatic pressures may cause 
direct injury to the lungs. Each of these modes of injury may be further exacerbated 
by a pro-inflammatory post-BSD environment (16;173;174;191). All these 
mechanisms could lead to pulmonary oedema, worsening lung function and is a 
primary reason for rejection of lungs for transplantation (90).  
Elevation of EVLWI precedes clinical, radiological and oxygenation manifestations of 
lung oedema (182;183). EVLWI measurement by thermodilution method is well 
validated, it guides treatment in critically ill patients (129;135). In a retrospective 
analysis of 373 critically ill patients EVLWI correlated significantly with poor outcome 
and on multivariate analysis found to be an independent predictor of prognosis (134). 
It is relatively non-invasive procedure requiring insertion of femoral arterial line and 
can guide fluid management in an organ donor.  
The epithelial Na+/K+-channels in alveolar epithelium have an important role in 
absorption of excessive fluid from the alveolar space. Steroids with their anti-
inflammatory property and up regulation of alveolar fluid clearance (AFC) may be 
beneficial in manipulating the lung water in a post-BSD lung donor (92;97).   In a 
prospective placebo controlled trial (BALTI trial) Perkins et al. had demonstrated that 
intravenous administration of beta-adrenergic agonist, salbutamol was associated 
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with significant reduction in EVLWI-T and a trend towards lower lung injury (187). 
Administration of nebulised beta-adrenergic agonists can achieve therapeutic levels 
in plasma and pulmonary oedema fluid and can augment the AFC (192). I had 
demonstrated that administration of methylprednisolone in the same cohort of donors 
was associated with significant reduction in progressive lung water accumulation 
(156).  
Pulmonary oedema as a result of reperfusion injury occurs in 15-35% of recipients 
and is associated with poor outcome (90). Although there was no correlation between 
EVLWI and arterial oxygenation, our study demonstrated donor lungs with EVLWI 
>10 ml.kg-1 was associated with worse peri-operative mortality and long term 
outcome.  Measurement of EVLWI-T helps in identifying donors with elevated lung 
water and can guide in donor fluid management and to use interventions that would 
increase AFC. Improved AFC has been shown to be associated with rapid resolution 
of hypoxia and improvement in radiological changes following transplantation (91).   
Thermodilution EVLWI measurement is well validated and in animal studies it has 
been reported to correlate well with the gold standard gravimetric lung water 
measurement (130;131).  In both these animal trials the EVLWI-T has over predicted 
the EVLWI-G. In our study we noted the same with thermodilution over predicting the 
gravimetric values. This discrepancy increased with progression of pulmonary 
oedema and in extreme levels the over prediction was higher. However, they both 
correlated well and this is a first study to demonstrate the use of ELWI measurement 
in potential lung donors. 
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Vasoparetic hypotension post-BSD is commonly treated by NA infusion, a potent but 
cardiotoxic α-adrenergic agonist (150). In our study EVLWI and PVPI were 
significantly elevated in donors receiving NA and this was not affected by NA 
withdrawal. The reason for the association between NA and elevation of lung water 
may reflect greater cardiac dysfunction, a greater pro-inflammatory response or a 
deleterious effect on pulmonary endothelium. Donor pressor support with NA has 
been associated but worse prognosis in heart and lung transplantation (152) and 
inferior post-transplant gas exchange (181). Therefore NA usage in potential organ 
donors is inadvisable.  
 
13.5. Conclusion 
 
In summary, measurement of thermodilution EVLWI is easy and reliable. It is found to 
be elevated in majority of potential lung donors. It predicted recipient outcome 
following transplantation.  Elevated EVLWI-T is a target for modifying therapy during 
optimisation. Donor treatment with noradrenaline is associated with lung water 
excess. Even though EVLWI-T intrinsically over-estimates gravimetric lung water, its 
measurement may aid assessment of organ suitability.  
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14. SUMMARY AND POTENTIAL AREAS FOR FUTURE 
RESEARCH 
 
14.1. Summary of findings  
 
This research study has examined the impact of early protocol driven management 
and the effects of tri-iodothyronine, methylprednisolone, combination of both or 
placebo in a randomised, factorially designed, double blind , controlled clinical trial in 
potential heart and lung donors. The effects of these interventions were examined 
and discussed in relation to donor heart and lung functions, impact on heart and lung 
retrieval rate, impact on pro-inflammatory post-BSD environment and 
echocardiographic assessment. The study demonstrated that early donor 
management was associated with improved donor heart function and can potentially 
increase the retrieval rate of hearts for transplantation. All haemodynamic parameters 
were significantly better prior to retrieval when compared with baseline parameters. 
This was achieved simply by adjusting the pre and afterload of the donors guided by 
invasive monitoring. Commencing vasopressin infusion lead to stability on donor 
haemodynamics and enabled weaning of noradrenaline. This was associated with 
significant improvement in donor cardiac index.  In contrast to heart function, the 
donor lung function continued to deteriorate despite donor management but with 
significant increase in retrieval rate of lungs for transplantation.  
 
Hormone replacement therapy with T3 and methylprednisolone either alone or in 
combination was not associated with any improvement in donor heart or lung function 
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when compared with placebo. It also does not influence the retrieval rate of hearts 
and lungs for transplantation. However, MP administration was associated with 
significantly less progressive lung water accumulation.  
 
Donor echocardiography is an effective non-invasive tool that correlates well with 
invasive monitoring data and helps in identifying hearts that are definitely likely to be 
successful and also helps in identifying hearts with moderate left ventricular function 
for targeted donor management. The hearts with poor LV ejection fraction were found 
to be unsuitable for transplantation and are unlikely to improve despite donor 
management.  
 
The study evaluated the prevalence of pro-inflammatory cytokines and found 
profound increase in IL-6 in all donors. High levels of TNF-α and PCT was associated 
with poor donor heart function. The dysfunction correlated with levels of PCT 
elevation. The cytokine level was not influenced by steroid administration and did not 
preclude hearts from transplantation. The study also evaluated the role of donor 
cardiac troponin-I levels in heart donors. CTnI levels were elevated in all donors and 
it negatively correlated with left ventricular function. Haemodynamic and 
echocardiographic parameters of LV function were significantly worse in donors with 
CTnI >1µg.L-1. However, the number of hearts transplanted from this group did not 
differ when compared with CTnI <1µg.L-1. The operative and early outcome following 
transplantation of hearts from each group did not differ. It demonstrated that donor 
CTnI is a surrogate of donor heart function and guides in targeted donor 
management but does not affect outcome. 
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The study evaluated the role of EVLWI measurement in lung donors. It demonstrates 
that EVLWI deteriorated despite donor management. The deterioration was worse in 
donors requiring noradrenaline support. The EVLWI correlated with PVPI suggesting 
permeability oedema. Measurement EVLWI differentiated the lungs that would be 
ultimately suitable for transplantation and also predicted operative and early post-
transplant outcome. The EVLWI measured by single injection thermodilution method 
correlated well with gravimetric lung water estimation.  Early steroid administration 
reduced the progressive lung water accumulation but did not influence the 
oxygenation.  
 
14.2. Early donor management-Future 
Early donor management was associated with improved donor heart function 
however the study did not show a statistically significant increase in heart retrieval 
rate. The study demonstrated that 20% of more hearts could have been used for 
transplantation at the end of assessment.  As it was a research trial the normal donor 
heart offering sequence took place simultaneous to the study conduct. Hearts that 
were rejected by transplant units earlier were not reoffered even if they were found to 
be suitable after a period of donor management. The study clearly demonstrated the 
need for trained donor management practitioners (DMP) to be involved in every 
retrieval operation. In future DMP should attend the donors early and institute the 
invasive monitoring and protocol driven management. The donor offering sequence 
should also be delayed by at least 2 to 3 hours enabling   insertion of monitoring lines 
and institution of management and weaning of vasoconstrictors. Offering donor 
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organs with more detailed invasive data will be preferable and will increase the donor 
heart acceptance rate. This should hopefully lead to increased heart retrieval and 
transplantation in future. 
 
Early donor management has another advantage, as seen during the study. A small 
proportion of donors with very poor heart function or gross aspiration/infection in 
airways on bronchoscopy, precluding lung donation, were identified early. Heart/lung 
offering was stopped in these donors thereby avoiding unnecessary delay and 
facilitating early mobilisation of retrieval teams for intra-abdominal organ retrieval. If 
the same process could be followed with the implementation DMP attending every 
donor there will be a reduction in the number of abandoned retrieval procedures. This 
will also avoid unnecessary delay in retrieval and even wastage of other organs due 
to sudden cardiovascular compromise of the donor.  
 
Donor retrieval is an expensive, labour intensive procedure. Each abandoned donor 
retrieval procedure impacts on the recipient centres financially and also affects the 
conventional cardiac surgery work load the following day.  Therefore early donor 
management should probably be instituted by every retrieval teams in the UK. 
Following this trial results we hope that this will be initiated by every transplant unit in 
the country and in future we should see an increase in both the quality and the 
quantity of the donor organs available for transplantation.  
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14.3. Hormone replacement therapy in organ donors-Future 
Hormone replacement therapy using T3 and methylprednisolone did not affect any of 
the measured parameters of donor heart function or retrieval rate in this study. This 
could be due to number of reasons. The study although prospective was numerically 
small which demonstrates the difficulties in undertaking such trial in donor population. 
The donors were managed for 6 to 7 hours prior to retrieval and the time duration of 
T3 therapy was probably inadequate to produce any haemodynamic effect in the 
donors. Based on our study I could not recommend avoiding hormone replacement 
therapy for multi-organ donors. In future studies involving larger number of donors 
managed for a longer duration may be required to clearly define the role of hormone 
replacement therapy on organ donors.  
 
I also did not assess the effect of hormone therapy on recipient haemodynamic 
function.  The delayed genomic effects of T3 therapy may influence the recipient 
haemodynamics and outcome post-transplantation. Analysis of myocardial biopsy 
specimens from the donor left ventricle prior to heart retrieval to study the genomic 
expression of T3 administration would be required. The effect of early steroid therapy 
and noradrenaline withdrawal on recipient organ rejection episodes is also unknown. 
Studies comparing the outcome on recipients from donor managed cohorts with 
matched contemporary non-donor managed recipients might answer some of the 
questions raised.  
 
Early steroid administration was associated with significantly reduced lung water 
accumulation during management in this study, but it was not associated with any 
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change in oxygenation. Steroids should probably be administered earlier, 
immediately after coning to get the benefit. However, managing a patient as an organ 
donor is ethically wrong at present before confirmation of BSD and consent for organ 
donation. A change in legislation to presumed consent for organ donation would be 
required in order to make changes in treatment. Laboratory analysis of alveolar 
epithelial fluid transport (alveolar fluid clearance) in donor lungs not used for 
transplantation would also help in evaluating the role of steroids in reducing lung 
oedema. Identifying such measures would be helpful in resuscitating marginal donor 
lungs in ex-vivo lung perfusion (EVLP) rigs.  
 
14.4. Transthoracic echocardiography assessment-Future 
Assessment of donor heart function correlated well with haemodynamic parameters 
in this study. It also guided hearts where targeted donor management is helpful. In 
this observational study we noted 4 hearts with baseline LVEF <30%. None achieved 
haemodynamic suitability for transplantation but their initial inotrope or 
vasoconstrictor requirements were not different. The size of the study does not allow 
us to make a general recommendation that hearts with an LVEF <30% should not 
enter a PA catheter guided optimisation protocol. Larger studies may be required to 
make a recommendation on rejecting hearts with poor LVEF. 
 
Acquisition of echocardiographic pictures to assess at least one parameter was 
possible in 70/80 (88%) donors but LVEF assessment was available only in 47/80 
(59%) donors. This demonstrates the difficulties in performing TTE in a supine, 
ventilated patient. Transoesophageal echocardiography would lead to much higher 
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data acquisition but it is invasive and requires expensive equipment and trained 
personnel to undertake the procedure. The use of echo contrast for LV opacification 
would increase the percentage of LVEF measurement by TTE. Most of the TTE 
parameters used in this trial are load dependant. The use of tissue dopplers for 
measurement of isovolumetric acceleration to evaluate biventricular function would 
be ideal. Studies using these parameters on donor population would be required in 
future to further establish the role of echocardiography in donor assessment.        
 
14.5. Inflammatory and bio-chemical marker assessment-Future 
This study demonstrated the prevalence of elevation of bio-chemical markers in 
organ donors and predicted poor donor organ function. Higher level of bio-marker 
was associated with worse outcome. However, this does not preclude successful 
resuscitation of organs for transplantation. Administration methylprednisolone did not 
affect the cytokine levels. This probably due to the administration steroids many 
hours after established BSD. Studies in future directed at earlier administration of 
methylprednisolone soon after coning and measurement of cytokines would be 
required to confirm the role of early steroids on post-BSD pro-inflammatory state. 
Larger studies using combination of bio-markers and other clinical investigations 
including electrocardiography and echocardiography will help in differentiating hearts 
that will be suitable for transplantation from donor hearts that would fail the recipient.  
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14.6. Conclusion 
 
Early donor management is the cornerstone to improve the donor heart function and 
increase the lung retrieval rate. It may also increase the heart retrieval rate. Serial 
transthoracic echocardiography may guide in identifying suitable hearts that respond 
to donor management. Hormone replacement therapy with T3 and 
methylprednisolone did not affect the donor haemodynamics, oxygenation or retrieval 
rate of heart and lungs for transplantation. Steroid administration was associated with 
reduced progressive lung water accumulation.  
 
14.2. Study impact 
The data generated from the trial was presented to the cardiothoracic transplant 
advisory group (CTAG) and to the national specialist commissioning advisory group 
(NSCAG) for thoracic organ transplantation. The data was well received and the 
need for early donor management and Donor Management Practitioners (DMP) was 
recognised. The NSCAG has funded the Birmingham heart and lung transplantation 
unit along with University of Birmingham to train 5 donor management practitioners 
who will be fully trained to initiate early donor management. They will undergo 18 
months of training and will receive a diploma in donor management. At present 3 
DMPs are in training in Birmingham and they will most probably starting early 
management by the end of 2010. Two further trainees will be employed this year. If 
the DMPs are successful in increasing the quality and the quantity of donor heart and 
lungs for transplantation and reduce the number of abandoned retrieval then this 
program will most probably be rolled to the rest of the transplant units in the country. 
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APPENDIX-A - Equations for calculation of derived variables 
 
Systemic vascular resistance indexed 
 
SVRI = (MABP-CVP)       × 80 
CI 
Pulmonary vascular resistance indexed 
 
PVRI= (MPAP-PAWP)       × 80 
CI 
Left ventricular stroke work indexed 
 
LVSWI = (MABP-PAWP)×CI    ×0.0136  ×1000 
   HR 
Right ventricular stroke work indexed 
 
RVSWI = (MPAP-CVP)×CI    ×0.0136  ×1000 
   HR 
Cardiac power output indexed 
 
CPOi =   CI×MABP×0.00222 
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